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Abstract 
 
 
 
The harmful effects of cannabis use and possible neuropsychological impairment 
associated with its use are a contentious topic of debate in both research and public 
health, as is the fact that cannabis use has been repeatedly shown to be a risk factor 
for the development of psychosis.  
Surprisingly, three different meta-analyses on cognition and cannabis, among 
schizophrenic patients, found better cognitive performance in patients with a 
lifetime use of cannabis (Potvin, Joyal, Pelletier, & Stip, 2008; Rabin, Zakzanis, & 
George, 2011; Yücel et al., 2012). This counterintuitive finding, coupled with the 
fact that most psychotic patients suffer from cognitive impairment (Reichenberg et 
al., 2009) make it more difficult to understand the relationship between these two 
risk factors.  
Two different explanations have been advanced for this counterintuitive finding: 
a) a “premorbid-driven hypothesis” and b) a “neuroprotective-derived hypothesis”. 
The latter explanation has gained greater support from the evidence that the CBD 
component has been useful as part of the treatment in several neurological 
disorders.  
Cognition has been established as a predictor of real world community 
functioning in schizophrenia. However, studies on the relationship between 
cannabis use and neurocognitive functioning in psychosis, which have controlled 
for the potential bias of premorbid functioning, are rarely represented in this context 
and often inconclusive.  
The main objective of the work presented in this Thesis was to explore this 
association in an epidemiologically-derived case-control study in a sample derived 
from The European Network of National Schizophrenia Networks Studying Gene-
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Environment Interactions (EU-GEI) in order to test the first of these two 
hypotheses, with the aim of exploring IQ and premorbid conditions and how they 
are related to cannabis use in patients at their first episode of psychosis (FEP), by 
comparing those cannabis using patients to non-users and to their respective healthy 
controls.  
The final aim of this work was to identify the relationship between IQ, premorbid 
social and academic adjustment with cannabis use in psychotic patients, compared 
to healthy controls, in order to be able to explain in which cases you can expect a 
better IQ and a better premorbid adjustment and why, by clustering the sample, first 
according to cannabis use and, secondly, to frequency of cannabis use.  
I hypothesize the existence of a subgroup of patients with a recreational use of 
cannabis, who are less cognitively impaired at the onset and less socially withdrawn 
in the premorbid period than other patients. 
The final sample of the present study included 1,895 subjects (834 cases and 
1,061 controls), with complete information about cannabis use (CEQ) and 
premorbid adjustment (PAS) at least. 1,739 subjects in total had also complete 
information on their IQ (derived from WAIS-short version). 
The study confirmed that patients who used cannabis in their lifetime with a 
recreational pattern of cannabis use have higher IQ scores and a better and more 
stable premorbid adjustment than other patients.  
The study also suggested that the better premorbid social adjustment of patients 
with cannabis-use might be responsible for the contact with the substance and that 
cannabis use increased the risk of psychosis in a subgroup of patients with less 
neurodevelopmental vulnerability. 
Taken together, these results are able to rule out the alternative explanation of a 
neuroprotective role of cannabis use on cognition, in favour of the hypothesis of a 
complex relationship between premorbid predisposition and different pattern of 
cannabis use in determining this paradoxical result.  
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Organization of the Thesis 
 
 
 
This Thesis comprises a total of 6 chapters.  
Chapter 1 is the introduction that covers, through an examination of the 
literature, the main topics of the thesis: the epidemiology of psychotic disorders and 
the risk factors associated with the development of psychoses; the concepts of 
premorbidity and Intellectual Quotient (IQ) and their characteristics in subjects with 
psychosis; cannabis prevalence and cognitive and premorbid characteristics of 
cannabis smokers with and without psychosis. 
Chapter 2 describes the aims and the hypotheses of the work of thesis. 
Chapter 3 presents methods, instrument and statistical analyses, along with the 
EU-GEI study and the study design. 
Chapter 4 describes the results of a previous study about cannabis use and 
psychosis on a UK sample, (conducted in 2011 at King’s College on a sample 
collected as part of the GAP study.  
Chapter 5 summarizes the results of the study: the sample carateristics, data 
manipulations, results from the model and its progression by frequency of cannabis 
use and exploratory analyses. 
Chapter 6 discusses the findings of the research project on the basis of the 
existing scientific data on the topic; it addresses methodological issues, strengths 
and limitations of the study and displays the conclusions.  
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Chapter 1 
Definition of the Terms and Relevant Literature 
 
 
 
 1. Introduction  
 
The harmful effects of cannabis use are a contentious topic of debate in both 
research and public health, especially in the context of its possible legalization and 
medicinal use. One of the most critical points concerns neuropsychological 
impairment, both specific and global, i.e. the impact of cannabis-use on individual 
psychological functions (memory, attention, executive functions), and its effects on 
the general Intellectual Quotient (IQ).  
Another issue concerns the fact that cannabis use has been repeatedly shown to 
be a risk factor for the development of psychosis (Casadio, Fernandes, Murray, & 
Di Forti, 2011; Di Forti et al., 2009; Henquet, Murray, Linszen, & van Os, 2005; 
Moore et al., 2007; Potvin & Amar, 2008). 
High efficiency, speed, and multitasking capacities are in great demand in 
today’s world, and detrimental effects on brain functions have been identified as 
risk factors for different psychiatric disorders (Bora, Yücel, & Pantelis, 2010; Hatch 
et al., 2007) and for higher rates of mortality for different causes (Batty, Deary, & 
Gottfredson, 2007; Batty, Deary, & Macintyre, 2007; Calvin et al., 2011).  
These considerations augment the significance and urgency surrounding the 
study of the problem of a probable detrimental long-term effect of cannabis on 
cognition, since cannabis is one of the most commonly-used illegal-drugs and the 
most widely-involved in the illegal market (European Monitoring Centre for Drugs 
and Drug Addiction and Europol, 2016).  
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The National Survey on Drug Use and Health in the United States, has identified 
cannabis as the leading drug associated with the initiation of illicit-drug use 
(Substance Abuse and Mental Health Services Administration, 2014). It also 
estimates that about 2.4 million people in the United States aged 12 or older had 
started using cannabis in 2012, and 5.4 million use marijuana on a daily basis 
(Substance Abuse and Mental Health Services Administration, 2014). 
Approximately 83.2 million of 15 to 64-year-olds adults in the European Union, are 
estimated to have tried this drug at least once in their lifetime (European 
Monitoring Centre for Drugs and Drug Addiction and Europol, 2016).  
European Monitoring Centre for Drugs and Drug Addiction Use reports that its 
use is higher among young adults (aged 15-34 years) than in other age ranges, with 
almost 16.6 million individuals having used cannabis in the last year; Europe has 
seen an increasing number of people seeking treatment for cannabis-related 
problems (European Monitoring Centre for Drugs and Drug Addiction and Europol, 
2016).  
All this data suggests that a significant proportion of young people are at risk, 
and are using or abusing cannabis during one of the most critical periods of their 
brain development, i.e. adolescence. 
While several studies report an acute adverse effect of cannabis on cognition, 
with obvious consequences on personal and public health, for example motor 
vehicle collision risk (Asbridge, Hayden, & Cartwright, 2012; Kalant, 2004), the 
long-term effects of cannabis use on cognitive functioning are still unclear (Grant, 
Gonzalez, Carey, Natarajan, & Wolfson, 2003; Schreiner & Dunn, 2012). This state 
of uncertainty is mostly attributed to the difficulty in controlling for relevant 
variables—first of all, premorbid cognition—in naturalistic designs, thus preventing 
the drawing of firm conclusions about the casual direction of positive results.  
To further complicate the matter, studies on cannabis use and cognitive 
impairment associated with schizophrenia have yielded controversial results. Three 
different meta-analysis have reported that among patients with psychosis, those who 
have used cannabis show better cognitive performance than those who have not 
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(Potvin, Joyal, Pelletier, & Stip, 2008; Rabin, Zakzanis, & George, 2011; Yücel et 
al., 2012). 
Two different explanations have been advanced for this finding. The first 
suggests that those psychotic subjects who use cannabis have less premorbid 
cognitive impairment than those who do not. This could be because good premorbid 
functioning is necessary to acquire and sustain an illegal drug habit (Joyal, Hallé, 
Lapierre, & Hodgins, 2003; Rodríguez-Sánchez et al., 2010; Stirling, Lewis, 
Hopkins, & White, 2005) or because cannabis use increases the risk of psychosis in 
a subgroup of patients with less neurodevelopmental vulnerability (de la Serna et 
al., 2010; Ferraro et al., 2013; Leeson, Harrison, Ron, Barnes, & Joyce, 2011; 
Løberg & Hugdahl, 2009; Schnell, Kleiman, Gouzoulis-Mayfrank, Daumann, & 
Becker, 2012; Schnell, Koethe, Daumann, & Gouzoulis-Mayfrank, 2009; Yücel et 
al., 2012). 
A second possible explanation, based on research into animal models of 
Parkinson’s disease and Alzheimer’s disease, suggests that some cannabinoids have 
a neuroprotective action (i.e. CBD) (Binukumar et al., 2015; Chung et al., 2011; 
Gómez-Gálvez, Palomo-Garo, Fernández-Ruiz, & García, 2016; Martín-Moreno et 
al., 2011; Ramírez, Blázquez, Gómez del Pulgar, Guzmán, & de Ceballos, 2005), 
which may help to prevent psychosis-related cognitive decline (Jockers-Scherübl et 
al., 2007; Løberg & Hugdahl, 2009). 
 In this work of Thesis, I am going to test the first of these two hypotheses, by 
exploring conditions in the premorbid phase of psychosis, as I believe that they are 
a very good starting-indicator in determining the observed effects of cannabis on 
cognition among clinical and non-clinical samples. 
 
 
2. Psychosis  
 
Emil Kraepelin (1919) first collected under the term dementia praecox some 
conditions such as hebephrenia, catatonia and paranoia, characterized by an early 
onset, an apparently deteriorating course with cognitive impairment, delusions, 
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hallucinations and emotional flattening, and distinguished this condition from 
manic-depressive psychosis.  
Then, Eugene Bleuler (1911) coined the term schizophrenia from the Greek 
words schizein-frenos, that means “separating-mind”, to highlight the “splitting” of 
the major psychic functions. He indicated primary symptoms such as autism, 
associative disturbance, affective blunting and ambivalence, and secondary 
symptoms, that is delusions and hallucinations.  
Kurt Schneider (1950) characterized schizophrenia by specific hallucinations (i.e. 
commenting voices or arguing voices), thought interference (i.e. thought 
withdrawal, insertion, broadcasting), and the experience of impulses or acts 
believed to be under external control (Schneider’s first rank symptoms). 
In the nineteenth century, the term psychosis indicated a heterogeneous group of 
diseases characterized by a loss of contact with reality, perceptual abnormalities 
such as hallucinations, thought disorders, cognitive impairment, emotional 
disorders, lack of insight and motor and behavioural abnormalities. Although many 
definitions of psychosis have been proposed, the diagnostic confines of 
schizophrenia and other psychosis remain ambiguous and the categorical distinction 
between schizophrenia and bipolar disorder is unsatisfactory, because of the 
incomplete knowledge about the aetiology and the pathogenesis of these disorders. 
In fact, schizophrenia merges on one side with bipolar disorder and on the other 
with schizotypal and paranoid personality disorder (Murray & Dean, 2008). People 
affected by psychosis may show a marked affective component and such conditions 
are often defined as schizoaffective disorders, but is not infrequent that their 
diagnosis stay unstable for the rest of their life.  
The International Classification of Diseases-ICD (World Health Organization, 
1992), and the Diagnostic and Statistical Manual of Mental Disorders-DSM 
(American Psychiatric Association, 2013) have furnished operational diagnostic 
criteria for schizophrenia. They differentiate psychotic disorders according to the 
type and duration of symptoms and to the presence of affective symptoms with 
some differences, i.e. the ICD-10 classification requests one month of psychotic 
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symptoms to make a diagnosis of schizophrenia, while in the DSM 5 recommends a 
duration of symptoms of six months, at least.  
Nowadays, a new continuum diagnostic model is emerging, based on findings on 
psychotic-like symptoms that can be experienced by the general health population, 
with a median annual incidence of 2.5% and a prevalence of 7.2%, most of which 
are transitory and disappear over time (Linscott & van Os, 2013; J van Os, Linscott, 
Myin-Germeys, Delespaul, & Krabbendam, 2009).  
Some studies show that first degree relatives of patients affected by a psychotic 
disorder have a higher probability to show paranoid, schizoid or schizotypal 
characteristics, together with some impairments in cognitive performance at an 
intermediate level between patients and normal controls (Murray & Dean, 2008). 
 
2.1. Epidemiology 
 
McGrath and colleagues (2004), in a systematic review of more than 100 large 
epidemiological sudies from 32 countries, reported a median incidence rate of 
schizophrenia of 15.2 per 100,000 persons per year, with a great variety between 
locations, thus replacing the notion that the incidence of schizophrenia doesn’t vary 
much. 
Schizophrenia onset is frequently placed in late adolescence or early adult life. 
Males have an earlier onset of schizophrenia than women and show a peak of 
incidence between 20 and 24 years while females show a peak between 29 to 32 
years, with a larger number of cases presenting later in life (Castle, Sham, & 
Murray, 1998). 
 
2.2. Risk Factors for Psychosis  
 
Schizophrenia is 1.4 times more common in males than in females (Aleman, 
Kahn, & Selten, 2003; McGrath et al., 2004); urbanization increases the risk 
(Allardyce et al., 2001), the larger the town and the longer the individual has lived 
there, the greater the risk (Krabbendam & van Os, 2005). Immigration has a similar 
impact in males and females (Cantor-Graae & Selten, 2005), socio-economic 
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inequalities (Boydell, van Os, McKenzie, & Murray, 2004), perinatal 
complications, such as hypoxia (Cannon, Jones, & Murray, 2002), maternal 
exposure to stressful life events (Jim van Os & Selten, 1998; Verdoux, 2004), 
infectious agents (Brown & Derkits, 2010), maternal vitamin D deficency (Eyles et 
al., 2009) etc. are also risk factors, some more widely replicated than others.  
Other earlier risk factors are childhood abuse and discrimination (Read, van Os, 
Morrison, & Ross, 2005; Stilo et al., 2013) parental loss or permanent separation 
from parents before age 16 (Craig Morgan et al., 2007) and childhood adversities in 
general (Matheson, Shepherd, Pinchbeck, Laurens, & Carr, 2013; Varese et al., 
2012). Other risk factors can occur later in life; a recent meta-analysis of 16 studies 
confirmed a positive association between adverse adult life events and onset of 
psychotic disorder with an overall weighted odd ratio of 3.19 (Beards et al., 2013).  
Social adversities are thougth by some to act in cumulative way e.g. being 
unemployed, single, living alone, having poor education and having no close friends 
are associated with an increased risk of psychosis (C Morgan et al., 2008; Stilo et 
al., 2013). This may be mediated by the effect of an influence of stressful events on 
the hypothalamic-pituitary adrenal axis HPA and subsequently on the dopamine 
system, or it might be a genetic-environmental interaction between stress and 
genetic susceptibility (Howes & Murray, 2014). 
People who develop schizophrenia tend to show subtle cognitive, social and 
motor impairments in childhood. This is often followed, in adolescence/early 
adulthood, by anxiety, low mood and social withdrawal, and then the emergence of 
prodromal symptoms of psychosis leading to the onset of the first psychotic episode 
(Figure 1) (Howes & Murray, 2014).  
Risk factors such as cognitive impairment, premorbid lower adjustment and drug 
consumption will be further discussed, as they are of crucial interest in this work. 
Almost all of the environmental risk factors affect quite a large proportion of  the 
general population, but presumably only a minority of exposed people with some 
genetic vulnerability will develop psychosis. In fact, schizophrenia is under 
considerable genetic influence.  
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A recent multi-stage schizophrenia genome-wide association study of 36,989 
cases and 113,075 controls has identified 108 independent associations spanning 
conservatively defined loci that meet genome-wide significance. These are enriched 
among genes expressed in brain and in tissues that play important roles in immunity 
(Ripke et al., 2014). 
 
Figure 1. The Trajectory to Schizophrenia Showing the Evolution of Symptoms and The Main Risk 
Factors (Howes & Murray, 2014). 
 
Legend: people who develop schizophrenia tend to show subtle cognitive, social and motor impairments in 
childhood. This is followed, in adolescence/early adulthood, by anxiety, low mood and social withdrawal, 
and then the emergence of prodromal symptoms of psychosis leading to the onset of the first psychotic 
episode. Some risk factors play a role early in life, whilst others can interact with predisposing factors later in 
life. This figure is taken for exemplificative purposes from Howes, O. D., & Murray, R. M. (2014). 
Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet, 383(9929), 1677–87. 
 
 
3. Premorbid Adjustment 
 
Premorbidity is generally considered as the condition before the start of 
psychological or physical diseases.  It is often used in relation to psychological 
function (e.g. premorbid personality or premorbid intelligence).  
Premorbid traits are important because they could be associated with adjustment 
and/or recovery from an injury or illness. In fact, other usage of this term in 
psychology includes premorbid adjustment which has important implications for the 
prognosis of mental illnesses such as schizophrenia (Bernstein, 2006). 
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The best way to know premorbid function is via longitudinally planned 
observations. Otherwise, data concerning premorbid conditions can be collected 
retrospectively, through clinical interviews with patients and their family, 
anamnestic notes or clinical records. Premorbid personality, for example, refers to 
patterns of thinking, interpreting, and understanding oneself relative to the 
environment, existing prior to illness or injury and there is evidence that lifelong 
personality traits persist even after a traumatic brain injury (Frank, 2011). It means 
that this kind of assessment could be useful in many circumstances where it is 
important to know individuals’ characteristics before planning treatments.  
In the research field and in the clinical ground, ICD-10 (World Health 
Organization, 1992) and DSM 5 (American Psychiatric Association, 2013) are the 
most widely-used diagnostic systems to assess personality disorders, by providing a 
common language among colleagues. While the ICD is approved by the World 
Health Assembly, composed of the health ministers of all 193 WHO member 
countries, the DSM is agreed by the assembly of the American Psychiatric 
Association. Despite some differences, they both are expected to be atheoretical and 
research-supported.  
Premorbid cognitive functioning is even more difficult to be measured. First of 
all, cognition embraces simple to complex mechanisms of the thinking process, 
such as perception, attention, comprehension, reasoning, linguistic procedures etc. 
But also understanding thoughts, empathising with others and further meta-
cognitive abilities.  
Intelligence is a concept that has born along with psychometric studies, which 
tried to condensate it into a model of Intellectual Quotient (IQ). IQ is often 
expressed with a measure from a test and which is not only a complex proxy for 
cognitive functions, but also one for social adaptation, environmental factors and 
genes (Wechsler, 1939). It is far from exhaustive of or independent from these other 
measures and, at the final end, is determined by a consensus on conventional and 
standardized samples of behaviour (Kaufman & Lichtenberger, 2006). 
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4. Intellectual Quotient (IQ)  
 
Psychometric studies developed throughout the 1930s and into the early 1950s, 
in two different main directions: the construct of global and composite indexes 
(scales able to originate IQ scores) and analytic measures of specific dimensions 
(mental batteries). 
The Stanford-Binet test first introduced the concept of IQ (Terman & Merrill, 
1937), as a revision of the Binet-Simon’s test for children (Binet & Simon, 1916) 
and covered areas of reasoning, vocabulary and problem solving.  
In this context, David Wechsler developed some new scales for measuring 
intelligence, defined as  «the global capacity of a person to act purposefully, to 
think rationally, and to deal effectively with his environment» (Wechsler, 1939).  
In his view, intelligence is a function of the entire personality and it is influenced 
by other non-intellectual factors, such as anxiety, perseverance and goal-directed 
behaviour; in fact, individuals who perform similarly in intellectual tests, do not 
cope identically with their environment, and part of the variance of the tests remains 
unexplained in factorial analyses.  
The Wechsler Adult Intelligence Scale was developed first in 1939 (Wechsler-
Bellevue Intelligence Scale - WAIS; Wechsler, 1939) for individuals aged 16–90 
years, and was revised in 1981 (WAIS-R; Wechsler, 1981), 1997 (WAIS-III; 
Wechsler, 1997) and 2008 (WAIS-IV; Wechsler, 2008). From the WAIS was 
derived –In 1949– the Wechsler Intelligence Scale for Children (WISC; Wechsler, 
1949) aged between 6 and 16 years.   
WAIS-III provides scores for Verbal IQ, Performance IQ and Full Scale IQ, 
along with four secondary theoretical indices that do not contribute to the IQ 
calculation (Verbal Comprehension, Working Memory, Perceptual Organization 
and Processing Speed) so resulting in a test able to measure different content areas 
with both an overall score and a score for each content area differently related to the 
general factor (Figure 2; Figure 3) (for further details see Taub & Benson, 2013).  
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Figure 2. WAIS-III Hierarchical Measurement and Scoring Model (Taub & Benson, 2013). 
 
 
Legend: The 11 subtests, contributing to an individual’s FSIQ are presented on the right side. These 11 
subtests are then subsumed by one of two first-order factors: Verbal IQ (VIQ) or Performance IQ (PIQ). 
The VIQ and PIQ are subsumed by a general factor of intelligence or FSIQ.  
This figure is taken for exemplificative purpose from: Taub & Benson (2013). Matters of Consequence: An 
Empirical Investigation of the WAIS-III and WAIS-IV and Implications for Addressing the Atkins 
Intelligence Criterion Historical Overview. Journal of Forensic Psychology Practice, 13, 27–48. 
Abbreviations: g: general factor; uf1-uf2: first order factors; u1-u11: sub-factors. 
 
 
WAIS scales were innovative because, even if created for nonclinical purposes, 
they can be administered as clinical test batteries; they use the point scale concept 
instead of the age scale, so an IQ of 120 has a different meaning when you are in 
your 60s or in your 20s, but it has the same value in the group based on the age-
range; they include a non-verbal performance scale, according with Wechsler’s 
concept of intelligence, and able to partially overcame the biases caused by 
language. WAIS has been administered in different clinical populations, in order to 
see how the scores change, in which domains (i.e. verbal vs. performance) and how 
IQ performance differs from the general population. For example, the above 
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mentioned four-factor organization (Figure 3) was found to  fit the data from a 
sample of 120 chronic schizophrenia and schizoaffective disorder outpatients, as 
well as it fitted the non-clinical comparison sample of 200 individuals drawn from 
the WAIS-III standardization sample; indeed it fitted the data from both samples 
better than alternative models (Dickinson, Iannone, & Gold, 2002).  
 
Figure 3. WAIS-III and WAIS-IV Theoretical Scoring Measurement Model (Taub & Benson, 2013). 
 
 
Legend: The 10 subtests, contributing to an individual’s FSIQ are presented on the right side. These 10 
subtests are then subsumed by one of the four first-order factors: Verbal Comprehension, Perceptual 
Organization, Working Memory and Processing Speed that are, in turn, subsumed by a general factor of 
intelligence or FSIQ.  
This figure is taken for exemplificative purpose from: Taub & Benson (2013). Matters of Consequence: An 
Empirical Investigation of the WAIS-III and WAIS-IV and Implications for Addressing the Atkins 
Intelligence Criterion Historical Overview. Journal of Forensic Psychology Practice, 13, 27–48. 
Abbreviations: g: general factor; uf1-uf4: first order factors; u1-u10: sub-factors corresponding to subtests. 
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Raw scores from each subtest (sometimes ameliorated with supplementary credit 
for timing performances) are converted in age-related scaled scores. These scores 
are used to derive the IQ that has a normal distribution with a mean of 100 and a 
standard deviation of ±3 that can be fitted into some ranges (See Table 1). 
 
Table 1. IQ classification (Wechsler, 1997). 
IQ Range IQ Classification 
130 and above Very superior 
120–129 Superior 
110–119 High average 
90–109 Average 
80–89 Low average 
70–79 Borderline 
69 and below Extremely low 
Abbreviations: IQ: intellectual Quotient. 
 
However, the full versions of the WAIS, often pose problems for many 
populations due to the length of administration (i.e. clinical populations or aged 
populations); furthermore, use of WAIS has been problematic in the research 
context. In fact, the complete test takes 80 min, on average, for healthy subjects 
(Wechsler, 1997), and close to 100 min in clinical samples (Ryan, Lopez, & Werth, 
1998). A first four-test abbreviation of the WAIS (Wechsler, 1939) was made by 
Doppelt in 1956, by selecting two predictors of the total verbal score (Arithmetic 
and Vocabulary) and two predictors of the total performance score (Block Design 
and Picture Arrangement) (Doppelt, 1956). Ward’s version (1990) estimated 
Verbal, Performance, and Full Scale IQs from seven subtests of the WAIS-R 
(Wechsler, 1981), and required about half of the administration time of the full test 
(Ward, 1990); this form has been revised by several authors. Wolfson and Bachelis 
(1960) first suggested a new methodology that has been broadly-used, based on the 
reduction of the items into each subtest, together with the subtest reduction 
(Wolfson & Bachelis, 1960). Since now, the development of short forms has been 
growing corresponding to the appearance of new versions of the full scale. A full 
revision of the shortened versions of the WAIS is reported in a recent review by 
Úbeda, Fuentes and Dasí (2016) that identified at least 5 short versions of WAIS 
published between 1953 and 1973, 12 shortened WAIS-R developed between 1982 
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and 1999, 6 shortened versions of the WAIS-III proposed between 1999 and 2010 
and 3 short version of the WAIS-IV settled between 2013 and 2015 (Úbeda et al., 
2016). In general, as the number of subtests increases, the predictive accuracy 
growths slightly so, the data indicate that is there not a perfect subtest combination 
for an abbreviated version, and that the best select-subtest combination may vary as 
a function of the type of subjects and of their efficiency to provide the information 
required (D. N. Allen et al., 1997; Guilmette, Dabrowski, Kennedy, & Gnys, 1999; 
Miller, Streiner, Goldberg, & Miller, 1996). For instance, in schizophrenia, the 
inclusion of an equal number of subtests from each factor could underestimate IQ, 
due to the deficits in working memory and processing speed (Blyler, Gold, Iannone, 
& Buchanan, 2000). So, Blyler and colleagues (2000) validated a short form of 
WAIS-III for schizophrenic patients, including one subtest from each of the four 
factors that was highly predictive of FSIQ for both schizophrenia patients and 
healthy controls, by comparing the validity of the four-factor short form with that of 
the best possible unrestricted four-subtest short form. Overall, the four-factor short 
form included Information, Blok Design, Arithmetic and Digit Symbol and was 
able to estimate IQ within five points for 70% of participants and within ten points 
for 94% of participants (both people with schizophrenia and controls). The extent of 
discrepancy between estimated and actual scores was unrelated to FSIQ level, so 
they possibly ruled out the potential flooring or ceiling effect that is often observed 
in several shortened versions of WAIS, especially when administered on psychiatric 
samples (Thompson, Howard, & Anderson, 1986).  
 
 
5. Premorbid IQ 
 
An estimate of premorbid intelligence is required when it is suspected that a 
patient has suffered cognitive decline, such as in brain injuries or in some 
psychiatric disease (i.e. schizophrenia). Clinicians often require information about 
pre-existing test results, academic records, employment history, or they can 
administrate tests that are assumed to be specific for measuring premorbid IQ.  
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Table 2 provides an overview of the most widely used methods to esteem 
premorbid IQ.  
 
Table 2. Instruments for Assessing Premorbid IQ. 
Type of 
test 
Examples  Task Strengths and limitations 
Verbal sub-
tests of the 
Wechsler 
Adult 
Intelligence 
Scale 
(WAIS), 
(Wechsler, 
1997). 
•  Vocabulary 
 
To provide the definition of a list 
of increasingly difficult words.  
They are considered less 
sensitive to the impact of 
age and various forms of 
brain damage.  
However, they are strongly 
affected by the integrity of 
long-term memory and 
might be unreliable in 
individuals with impaired 
memory. 
•  Information   
 
To answer a list of questions 
regarding general culture (i.e. in 
what continent is Argentina?).  
The total RS are converted in SS 
used to calculate the Full IQ. 
Reading 
tests 
•  Wechsler Test for 
Adult Reading, 
WTAR (Holdnack, 
2001).  
•  National Adult 
Reading Test, NART 
(Nelson & Willison, 
1991) .  
•  Wide Range 
Achievement Test 
(WRAT) (Wilkinson, 
1993). 
To read aloud a list of irregularly 
spelled words (whose 
transcriptions do not correspond to 
their pronunciation).  
The score obtained for each 
correct phonation is used to 
calculate the total RS, which is 
converted in a SS.    
Since general spelling rules 
cannot be applied to 
irregular words, the correct 
pronunciation mainly relies 
on remote simple learning 
of vocabulary. 
However, they are not 
available for non-irregular 
languages.  
Best 
estimate 
method  
•  (Lezak, 1983) . The highest test scores or the best 
performance in everyday tasks are 
the best estimate of the subject’s 
premorbid ability, by using tests, 
other observations and historical 
data. This is the standard against 
which all other performance is 
measured. 
A broad range of abilities 
are taken into account and 
not only a single battery of 
tests. 
Nonetheless, this test is not 
well linked to WAIS scores 
and tends to overestimate IQ 
scores. 
Regression 
formulae 
 
 
 
•  (Barona, Reynolds, & 
Chastain, 1984)  – 
USA sample. 
Education, race, and occupation 
are the most powerful predictors 
of premorbid IQ.  
Each variable assumes a 
value that can be used for a 
formula (e.g. sex-male=1; 
female=2 etc.). 
Demographic variables are 
easy to be obtained. 
However, the regression 
toward the mean artificially 
lowers or raises the 
estimated scores for cases 
falling outside one standard 
deviation of the population 
mean (i.e. above 120 or 
below 69). 
•  (Crawford & Allan, 
1997) –UK sample. 
Occupation is the best predictor 
followed by age and years of 
education. 
•  Oklahoma Premorbid 
Intelligence 
Estimations (OPIE) 
(Scott, Krull, 
Williamson, Adams, 
& Iverson, 1997) .  
This procedure combines both 
premorbid demographic variables 
of age, education, occupation, and 
race with current performance on 
the WAIS-R Vocabulary and 
Picture Completion subtests in 
estimating premorbid IQ.  
Legend: the table provides a critical summary of the principal instruments used to assess premorbid IQ. 
Abbreviation: RW: raw score; SS: Scaled Scores; IQ: intellectual quotient 
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Methods to estimate premorbid intelligence, traditionally rely on current 
performance levels believed to be resistant to deterioration, for instance starting 
from Cattel’s theory of “Fluid and Crystallized Intelligences” (Horn & Cattell, 
1966), several “hold tests” have been created. Subtests from WAIS – such as 
Information or Vocabulary – reading tests, i.e. the Wechsler Test for Adult Reading 
(Holdnack, 2001), the National Adult Reading Test (Nelson & Willison, 1991) or 
the Wide Range Achievement Test (Wilkinson, 1993). Other methods are based on 
inferring the best performance in everyday tasks, as the best estimate method 
(Lezak, 1983) or in regression formulae on demographic data (Barona et al., 1984; 
Crawford & Allan, 1997) and demographic variables and current performance 
(Scott et al., 1997). However, many of these methods demonstrate problems such as 
under- or overestimation of IQ and range restrictions (Mortensen, Gade, & 
Reinisch, 1991) so they are not reliable for the purpose of assessing people who 
develop psychosis, who are generally on the low average range for IQ. Therefore, 
the most accurate strategy is using different premorbid IQ estimates depending upon 
the estimated range of intelligence of the individual being assessed (Griffin, Mindt, 
Rankin, Ritchie, & Scott, 2002). 
  
5.1. Psychosis, Cognition and Premorbid Adjustment 
 
Premorbid adjustment in psychosis is defined as the ability of a person to make 
social and intimate relationships as well as the academic achievements before the 
onset of psychotic symptoms and is related to the onset and the prognosis of the 
illness (Addington & Addington, 2005; Bailer, Bräuer, & Rey, 1996; Torgalsbøen, 
1999).  
In schizophrenic patients, an impairment of premorbid adjustment involving 
several areas of functioning has been broadly reported, especially disturbances in 
interpersonal relations, withdrawal from normal social interactions and poor 
relationships with peers (Cannon et al., 2001; Hans, Marcus, Henson, Auerbach, & 
Mirsky, 1992). When present in childhood, the impairment has been suggested to be 
variable in its age of onset and course over time, degree of severity, functional 
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domains involved and specificity (Cannon et al., 2001; Neumann, Grimes, Walker, 
& Baum, 1995).  
Furthermore, women generally report significantly better premorbid functioning 
than men (Foerster, Lewis, Owen, & Murray, 1991; Torgalsbøen, 1999) and they 
have different neurodevelopmental trajectories in social and academic domains (D. 
N. Allen et al., 2013).  
Nonetheless, premorbid impairment is not present in all patients, since a 
proportion of them (frequently those with an abrupt onset) have a relatively good 
premorbid functioning (McGlashan, 2008; Neumann et al., 1995).  
It has been reported that premorbid social and academic function constitute fairly 
independent dimensions (D. N. Allen, Kelley, Miyatake, Gurklis, & van Kammen, 
2001; Barajas et al., 2013; Larsen et al., 2004).  
A better premorbid social adjustment is an important aspect in functional 
outcome (Ayesa-Arriola et al., 2013) and it is related with an earlier age of onset 
(Cannon-Spoor, Potkin, & Wyatt, 1982; Goldberg et al., 2011; Larsen et al., 2004). 
While good premorbid adjustment appears to be associated with an acute onset of 
the illness, poor premorbid adjustment is more often related to an insidious onset 
(Bailer et al., 1996). In fact, impaired premorbid functioning is associated with a 
higher severity of negative symptoms and poorer post-morbid social functioning 
(Ayesa-Arriola et al., 2013; Chang et al., 2013; Galderisi et al., 2013; Rabinowitz, 
De Smedt, Harvey, & Davidson, 2002).  
Moreover, schizoaffective disorder was found to be associated with better 
premorbid adjustment than schizophrenia in the academic domain, but not in the 
social domain, that remains the most impaired function across all the schizophrenic-
related disorders; whilst mood disorders with psychotic features have better 
premorbid adjustment than schizoaffective and schizophrenic disorders (Norman, 
Malla, Manchanda, & Townsend, 2005; Saracco-Alvarez, Rodríguez-Verdugo, 
García-Anaya, & Fresán, 2009; Tarbox, Brown, & Haas, 2012).  
A possible explanation is that, while in schizophrenia spectrum patients a better 
cognitive performance is predictive of higher psychosocial functioning, depressive 
symptomatology is a stronger predictor of psychosocial functioning than cognition, 
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in bipolar patients; that seems to reflect the fact that the impact on daily life is 
present in schizophrenia to a greater extent than in bipolar disorder (Jabben, Arts, 
Van Os, & Krabbendam, 2010). 
Premorbid functioning –especially premorbid academic adjustment– is related to 
premorbid IQ (Barajas et al., 2013; Norman et al., 2005) and both directly predict 
post-morbid IQ and negative symptoms, and indirectly predict post-morbid social 
and occupational functioning, through negative symptoms (Brill et al., 2009).  
Other evidence in this direction suggests that better social and occupational 
outcomes, along with more education and more meaningful activities, occur in 
patients with few negative symptoms, better working memory and higher childhood 
academic functioning (Larsen et al., 2004).  
It has been suggested that premorbid academic impairment could be related to 
the genetic risk for schizophrenia, as poor academic functioning has been observed 
among unaffected siblings of people with familial schizophrenia, compared with 
healthy controls (Walshe et al., 2007). 
It has been proposed that the supposed entity of “Deficit Schizophrenia” or 
“Negative Syndrome” as opposed to “Non-Deficit Schizophrenia”, is related to 
male gender (Roy, Maziade, Labbé, & Mérette, 2001), increased presence of 
familial history of psychosis (Kirkpatrick, Ross, Walsh, Karkowski, & Kendler, 
2000) and poor premorbid adjustment –especially in the social domain (Strauss et 
al., 2012) – as well as  more severe clinical outcome in terms of cognition and 
symptomatology (Bucci et al., 2015; Carpenter, Heinrichs, & Wagman, 1988; 
Fenton & McGlashan, 1994; Malaspina et al., 2000).  
In this model, age at onset and premorbid functioning are proposed as mediators 
between gender, familial history of psychosis and clinical outcome (Bucci et al., 
2015), in accordance with the notion that the “deficit” entity has a different 
developmental trajectory, and that premorbid adjustment is one of the essential 
aspects of its characterization (Galderisi & Maj, 2009; Goldberg et al., 2011).  
Figure 4 describes all the theoretically-driven associations between markers of 
liability to schizophrenia, into the model of the Deficit Syndrome (Goldberg et al., 
2011).  
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Figure 4. The Model of Deficit Syndrome and the Associations Between Markers of Liability to 
Schizophrenia (Goldberg et al., 2011). 
 
 
Legend: this model includes all theoretically-driven associations between markers of liability to 
schizophrenia. Lack of statistical significance of some of the explored effects suggests that the model may be 
overcomplicated. Standardised regression weights for the direct effects are shown. *=p<0.05. **=p<0.01. 
***=p<0.001 
 
Despite the plausibility of this model, it has not been demonstrated that deficit 
schizophrenia is a discrete entity rather than the end of a distribution. 
 
5.1.1. Psychosis and Cognition: life-long disease? 
 
Cognitive abnormalities have been noted since Emil Kraepelin named  what later 
became schizophrenia as dementia praecox and commented «The patients are 
distracted, inattentive... they cannot keep the thought in mind» (Kraepelin E, 1919). 
However, it was long thought that the deficits displayed on formal psychologic 
testing were due to impaired motivation or cooperation or to the symptoms (Brody, 
1941).  
At present, it is well recognized that intellectual impairment is a common feature 
of schizophrenia (Bora et al., 2010; Matheson, Shepherd, Laurens, & Carr, 2011; 
Mohamed, Paulsen, O’Leary, Arndt, & Andreasen, 1999; Zanelli et al., 2010) that 
also occurs, though to a lesser extent, in affective psychosis (Bora, Yucel, & 
Pantelis, 2009; Krabbendam, Arts, van Os, & Aleman, 2005; Kravariti et al., 2009). 
The average cognitive impairment in schizophrenia can reach two standard 
deviations below the healthy controls’ mean (Heinrichs & Zakzanis, 1998); patients 
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generally perform more poorly than would be expected based on their parent’s 
education level (Keefe, Eesley, & Poe, 2005), their unaffected monozygotic twins 
(Goldberg et al., 1990) and their premorbid level (Mesholam-Gately, Giuliano, 
Goff, Faraone, & Seidman, 2009). 
However, two different meta-analyses have found that children who later develop 
schizophrenia are generally 0.4–0.5 standard deviations below the population 
average on IQ (Khandaker, Barnett, White, & Jones, 2011; Woodberry, Giuliano, & 
Seidman, 2008). 
Cognitive deficits are present at the time of the first episode (Harvey & Bowie, 
2003) and there was a long debate about the possibility that these deficits progress 
before or after the onset or whether they stay stable during the course of the illness; 
i.e. a debate regarding the neurodevelopmental (Murray & Lewis, 1987; Murray, 
O’Callaghan, Castle, & Lewis, 1992) or neurodegenerative (McGorry, Hickie, 
Yung, Pantelis, & Jackson, 2006) trajectory of cognitive deficits in schizophrenia. 
First studies suggested the occurrence of a light-to-mild general intellectual 
decline in schizophrenia, within the first five years (Johnstone, Leary, Frith, & 
Owens, 1991; Nelson et al., 1990; Waddington & Youssef, 1996; Waddington, 
Youssef, & Kinsella, 1990) but they generally considered chronically 
institutionalized patients.  
More recent studies have made an effort to consider differences between people 
at risk for psychosis, first episode psychotic patients and the subgroup of them that 
came into the strictest diagnosis of schizophrenia. 
Some cross-sectional studies indicate a cognitive decline over the onset, followed 
by a selective drop in some domains, i.e. shift attentional set  (Pantelis et al., 2009), 
within the first years after the onset and present in patients with 
established schizophrenia. A meta-analysis also suggests a larger IQ impairment in 
the first episode psychotic patients compared to the premorbid period, but 
comparable to later phases of illness and followed by a deficit stability (Mesholam-
Gately et al., 2009). In contrast, other studies have demonstrate that, following 
psychosis onset, the IQ of patients stays stable (Leeson, Sharma, et al., 2011). Also 
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the two abovementioned meta-analyses on premorbid IQ, did not evidence a greater 
IQ deficit with advancing age (Khandaker et al., 2011; Woodberry et al., 2008).  
A recent meta-analysis by Bora and Murray (2014) on 25 studies compared 
people at risk for psychosis, first episode psychotic patients followed up within the 
first five years and healthy controls. The study has shown that there is no evidence 
of a cognitive deterioration, and there are no differences in global cognition and 
single domains improvement between these three groups (Bora & Murray, 2014), 
thus contradicting the theory of a deterioration in psychotic patients (Hedman, van 
Haren, van Baal, Kahn, & Hulshoff Pol, 2013) and sustaining the 
neurodevelopmental origin of a life-long and stable cognitive impairment.  
 
5.1.2. Psychosis and Cognition: General vs. Specific 
 
5.1.2.1. Domains vs. General Factor 
Some separable cognitive factors have been presented as fundamental 
dimensions of cognitive deficit in schizophrenia: speed of processing, 
attention/vigilance, working memory, verbal learning and memory, visual learning 
and memory, reasoning and problem solving, verbal comprehension and social 
cognition (Nuechterlein et al., 2004).  
Memory and verbal memory are generally impaired in first episode patients 
regardless of IQ (O’Connor et al., 2012). It has been suggested that impairment in 
verbal learning and memory shares a genetic overlap with schizophrenia, is a valid 
endophenotype for the condition (Owens et al., 2011), and it is associated with an 
earlier disease onset (Tuulio-Henriksson, Partonen, Suvisaari, Haukka, & 
Lönnqvist, 2004). The specific domain of working memory has been suggested as a 
core component in schizophrenia cognitive deficit (Silver, Feldman, Bilker, & Gur, 
2003), as it is related to prefrontal cortical regions (Callicott et al., 1999) such as 
processing speed. This latter component accounts for most of the differences in 
cognition between patients with schizophrenia and healthy controls and might be 
mediating impairments of working memory, executive functioning, and other 
cognitive disturbances (Ojeda et al., 2012; Rodríguez-Sánchez, Crespo-Facorro, 
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González-Blanch, Pérez-Iglesias, & Vázquez-Barquero, 2007). A recent meta-
analysis on 40 studies (1,961 patients and 1,444 controls) confirmed that processing 
speed measures discriminate people with schizophrenia from comparison 
individuals better than more widely studied neuropsychological instruments 
(Dickinson, 2008; Dickinson, Ramsey, & Gold, 2007).  
Nevertheless, some authors have noticed that cognitive ability, as reflected in test 
performance, appears to be more unitary in schizophrenia than in healthy subjects 
(Dickinson, Ragland, Calkins, Gold, & Gur, 2006) so they refer to a “g” common 
cognitive ability factor that appear to be largely impaired in schizophrenia 
(Dickinson & Gold, 2008; Dickinson, Iannone, Wilk, & Gold, 2004; Dickinson, 
Ragland, Gold, & Gur, 2008). 
General impairment has been proposed as associated with reduced grey matter, 
diminished myelin density and inflammation, oxidative stress, poor signal 
integration and abnormalities associated with glutamate (Dickinson, 2008). But this 
deficit could also be related to other factors such as substance misuse and the effects 
of prescribed medications (Zipursky, Reilly, & Murray, 2013).  
Moreover, to be involved in a less challenging social world could play a role, 
thus decreasing stimuli in a two-way relationship with cognitive functions. In fact, 
impairments in vigilance and verbal memory are related to social deficits, lower 
community functioning and skill acquisition, probably through a difficulty in 
following simple activities such as social conversations, instructions and reading 
(M. F. Green, 1996; M. F. Green, Kern, Braff, & Mint, 2000). Speed processing, 
and working memory impairment are associated with employment status (Gold, 
Goldberg, McNary, Dixon, & Lehman, 2002; McGurk & Meltzer, 2000) and a 
generalized impairment in multiple domains is related to an amount of daily life 
activities (Evans et al., 2003). 
 
5.1.2.2. All Patients vs. Subgroups of Patients  
However, not all psychotic patients show cognitive impairment (Kremen, 
Seidman, Faraone, Toomey, & Tsuang, 2000). From an epidemiological study of 
first-admission psychotic patients, we know that as many as 16% of schizophrenic, 
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20% schizoaffective, 42% of bipolar, and 42% of depressed patients may not be 
cognitively impaired (Reichenberg et al., 2009). Furthermore, there are some 
patients meeting diagnostic criteria for schizophrenia who have markedly superior 
premorbid intellectual and actual level and appear indistinguishable from IQ-
matched healthy controls; these subjects appear be free of gross neuropsychological 
deficits (MacCabe et al., 2012).  
So questions remain about the amount of premorbid IQ deficit, whether this is 
due to a decrement in the majority of future cases (a left-shift of this population), or 
whether it is due to a minority effect driven by a sub-group with conspicuously low 
IQ (Khandaker et al., 2011). 
 
5.1.2.3. Continuum vs. Categorical Disorders  
Although neurocognitive deficits are evident both in schizophrenia and bipolar 
disorder, two longitudinal studies have suggested that neurodevelopmental 
abnormalities are present in schizophrenia but not in bipolar disorders, and that 
individuals with better cognitive functioning in childhood or adolescence have an 
increased risk for later bipolar disorders (Koenen et al., 2009; MacCabe et al., 
2010).  
A recent meta-analysis by Trotta, Murray and McCabe (2014) has revealed that 
the severity of cognitive deficits and its consequences appear to partly differ 
between schizophrenia and bipolar disorder. Although impairment on overall 
intellectual functioning is present in both schizophrenia and bipolar patients, 
schizophrenia, not only shows significant deficits in premorbid cognitive function, 
but also is characterized by severe post-onset impairment. Bipolar disorders, show a 
much smaller premorbid deficit, that becomes null when the analysis is restricted to 
prospective studies, and suffer a greater degree of post-onset impairment, though 
ultimate impairment remaining much smaller than that found in schizophrenia 
(Trotta, Murray, & MacCabe, 2015). It has been proposed that, on a background of 
shared genetic predisposition to psychosis, schizophrenia, but not bipolar disorder, 
is subject to additional genes or early insults, which impair neurodevelopment, that 
make the difference between these two diseases (Murray et al., 2004).   
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Other clinical entities that lie in an intermediate position between the 
schizophrenia–bipolar disorder continuum are affective psychoses (psychotic 
depression, psychotic bipolar disorder/mania) and schizoaffective disorders 
(American Psychiatric Association, 2013). A meta-analysis by Bora, Yucel and 
Pantelis (2009) has suggested that diagnoses in the schizoaffective disorder and 
affective psychosis group only slightly affect the degree of cognitive impairment in 
these groups relative to schizophrenia (Bora et al., 2009). 
Bipolar disorder has been proposed as an intermediate phenotype between 
schizophrenia and healthy controls (Bora & Pantelis, 2015), in a common genetic 
vulnerability in which more prominent affective features and less enduring 
psychosis are associated with less cognitive impairment, thus including in the 
continuum affective psychoses and schizoaffective disorders (Hill et al., 2013; Hill, 
Harris, Herbener, Pavuluri, & Sweeney, 2008). 
 
 
6. Cannabis 
 
Cannabis embodies the 38% of the European illicit-drug market that supplies 
over 22 million annual users by constituting the largest drug market in Europe 
(European Monitoring Centre for Drugs and Drug Addiction and Europol, 2016). 
Despite its large impact on the community, little is known on this substance and its 
potential harmful effects.  
Talking with people from my community and with patients suffering of several 
diseases, I had the impression that most young people believe that laws on cannabis 
are too restrictive, in light of its relatively innocuous consequences on people and it 
is not infrequent to see articles in newspapers on this issue (e.g. Turrini, 2015). In 
Italy there is now an association that is nowadays collecting firms for claiming 
rights on therapeutic use of cannabis and legalization (Associazione Cannabis 
Terapeutica; ACT, 2001). Other people simply disagree with the idea of its 
legalization, for moral reasons (e.g. Ricciardi, 2014). Someone else hopes for 
medical benefits, or affirms that its even illegal-use is a self-cure approach against 
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social inhibition, stress, insomnia, rumination or psychological pain and for positive 
affect enhancement (B. Green, Kavanagh, & Young, 2004).  
Even if several studies have demonstrated a relationship between social anxiety 
and cannabis problems (Buckner & Zvolensky, 2014; Foster, Ecker, Zvolensky, & 
Buckner, 2015; Foster, Garey, Buckner, & Zvolensky, 2016), other  studies 
suggested a protective function of symptoms of social anxiety for cannabis in 
adolescents from the general population, probably through a less peer involvement 
(suggesting increased social isolation) for those adolescents with higher levels of 
symptoms of social anxiety (Nelemans et al., 2016; Schmits, Mathys, & 
Quertemont, 2015). So, the precise relationship between cannabis use and anxiety 
has yet to be established (Crippa et al., 2009).  
While the psychological involvement with cannabis will be one of the points of 
interest of this thesis, the controversial legal issue about cannabis is no-longer 
debated in this context, but it suggests that it’s difficult to identify an “overall” 
dangerous effect of this substance, because it depends on the users and the pattern 
of use and the type of cannabis used. In fact, although for many people cannabis use 
is experimental and short-lived, for a minority its use can become problematic and 
have serious long-term consequences (European Monitoring Centre for Drugs and 
Drug Addiction and Europol, 2016).  
The National Survey on Drug Use and Health has estimates that 5.4 million use 
marijuana on a daily basis (Substance Abuse and Mental Health Services 
Administration, 2014); daily users in the European Union (EU) are estimated at 3 
million (European Monitoring Centre for Drugs and Drug Addiction and Europol, 
2016). Approximately 83.2 million of 15 to 64-year-olds adults in the EU, are 
estimated to have tried this drug at least once in their lifetime. Use is higher among 
young adults (aged 15-34 years), with almost 16.6 million individuals, having used 
cannabis in the last year (European Monitoring Centre for Drugs and Drug 
Addiction and Europol, 2016).  
In some high-consuming countries (i.e. UK), trends in prevalence of use have 
been showing marked declines, but other countries show intensification; in fact, EU 
has seen an increasing number of people seeking treatment for cannabis-related 
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problems overall (European Monitoring Centre for Drugs and Drug Addiction and 
Europol, 2016).  
Cannabis is a naturally occurring plant with psychotropic properties that can be 
cultivated out- and indoors, and marijuana is produced by drying the flowering tops 
of the plants. Hashish is the other most common form of cannabis product, deriving 
from plant resin and generally compacted into blocks. While the latter is largely 
mass-produced for export, mostly in Morocco, the former is increasingly grown for 
domestic markets: it is less likely to be intercepted by authorities, it increasingly 
dominates the market in EU and it can be rendered of high potency by indoor 
techniques (European Monitoring Centre for Drugs and Drug Addiction and 
Europol, 2016), in order to respond to market requests.  
The main psychoactive component, tetrahydrocannabinol (Δ-9-THC) has 
increased in commercially herbal products in the past 50 years from 1% up to 15% 
(Levounis & Herron, 2014) in products called “skunk” and “super-skunk”, from 
their strong smell. This constituent is responsible for the positive psychoactive 
effect of the drug, and it is potentially able to produce tolerance and desensitization.  
The other main constituent of cannabis is cannabidiol (CBD), which has 
anxiolytic and antipsychotic properties, and seems to “balance” the psychotogenic 
effect of THC (S. Bhattacharyya et al., 2010; Di Forti et al., 2009). Consequently, 
any reduction of CBD in illicit cannabis (such as in “skunk” variety) can have 
implications for the overall negative health consequences associated with 
consumption (European Monitoring Centre for Drugs and Drug Addiction and 
Europol, 2016).  
The endogenous cannabinoid system is involved in mood and appetite regulation, 
immunity-system, pain management and memory; however, the exact subtle 
elements of how cannabis influences them are still broadly obscure (Grant & Cahn, 
2005). 
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6.1. Cannabis and Intellectual Quotient (IQ) 
 
The association between cannabis use and cognitive performance has been 
widely studied. The following paragraphs are a revision of a previously published-
review on this topic (Ferraro, Sideli, & La Barbera, 2017-in press).  
Table 3 shows a non-exhaustive summary of the principal reviews on this 
subject with authors’ conclusions.  
In 1995, Pope and colleagues (H. Pope, Gruber, & Yurgelun-Todd, 1995) first 
tried to distinguish between the acute and residual effects of cannabis in individuals 
without any psychiatric disorders. They revealed a residual effect on attention, 
psychomotor tasks, and short-term memory during the 12-24 hours-period 
immediately after cannabis use, among naturalistic and controlled studies. They also 
considered long-term effects as these lasting after 24 hours of abstinence, but they 
revealed insufficient evidence to support or refuse a more prolonged drug residue 
effect, after this period (H. Pope et al., 1995); so the authors argued that, in future 
studies, it would be very important trying to exclude the virtual continuous effect of 
acute intoxication and the confounding effect of withdrawal syndrome, that could 
have been responsible for the effect detected during the first 24 hours. 
With this consideration in mind, they later tried to define the neurotoxicity of 
cannabis as its long-term residual effect lasting after 28 days of abstinence and 
tested people who had used cannabis on an almost daily basis (H. Pope, Gruber, 
Hudson, Huestis, & Yurgelun-Todd, 2002, 2001; H. Pope, Gruber, & Yurgelun-
Todd, 2001). Their results suggested deficits in memory and attention present for 
days after discontinuing use but mainly reversible after four-five weeks (H. Pope, 
Gruber, & Yurgelun-Todd, 2001), regardless of the cumulative amount of lifetime 
cannabis use (H. Pope et al., 2002). 
Gonzalez and colleagues (2002) examined the methodology adopted in the 
previous literature on the basis of the correspondence to a priori criteria (see Figure 
5) in order to ensure that between-group (case/control) differences could be 
attributable to differences in history of cannabis use, without any effect of potential 
confounders.  
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Table 3. Reviews and Meta-analysis on Cannabis and Cognition. 
Authors Study type Number of studies 
included (years of 
publication) 
Cannabis 
effect 
targeted    
Impaired domains   
Pope et al., 
1995 
Review 42 (1972-1993). RE =12-24 
HA. 
LTE >24 HA.   
RE: attention, psychomotor 
tasks, short-term memory. 
LTE: minimal. 
Pope, 
Gruber, 
Hudson, et 
al., 2001 
Review  8 (1996-2001) RE.  
7 (1989-2000) LTE.  
RE <28 DA. 
LTE >28 DA. 
RE: memory and selective 
attention. 
LTE: minimal. 
Gonzalez, 
Carey, & 
Grant, 2002 
Review 40 (1973-2002). RE >24 HA. RE: attention and working 
memory. 
Grant et al., 
2003 
Meta-analysis 11 (1977- 2002). RE >24HA. RE: global performance, 
learning and forgetting. 
Gonzalez, 
2007 
Review 20 (1980-2007) AE.  
19 (1999-2006) RE. 
AE ≤12 HA. 
RE >24 HA. 
AE: memory retrieval.  
RE: memory. 
Jacobus, 
Bava, 
Cohen-Zion, 
Mahmood, 
& Tapert, 
2009  
Review 16 (1989-2008). 
 
RE <28 DA.  
LTE >90 DA.  
RE: attention, processing speed, 
verbal learning and memory. 
LTE: none. 
Solowij & 
Pesa, 2010  
Review  116 (2000-2010).  
 
AE ≤24 HA  
RE =24 HA -
28 DA. 
AE and RE: attention, 
inhibition, verbal memory and 
other memory processes.  
Crean, 
Crane, & 
Mason, 2011  
Review  12 (1970-2009) AE; 
14 (1995-2010) RE; 
11 (1995-2006) 
LTE. 
AE ≤6 HA. 
RE =7-20 DA. 
LTE >21 DA. 
AE: working memory, attention 
and inhibition.   
RE: decision making and risk 
taking.  
LTE: none. 
Schreiner & 
Dunn, 2012 
Meta-analysis 33 (2000-2011) RE; 
13 of them on LTE. 
RE >4 HA. 
LTE >25 DA. 
RE: global performance, most 
cognitive domains.  
LTE: none. 
Crane, 
Schuster, 
Fusar-Poli, 
& Gonzalez, 
2013 
Review  34 (2007-2012) AE;  
61 (2007-2012) RE. 
 
AE <8 HA 
RE >8 HA. 
 
AE: learning and memory, 
attention, concentration and 
working memory. 
RE: episodic memory, attention, 
concentration, risk taking and 
decision making.  
Legend: the table presents a summary of the principal reviews about cannabis use and acute, residual and 
long-term effects on cognition with authors’ findings. 
Abbreviations: AE: Acute Effect; RE: residual Effect; LTE: Long-Term Effect; HA: Hours of 
Abstinence; DA: days of abstinence. Ferraro et al. (in press). 
 
Their results were consistent with those from Pope and colleagues. Twenty-two 
of the 40 studies included in their review, reported at least some subtle impairments 
(mainly in attention and working memory) after 24 hours of abstinence. Despite 
methodological rigor authors indicated, as a limitation, that very few studies, among 
those considered, assessed premorbid neuropsychological abilities and they, 
usually, looked at vocabulary or verbal fluency tests. 
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Figure 5. A priori Criteria Established from Gonzalez et al. (2002) in Studying Non-acute Cannabis 
Effect. 
 
Legend: this table is taken for exemplificative purpose from Gonzalez, R., Carey, C. & Grant, I. (2002). 
Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic 
review. J Clin Pharmacol, 42, 48S-57S. 
 
The same group performed a meta-analysis in 2003 (Grant et al., 2003). The 
average global neurocognitive effect was small and was expressly observed in 
memory and forgetting/retrieval tests, but very few studies on the non-acute 
neurocognitive effects of cannabis meet current research standards. A small effect 
was also been observed by Gonzalez (2007) in frequent and heavy cannabis users, 
and this was not necessarily matched with changes in brain functioning. Authors 
conclude that heavy cannabis use may produce some deficits, but it has not been 
determined if such deficits are a result of cannabis use or if they represent 
premorbid problems that may have contributed to the development of a cannabis 
use disorder (Gonzalez, 2007). 
All the same, results from Gonzalez and Grant’s group appear not to be able to 
resolve the question about long-term neurotoxicity, given that most of the cannabis 
users included in their studies had been abstinent for a maximum of two weeks. In 
fact, in a recent update of Grant’s work published by Schreiner and Dunn (2012), 
most of the cognitive domains assessed as well as the overall performance remained 
impaired when subjects were tested within the first 25 days of abstinence but not 
after this period. So, the clinical significance of these findings remained unclear due 
to the possible effect of the withdrawal syndrome. To sum up, this study including 
two different meta-analyses, indicated a small negative residual effect and no 
	  
 43 
 
lasting effects on neuropsychological performance, regardless of the duration of use 
(Schreiner & Dunn, 2012).  
Besides the amount of cannabis used and abstinence length, another crucial point 
when considering the harmful effects of cannabis on cognition, is the age of first 
cannabis use. Jacobus and colleagues (2009) addressed this point in a review and 
concluded that adolescents who use marijuana heavily tend to show disadvantages 
in attention, processing speed, verbal learning and memory that persist beyond one 
month of abstinence, but largely remit after three months of sustained abstinence. 
Once again, without any measure of premorbid IQ, it is difficult to establish 
whether a causal direction exists between cannabis use and cognition.  
Di Forti, Morrison, Butt, & Murray (2007) addressed “the chicken or the egg” 
question by claiming the role of an earlier age of onset in using cannabis as 
determinant in the detrimental effect of the substance on cognition and 
hypothesizing a gene-environment pattern of common vulnerability to cannabis 
effect and psychosis, where neuropsychological deficits underlay a profile of people 
at-risk to develop psychosis without the need for the additional risk factor of 
cannabis use. This is of particular interest in this context and is going to be 
subsequently taken into account.  
Other executive functions have received more attention in recent years (Crane et 
al., 2013; Crean et al., 2011). For example, residual effects of cannabis on risk 
taking and decision making were found to be impaired in two reviews, especially 
when studies take into account the distinction between chronic, heavy cannabis 
users, as opposed to light and occasional users (Crean et al., 2011) and the necessity 
to take into account the role of gender in producing such as impact, as it has been 
less studied (Crane et al., 2013). However, these studies are far from clarifying the 
temporal ordering of cognitive deficits and cannabis use. As is shown in Figure 6, 
most of the reviews concentrate on residual and long-term effects. Residual effects 
are the most-represented findings over the years, especially in the memory domain, 
and positive results on long-term effects of cannabis probably depend on 
ameliorated research designs. Very few papers from those mentioned above 
considered general IQ as a measure of interest; those that did, largely found a small 
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residual effect on overall impairment but not after a long-term period of abstinence 
(Grant et al., 2003; Schreiner & Dunn, 2012). 
 
Figure 6. Cannabis use and cognitive functioning. 
 
Legend: this histogram provides an overview of the main findings on cannabis use and cognition mentioned 
in this chapter. Cognitive functions are on the X-axis, and the number of studies with positive findings on 
deterioration for each domain, divided according to acute effect (in blue), residual effect (in red), and long-
term effect (in green), are counted on the Y-axis. Each bar cumulates studies on the field indicated, by 
referring to their year of publication – from the holder to the newest – Ferraro et al. (in press).  
 
Other reviews have restricted their interests to memory (data not shown in table), 
by ascertaining an impairment in this domain during the acute phase (Ranganathan 
& D’Souza, 2006) and in the long-term (Solowij & Battisti, 2008) together with 
attention and inhibition, depending on duration, frequency, dose and onset of 
cannabis use in adolescence (Solowij & Pesa, 2010).  
Ranganathan and D’Souza (2006) controlled dose, route of administration, 
sample sizes and sample selection effects, other drug use, tolerance and dependence 
to cannabinoids, and the timing and sensitivity of psychological tests towards 35 
studies conducted between 1970 and 2006. They concluded that acute 
administration of Δ-9-THC transiently impairs immediate and delayed free recall of 
information presented after, but not before, drug administration in a dose- and 
delay-dependent manner, particularly with the inhaled and intravenous route.  
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Schoeler & Bhattacharyya, 2013 have recently highlighted the role of the mix of 
different cannabinoids present in the type of cannabis used in studies on cognition; 
this is another point of important concern, as the components of street-cannabis 
have been changing in the last years. In the long-term, impairments in memory 
seem particularly likely to persist following abstinence if regular and heavy use of 
cannabis high in Δ-9-THC is started at an early age (Schoeler & Bhattacharyya, 
2013). These data are consistent with those from a recent review (Lorenzetti, 
Solowij, & Yücel, 2016) on 31 studies of neuro-anatomic alterations related to 
cannabis use, which are mostly present in regions that are highest in cannabinoid 
receptors, such as prefrontal cortex, hippocampus, amygdala and cerebellum and 
that are associated with greater dose and earlier age of onset. Authors highlight that 
preliminary evidence shows that THC exacerbates, whereas CBD protects from, 
such harmful effects (Lorenzetti et al., 2016).  
The best way to address this issue would be a longitudinal study, able to measure 
cognitive performance before and after the period of life in which cannabis is 
consumed. On the other hand, although the problem of possible confounding and 
the difficult to control the street-drug components, some principal authors on this 
topic claim that naturalistic and retrospective studies of drug users remain the most 
efficient way to assess the long-term cognitive effects of cannabis consumption. 
Prospective designs are extremely expensive, time-consuming and, in some cases, 
unethical (H. G. Pope, 2002; Solowij, Stephens, Roffman, & Babor, 2002).  
In the next section we will review the existing longitudinal studies on premorbid 
IQ in cannabis users, along with measures of premorbid IQ assessed in the 
aforementioned papers. 
  
6.2. Cannabis and Premorbid-IQ 
 
Pope and colleagues estimated premorbid IQ by using a vocabulary test which 
resulted in lower scores among heavy users than controls, additionally attenuating 
differences in cognitive performance between the two groups when entered as 
covariates (H. Pope, Gruber, Hudson, et al., 2001). Solowij and Battisti (2008) 
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reported three studies showing lower vocabulary scores in cannabis users compared 
to controls. Schreiner and Dunn (2012) indicated a similar impairment on overall 
performance in the verbal/language domain – assessed by vocabulary, verbal 
fluency and naming tests – within the first 25 days of abstinence, but surprisingly 
not after this period of time.  
Taken together, these results suggest, as already mentioned, that vocabulary and 
– not surprisingly – verbal fluency tests, behave more as measures of actual 
capacities than as an estimation of premorbid IQ. In retrospective studies, reading 
tests have been suggested as a better method, because they are able to provide a 
broad estimate of general ability before eventual impairment as opposed to other 
tests (Griffin et al., 2002).  
Table 4 provides a resume of longitudinal studies that specifically assessed IQ 
before and after cannabis use. In the early 80’s Kellam, Ensminger & Simon (1980) 
tested a large cohort of Afro-American adolescents from Woodlawn, an urban, poor 
community on the South Side of Chicago, at their first degree school and re-tested 
them ten years later, revealing that people with higher IQ, better social adaptive 
capacities and readiness-for-school higher scores were more likely to use cannabis 
in their teenage years. Fleming Kellam & Brown (1982) later showed on the same 
population that boys with higher IQ and readiness-for-school tended to initiate 
substance use at an earlier age and girls who were rated as shy or having learning 
problems, tended to initiate use at a later age. Ensminger, Juon & Fothergill (2002) 
re-interviewed 952 subjects from this original cohort at age 32 and confirmed that 
males having superior IQ scores in childhood were more likely to initiate cannabis 
use in adolescence but were also more likely to discontinue this behavior as young 
adults, while to be shy or aggressive was a risk factor for becoming a persistent 
cannabis user as an adult.  
Fried and colleagues (2002, 2005) had the opportunity to follow-up a group of 
young subjects as part of The Ottawa Prenatal Prospective Study, and assessed their 
IQ before, during and after cessation of regular marijuana use. Young adults with 
heavy actual or former use, started with a lower IQ compared to non-users (who had 
never used cannabis regularly, i.e. once a week) and who had not used any cannabis 
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in the past 2 weeks) and light users (less than 5 joints per week, at least once a 
week); but only heavy use (at least 5 joints per week) was related to a lower IQ 
when compared to the other groups. However, similar deficits were no longer 
apparent 3 months after cessation of regular use (Fried, Watkinson, & Gray, 2005; 
Fried, Watkinson, James, & Gray, 2002). 
Different findings were derived from two different British cohort studies by 
White and colleagues (White & Batty, 2012; White, Gale, & Batty, 2012). They 
found that a higher childhood IQ may increase the risk of illegal drug use – e.g. 
“cannabis lifetime” – in adolescence and adulthood, even when correcting for 
material disadvantage, antisocial behavior, social distress and anxiety. However, the 
same group (White, Mortensen, & Batty, 2012) found an apparently contrasting 
result on a group of males US Vietnam veterans with IQ assessed at the time of the 
military service enrollment. That is, subjects with higher IQ scores were less likely 
to be habitual users of cannabis, during active service (i.e. for once a week, ≥3 
months) and in civilian life (in the past 12 months, ≥once a week), with a 
moderating effect of socioeconomic status in adulthood.  
Meier and colleagues (2012) published a paper where people from the Dunedin 
Cohort Study were followed-up from childhood to the age of 38. Subjects with 
more persistent cannabis dependence (that had generally started in adolescence) 
presented greater IQ decline, not specific to any domains, when compared to study 
members who never used cannabis. Persistence of regular cannabis use was defined 
as the total number of study waves out of five at which a study member reported 
using cannabis four days a week or more (the majority of days in a week) (Meier et 
al., 2012). Study members who never used cannabis, experienced a slight increase 
in IQ. Results stayed significant after ruling out possible confounders such as 
education, diagnosis of schizophrenia, tobacco and other-drug dependence and past-
week cannabis consumption. Interestingly, people who reported a lifetime 
recreational use of cannabis, but not dependence, started with a higher IQ than 
people that never used cannabis. These two groups had similar IQ levels at age 38.  
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Table 4. Longitudinal Studies on Premorbid IQ and Cannabis Use. 
Authors  Study  Sample 
size  
Pattern of 
cannabis 
use as 
described 
by authors  
Measures  
(age in 
years of 
the 
valuation) 
Conclusions 
Kellam, 
Ensminger 
& Simon, 
1980 
1966-1967 
first 
graders 
Woodlawn 
African 
Americans 
–USA. 
705 
 
Lifetime IQ  
(6; 16) 
Higher IQ, social adaptive capacities 
and readiness-for-school scores in 
childhood predict cannabis use in 
teenage years. 
Fleming, 
Kellam, & 
Brown, 
1982 
Subjects with higher IQ and readiness-
for-school in childhood tend to initiate 
cannabis use at an earlier age. Shy girls 
or girls with learning problems tend to 
start use later. 
Ensminger
et al.,  
2002 
952 Discontinue; 
Persistent 
IQ  
(6; 32) 
Males having higher IQ in childhood 
are more likely to initiate in 
adolescence but also to discontinue use 
as young adults. Low-scoring females 
are less predisposed to a persistent use. 
Fried, et 
al., 2002 
Ottawa 
Prenatal 
Prospectiv
e Study 
(OPPS) – 
Canada. 
70  
 
Light current 
regular; 
Heavy 
current 
regular; 
Former 
regular; 
None. 
IQ  
(12; 17-20) 
Overall IQ and other domains impaired 
in heavy current users but for no longer 
than 3 months after cessation of regular 
use. 
Fried, 
Watkinson
& Gray, 
2005 
113  IQ, 
processing 
speed, 
memory, 
vocabulary  
attention, 
abstracting 
abilities.  
(12; 17-20) 
White & 
Batty, 
2012 
1970 
British 
Cohort 
Study – 
UK. 
7,946  Lifetime IQ  
(5; 10) 
 
High childhood IQ increases the risk of 
use in adolescence and adulthood, 
especially in women.  
White, 
Gale, & 
Batty, 
2012 
1958 
National 
Child 
Developm
ent Survey 
– UK. 
6,713 Lifetime IQ  
(11; 42) 
 
Use in middle age is more probable in 
children with a greater IQ, especially 
woman. 
White, 
Mortensen
, & Batty, 
2012  
Vietnam 
Experience 
Study – 
USA. 
14,362 Habitual IQ  
(22; 40) 
Subjects with higher IQ at 22 are less 
likely to be habitual users, during 
active service and in civilian life. This 
association is attenuated by 
confounding variables. 
Meier et 
al., 2012  
Dunedin 
Cohort 
Study – 
New 
Zeland. 
1,037 Persistent IQ  
(7-13; 38) 
A drop from childhood to adult average 
full-scale IQ especially in adolescent-
onset users. 
Legend: in this table is offered an overview of longitudinal studies that expressly assess IQ before and after 
cannabis use.  
Abbreviation: IQ: Intellectual Quotient. Ferraro et al. (in press). Modified.  
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However, authors did not have the opportunity to test the subjects after a period 
of abstinence of at least four weeks. Therefore, their findings are likely to be 
influenced by the residual effects of cannabis. 
When looking at the results from above studies, it seems that premorbid IQ is 
linked to cannabis use, toward complex mechanisms.  
Moreover, there are some important variables that have to be taken into account 
while studying the relationship between premorbid IQ and cannabis use: first of all, 
gender and the age at which cannabis consume started, socio-economic factors and, 
most significantly, frequency of cannabis use.  
This study has raised a debate surrounding other potential confounders of the 
results. For example Rogeberg, (2013a) argues that socioeconomic status alone can 
potentially explain the IQ decline observed by Meier and colleagues and recalls the 
Flynn–Dickens model of IQ (Dickens et al., 2001) that emphasizes a two-way 
causality between IQ and environment with both a direct effect of the genotype on 
IQ and the opposite. That is, those with a higher IQ tend to seek out- or be sorted 
into more cognitively challenging environments that further increase IQ. Daly 
(2013) intervenes in the debate saying that the personality trait of 
“conscientiousness” may be protective for same people.  
The cut and thrust of this debate is contained in two successive letters in the same 
volume of the Proceedings of the National Academy of Science (Moffitt, Meier, 
Caspi, & Poulton, 2013; Rogeberg, 2013b). 
In a recent study, Power et al. (2015) divided a cohort of 1,237 participants with 
an established ICD-10 diagnosis of schizophrenia in non-users of cannabis and 
those with a lifetime history of cannabis use or dependency. They found no 
differences in premorbid cognitive ability between non-users of cannabis and those 
with a lifetime history of cannabis use or dependency, after controlling for age, age 
at onset of illness, and socio-economic status. 
Interestingly, longitudinal studies present a point of consistence, as indicated in 
Figure 7, i.e. a relationship between higher premorbid IQ and recreational or 
discontinued use, though a lower premorbid IQ results as a predictor for regular or 
heavy cannabis use. 
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6.3. Cannabis and Premorbid Adjustment: Enlarging the View  
 
Longitudinal studies focused on different theories of predisposing factors to drug 
use and a number of variables have been identified. 
The 1966-1967 first graders Woodlawn project (Kellam et al., 1980; Fleming et 
al., 1982; Ensminger et al., 2002), as already mentioned, enlarged their view to 
include social adaptive capacities, readiness-for-school and aggressiveness for 
males as risk factors and, alternatively, shyness and learning problems for girls as 
protective factors.  
In a review of longitudinal studies on drug use, Wills, Walker, and Resko (2005) 
indicated some common risk and protective factors frequently identified in this 
field, as is shown in Figure 8.  
 
 
 
Figure 7. Premorbid IQ and Cannabis: Main Findings from Longitudinal Studies. 
 
Legend: this graph provides a simplification of the results of longitudinal studies on premorbid IQ, 
categorized into “higher” and “lower” on the y-axis and differentiated by patterns of cannabis use, 
recreational versus regular use, in the x-axis. Ferraro et al. (in press). 
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Figure 8. Risk and Protective factors for Drug Use Mostly-Identified by longitudinal Studies (Wills, 
Walker & Resko, 2005). 
 
Legend: this table is taken for exemplificative purpose from Wills TA, Walker C, Resko JA. Longitudinal 
studies of drug use and abuse. In: Sloboda Z, (ed.) Epidemiology of drug abuse. Springer; New York: 2005. 
pp. 177–192.  
 
To summarize, the main fields of the interest are: 
 
a)   parental influence and familial relationships (parental problems, parental use 
of drugs, attachment vs. family support, discipline and monitoring);  
b)   poor self-control (externalizing symptoms, negative emotionality, 
impulsiveness, sensation seeking vs. the ability to plan life-activities 
(planfullness), executive functioning, attentional focusing); 
c)   life stress or discrimination vs. good self-esteem and ethnic identity; 
d)   deviant peer affiliation (deviance-prone, unconventional attitudes vs. 
conventional attitudes); 
e)   cultural context (availability of drugs, neighborhood disorganization vs. moral 
beliefs); 
f)   pattern of use (early onset, motive for use vs. perceived harmfulness of drugs, 
resistance efficacy); 
g)   academic involvement (poor vs. good); 
h)   genetic factors. 
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Verweij and colleagues (2010) carried out two meta-analysis (by distinguishing 
between males and females) of existing twin studies, in order to provide a more 
accurate estimate of the magnitude of genetic and environmental influences on 
cannabis use initiation and problematic cannabis use. The influence of genes in 
initiating cannabis use (results from the sum of allelic effects) was estimated to 
account for 48% of the variance for males (51% for problematic use) and 40% for 
females (59% for problematic use). Shared environment (family environment, 
prenatal influences, parental style and socio-economic status) explained the 25% of 
the variance in males (20% for problematic use) and 39% in females (15% only for 
problematic use); unshared environment (e.g. idiosyncratic events and experiences, 
unshared peers) accounted for 27% of the variance for males (29% for problematic 
use) and 21% of the variance in females (26% for problematic use). This study 
concludes that heritability is the most important factor in determining initiation and 
especially problematic use (with a substantial overlapping).  
Furthermore, while the initial stages of the process of cannabis use are more 
sensitive to environmental factors (drug availability and use by peers), the 
likelihood of dependence could be more influenced by genetic factors (Verweij et 
al., 2010). 
Genetic factors, coupled with early environment, could also explain 
temperamental attitudes and variables with more cognitive implications – poor self-
control i.e. executive functions – that could, in turn, explain other risk-factors as, for 
example, deviant peer affiliation, lack of coping strategies and more lifetime stress. 
On the other hand, good self-control could have protective effects through 
promoting better academic competence (Novak & Clayton, 2001; Wills, Sandy, 
Yaeger, & Shinar, 2001; Wills & Stoolmiller, 2002).  
For example, Wills and colleagues (2008) assessed planning and problem solving 
abilities in a 1,810 subjects baseline-sample – over the period from 11 to 15 years of 
age – as a buffering factor for the impact of three different risk factors: family life 
events (those occurring directly to a family member), adolescent life events (those 
occurring directly to the adolescent him/herself), and peer substance use (tobacco, 
alcohol, and marijuana). For each risk factor, subjects with higher scores on good 
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self-control showed less impact of that risk factor on their level of substance use, 
both concurrently and longitudinally (Wills, Ainette, Stoolmiller, Gibbons, & 
Shinar, 2008). 
Once again, the impact on executive functions shown in studies on long-term 
cannabis effect (see Figure 6), could reflect some premorbid predisposition to 
cannabis use rather than a pure consequence of it. The impairment in executive 
functions could have consequences in the academic and the social adaptation fields 
by predisposing to a lesser capability to refuse the substance in a context where 
peers are using it (Wills et al., 2008). This could be useful in explaining the findings 
about premorbid social adjustment, IQ and premorbid academic adjustment, which 
are variables of interest in the context of this work. 
 
6.3.1. Do Relationships Increase Opportunities for Cannabis Use? 
 
Peer influence seems to be one of the most important predisposing factors to 
drug-use initiation (Bauman & Ennett, 1996; Vervaeke, van Deursen, & Korf, 
2008). The idea that peer pressure in using drugs or peer selection is significant, has 
been sustained by different authors.  
Peer influence has been shaped on a “social influence paradigm”, which states 
that peers contribute to adolescent drug use by modeling drug use, by shaping 
norms, attitudes and values, and by providing opportunities and support for drug use 
(M. Allen, Donohue, Griffin, Ryan, & Turner, 2003; Chabrol, Mabila, Chauchard, 
Mantoulan, & Rousseau, 2008; Graham, Marks, & Hansen, 1991; Guxens, Nebot, 
Ariza, & Ochoa, 2007; Scherrer et al., 2008).  
Bauman and Ennet (1996) have suggested that failure to control for selection 
effects, when examining the association between drug behaviours of friends and 
individuals’ drug-use, may overestimate peer influence. In fact, friendships are also 
determined by drug use, i.e. drug users choose other users to be friends and vice-
versa, thus reinforcing each other. Another reason of concern, in auto-reported data 
on friends’ behaviour, is that adolescents tend to attribute their own choice to 
friends (Bauman & Ennett, 1996).  
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Peer selection has also been supported by a genetic-twin study (Gillespie, Neale, 
Jacobson, & Kendler, 2009) that collected data at three stages from 15 to 25 years. 
Authors suggested a direction to causality: a combination of genetic and 
environmental factors is able to explain inclination to cannabis use that, in turn, 
influences the liability to affiliate with deviant peers. 
Both socialization and selection might provide crucial influence on adolescent in 
an interactive way (Simons-Morton & Farhat, 2010) especially in the context of 
different patterns of cannabis use.  
 
6.3.2. Does School Prevent Individuals from Smoking Cannabis? 
 
There are generally consistent findings among studies on the effects of cannabis 
that suggest that its early use reduces the likelihood of progressing further in formal 
education (Macleod et al., 2004; Townsend, Flisher, & King, 2007).  
Linking to the abovementioned issue, Newcomb et al. (1988), surveyed 
participants from middle school, until young adulthood. Once more, social 
nonconformity predicted daily cannabis use, which anticipated a poor academic and 
vocational adjustment (Hays & Revetto, 1990; Newcomb & Bentler, 1988). 
However, the direction of this association has been an issue of debate. 
While some studies suggest a link between academic failure and subsequent 
cannabis use (Apantaku-Olajide, James, & Smyth, 2014; Krohn, Lizotte, & Perez, 
1997; Lee, Winters, & Wall, 2010), Fergusson’s team controlled for several 
confounders and did not confirm this pathway (Fergusson & Horwood, 1997; 
Fergusson, Lynskey, & Horwood, 1996; Fergusson, Norwood, & Beautrais, 2003); 
they also suggested that it is likely that this association reflected the effects of the 
social context within which cannabis is used, rather than any direct effect of 
cannabis on cognitive ability or motivation, and that its effect is greater between 
frequent and early smokers (Fergusson et al., 2003).  Esch and colleagues (2014) in 
a recent review of 51 studies, after controlling for socio-demographic, family and 
academic factors, found that adolescents who use cannabis before the age of 16 
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were up to five times more likely to drop out of secondary school than their peers 
who did not consume any drugs (Esch et al., 2014). 
In a later review on this subject, Townsend and colleagues (2007) pointed out 
some potential confounders, such as social disadvantage or living in rural or urban 
area, difference in drop-out from school definitions and different measures of 
substance use across studies. Nevertheless, the main findings of the study indicated 
a largely consistent relationship between substance use and dropping out of high 
school, where the former preceded the latter (Townsend et al., 2007).  
The problem of social disadvantage has been addressed specifically by Meier et 
al., (2015) who followed youth from an upper middle class community through the 
four years of high school, in order to rule-out the confounding effect of low 
socioeconomic status in the link between cannabis use and poorer academic 
performance. They confirmed the associations between cannabis use and inferior 
educational achievement and greater externalizing behavior, especially if the use 
was persistent through the four years of the study (Meier, Hill, Small, & Luthar, 
2015). Nevertheless, this study was not able to disentangle the effect of cannabis 
and alcohol.  
This question was recently studied by Silins et al. (2015), who examined three 
longitudinal studies from Australia and New Zealand. An at least weekly adolescent 
cannabis use was associated with two-fold increases in the odds of high school non-
completion and university non-enrolment, and accounted for a greater proportion of 
variance than adolescent alcohol use (Silins et al., 2015). 
Once again, could be interesting to examine separately cannabis abuse and 
cannabis recreational use, in relation to premorbid adjustment, in order to see the 
direction of this association.  
 
 
7. Cannabis and Psychosis 
 
Despite the failure to find a certain association between cannabis use and long-
lasting detrimental effect on general IQ, it is very difficult to believe that a 
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psychotropic substance acting on the endocannabinoid system and through it 
important neurotransmitters such as acetylcholine, dopamine, GABA, glutamate, 
serotonin (Grotenhermen, 2004) does not have any neuropsychological effects in 
the long term.  
Its effects may be so subtle that they are difficult to detect (Gonzalez, 2007), or 
alternatively cannabis may be relatively innocuous for most people, but quite toxic 
for the occasional individual (H. Pope, Gruber, Hudson, et al., 2001), depending on 
dose, type of cannabis used, of onset of use (Solowij & Pesa, 2010) gender (Crane 
et al., 2013), and genetic susceptibility. 
Cannabis use is prevalent among people with first episode psychosis. One study 
in South London showed its use has increased markedly between 1965 and 1999, 
and disproportionately so compared to increase in cannabis use in other psychiatric 
disorders (Boydell et al., 2006). A recent meta-analysis reported an estimated 
prevalence of current cannabis use in people with first episode psychosis of 33.7% 
(35 samples, 95% confidence interval: 31%, 39%), with an initiation of regular use 
that starts 6.3 years before the onset of psychosis (10 samples, standardized mean 
difference = 1.56, 95% confidence interval: 1.40, 1.72) (Myles, Myles, & Large, 
2016).  
The causal association between cannabis use and psychosis was first formally 
studied by Andreasson and colleagues in 1987 (Andréasson, Engström, Allebeck, & 
Rydberg, 1987). Nowadays we know from subsequent replications of these results, 
that there are strong enough evidences of the fact that risk of psychosis is 
augmented by cannabis use (Moore et al., 2007; Potvin & Amar, 2008; Gage, 
Matthew, & Zammit, 2015). 
Two meta-analyses estimated that cannabis consumption is associated with 
approximately twofold increased risk of developing a psychotic disorder (Henquet 
et al., 2005; Moore et al., 2007). 
Cannabis may lead to an earlier age of onset of the illness and, interestingly, the 
difference by gender in age of onset appears to be reduced in cannabis users (Di 
Forti et al., 2009, 2014; Donoghue et al., 2014). An earlier onset of the disease is 
more likely if cannabis use starts in early adolescence, with a pattern of daily use of 
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high potency cannabis (Casadio et al., 2011; Di Forti et al., 2009, 2014; Large, 
2011). In a recent analysis on patients aged 18-65 years, presenting to the South 
London and Maudsley NHS Foundation Trust, with first-episode psychosis, the 
population attributable fraction of first-episode psychosis for high-potency cannabis 
use was 24% (95% confidence interval: 17, 31) and much higher than the risk 
associated with use of hash (Di Forti et al., 2015). That means that a portion of 
psychosis could be prevented if heavy cannabis use was avoided (Di Forti et al., 
2015). Van Os and colleagues reported a three times higher risk of developing 
psychotic symptoms in the general population, associated to cannabis consumption 
(NEMESIS study, van Os et al., 2002). Experiments, have shown that healthy 
people who are administered THC intravenously are more likely to develop 
transient psychotic-like experiences (Morrison et al., 2009) and that THC worsens 
psychotic symptoms in people suffering from psychosis (D’Souza et al., 2004).  
In summary, cannabis use is responsible for an increased risk of both the onset of 
psychosis in previously psychosis-free people (Murray & Di Forti, 2016) and poor 
prognosis for those with an established vulnerability to psychotic disorder (van Os, 
2002; Schoeler et al, 2015).  
Individual predisposing genetic factors that increase vulnerability, or resilience, 
to the effects of cannabis have been reported to include a functional polymorphism 
in the catechol-O-methyltransferase (COMT Val158Met) gene (which has a role in 
the catabolism of dopamine in the prefrontal cortex) along. However, this 
mechanism is not fully understood and remains controversial. Another suggestion 
concerns genetic variation at rs2494732 of AKT1 (involved in the dopamine 
neurotransmission) as influencing the risk of developing a psychotic disorder in 
cannabis users (Di Forti et al., 2012; van Winkel, 2011). Another study indicated 
that a variant in the dopamine D2 receptor gene may also increase psychosis risk 
(Colizzi et al., 2015). These two mechanisms, involving postsynaptic genes, are 
compatible with the hypothesis of a postsynaptic supersensitivity in cannabis-
related psychosis (Murray, Mehta, & Di Forti, 2014). 
A recent meta-analysis on a sample of over 32,000 individuals from genome-
wide association studies (GWAS), has identified four genes as involved in lifetime 
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cannabis use (NCAM1, CADM2, SCOC and KCNT2) with a high degree of genetic 
sharing with lifetime cigarette smoking (Stringer et al., 2016).  
A pattern of genetic vulnerability to psychosis could also predispose subjects to 
cannabis use, as was suggested in a recent study on 2,082 healthy individuals 
conducted by Power and colleagues (R. A. Power et al., 2014), but further studies 
are required to clarifying this question. 
 
7.1. Cannabis, Psychosis and IQ 
 
Surprisingly, three different meta-analyses on cognition and cannabis, among 
schizophrenic patients, found better cognitive performance in patients with a 
lifetime use of cannabis (Potvin et al., 2008; Rabin et al., 2011; Yücel et al., 2012). 
This counterintuitive finding, coupled with the fact that most psychotic patients 
suffer from cognitive impairment (Reichenberg et al., 2009) make it more difficult 
to understand the relatioinship between these two risk factors.  
Two different explanations have been advanced for this finding. The first 
suggests that those psychotic subjects who use cannabis have less premorbid 
cognitive impairment than those who do not. This could be because good premorbid 
functioning is necessary to acquire and sustain an illegal drug habit (Joyal et al., 
2003; Rodríguez-Sánchez et al., 2010; Stirling et al., 2005) or because cannabis use 
increases the risk of psychosis in a subgroup of patients with less 
neurodevelopmental vulnerability (de la Serna et al., 2010; Ferraro et al., 2013; 
Leeson, Harrison, et al., 2011; Løberg & Hugdahl, 2009; Schnell et al., 2012, 2009; 
Yücel et al., 2012). 
A second possible explanation, based on research in vitro and in vivo into animal 
models of Parkinson’s disease and Alzheimer’s disease, suggests that some 
cannabinoids (i.e. CBD) have a neuroprotective action by activating CB-receptors 
that possesse anti-inflammatory properties and inhibits microglia-mediated 
oxidative stress (Binukumar et al., 2015; Chung et al., 2011; Gómez-Gálvez et al., 
2016; Martín-Moreno et al., 2011; Ramírez et al., 2005), which may help to prevent 
psychosis-related cognitive decline (Jockers-Scherübl et al., 2007; Løberg & 
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Hugdahl, 2009). For example Martín-Moreno et al. (2011) showed that CBD, after 
subchronic administration for 3 weeks, was able to prevent learning of a spatial 
navigation task and cytokine gene expression in β-amyloid-injected mice, by 
modulating microglial cell function. Gómez-Gálvez et al. (2016) provided 
evidences on the up-regulation of CB2 receptors in glial elements in postmortem 
tissues of PD patients, in relation with the activation of microglial cells and also 
towards certain capability of these cells to generate proinflammatory factors. 
This alternative explanation has recently gained greater attention from 
considering the CBD component as part of the treatment in several neurological 
disorders, such as multiple sclerosis, neurodegenerative disorders and stroke, pain 
treatment, epilepsy, dystonia, and tics, but also anxiety, drug abuse, autism and 
schizophrenia (for a deepest look see Cannabinoids in the Treatment of 
Neurological Disorders, by  Devinsky, Whalley, & Di Marzo, 2015).  
Furthermore, an increasing number of human studies have been performed to 
provide insight into the antipsychotic properties of CBD (Iseger & Bossong, 2015; 
Schubart et al., 2014; Zuardi et al., 2012). It has been reported that pre-treatment 
with CBD inhibits THC-elicited psychosis and cognitive impairment in healthy 
subjects (Englund et al., 2013). In fact, Δ-9-THC and CBD can have opposite 
effects on regional brain function, which might underlie different symptomatic and 
behavioural effects, and CBD’s ability to block the psychotogenic effects of Δ-9-
THC (S. Bhattacharyya et al., 2010).  
Data observation suggests that while studies on animal models could precisely 
measure the proportion between Tetrahydrocannabinol (THC) and Cannabidiol 
(CBD), types of cannabis that are encountered by real-world users have a wide 
range of THC:CBD ratios (R. J. M. Niesink & van Laar, 2013).  
A recent report suggest that adolescents (13-18 years old) engaged in regular 
marijuana use can raise their expected odds of experiencing subsequent subclinical 
psychotic symptoms up to 133% and this effect can persist even when they stopped 
using marijuana for at least one year (Bechtold, Hipwell, Lewis, Loeber, & Pardini, 
2016). Also, healthy people who smoke higher THC concentration cannabis are 
more likely to develop psychosis-like symptoms (like for example paranoia) (C. J. 
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A. Morgan & Curran, 2008) even with a recreational pattern of use (Craig Morgan 
et al., 2012).  Additionally, among the tiny percentage of smokers who develop 
psychosis, the increasingly preferred variety used is skunk (Di Forti et al., 2009), 
which has a relatively high concentration of THC.  
Therefore, there is not enough evidence to sustain the possibility that paradoxical 
effects of recreational cannabis use, frequently observed in naturalistic studies with 
psychotic patients, are derived from a neuroprotective action of CBD on the brain. 
Other insights, regarding the first of the two hypothesis, are provided from 
studies that report that different patterns of cannabis use are differently related to 
cognition, i.e. that any lifetime use of cannabis is associated with a better cognitive 
performance (Meijer et al., 2012; Rabin et al., 2011; Yücel et al., 2012), while 
current cannabis use is associated with poorer performance (Meijer et al., 2012). 
Buchy and colleagues (2015) have recently suggested that people at clinical high 
risk for psychosis, who were late-onset users, showed significantly higher IQ than 
those who were early-onset users (Buchy et al., 2015). 
These data suggest that, age at onset of cannabis or frequency of its use may be 
important factors for IQ, and that lifetime cannabis-using individuals might 
constitute a subgroup with a higher cognitive potential. 
 
7.2. Cannabis, Psychosis and Premorbid IQ 
 
To my knowledge, only one study (Leeson, Harrison, et al., 2011) has found 
higher premorbid IQ in patients who smoked cannabis –among 99 subjects at their 
first episode of psychosis– using the Wechsler Test of Adult Reading (WTAR) 
(Holdnack, 2001) as an estimated measure of premorbid IQ. Other studies 
(DeRosse, Kaplan, Burdick, Lencz, & Malhotra, 2010; Helle et al., 2015; Jockers-
Scherübl et al., 2007; Ringen et al., 2013; Sevy et al., 2007; Tosato et al., 2013; 
Yücel et al., 2012) that have incidentally examined premorbid IQ in psychosis in 
relation to cannabis use have reported inconsistent findings, probably due to their 
small sample size and other methodological problems. In a recent pilot study (in 
Chapter 4), my colleagues and I  found strong evidence for a better IQ, a better 
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premorbid IQ and a minor deterioration in IQ from premorbid IQ in FEP patients 
who had used cannabis in their lifetime (Ferraro et al., 2013).  
 
7.3. Cannabis, Psychosis and Premorbid Adjustment 
 
Cognition has been established as a predictor of real world community 
functioning in schizophrenia (Evans et al., 2003; M. F. Green et al., 2000). 
However, studies on the relationship between cannabis use and neurocognitive 
functioning in psychosis, which have controlled for the potential bias of premorbid 
functioning, are rarely represented in this context and often inconclusive.  
Ringen et al. (2013), in a naturalistic study of 364 patients with schizophrenia 
spectrum disorder – from catchment areas in Oslo, Norway – reported that cannabis 
use, detected in the urine of 21 patients, was associated with significant dysfunction 
in several neurocognitive domains, independent of a current diagnosis of cannabis 
abuse. However, level of premorbid functioning explained the associations for all 
measures. They concluded that differences in premorbid functioning may explain 
apparent differences in neurocognitive function between schizophrenia spectrum 
patients using cannabis or not and that illness-related traits, present early in life, can 
affect both later cannabis use and neurocognition (Ringen et al., 2013).  
Gonzalez-Blanch et al. (2015) suggested that cannabis misuse (defined as 
meeting DSM-IV-TR criteria for cannabis abuse or dependence) is not associated 
with social functioning at baseline. Nevertheless, over a 30-month follow-up, first 
episode psychosis patients without cannabis use disorder showed significant 
improvements in their social functioning, whereas patients with cannabis misuse at 
baseline displayed no such improvement. They adjusted their analysis for potential 
confounders, such as age, gender, negative symptoms, premorbid functioning, 
DSM-IV diagnoses, baseline social functioning and other substance use (González-
Blanch et al., 2015). Both these studies, have found worse actual and premorbid 
social functioning in patients with current or heavy cannabis use. Conversely, Sevy 
et al., (2010) have incidentally found among 49 first-episode schizophrenia subjects 
with cannabis use disorder (cannabis abuse or dependence), that use of cannabis 
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commonly started before the onset of positive symptoms and that subjects were 
predominantly male, younger at study entry, had a better premorbid childhood 
social adjustment, a trend for poorer premorbid childhood academic adjustment, 
earlier age at onset of positive symptoms, less educational attainment, a lower self-
socioeconomic status, less motor abnormalities but more severe hallucinations and 
delusions, compared to non-substance abusing subjects (Sevy et al., 2010). In line 
with these findings, Compton et al., (2011) reported that psychotic patients having 
used cannabis at ≤15 years, had better social functioning in their early adolescence 
than those who had not, whilst those who had used cannabis later, but before 18 
years, had poorer late adolescence academic functioning (Compton, Broussard, 
Ramsay, & Stewart, 2011). Neither of these two studies considered cognition, so it 
is difficult to establish a continuity of their finding with those reporting a better IQ 
in psychotic patients who used cannabis. Furthermore, they report a worse academic 
adjustment, which remains unexplained.  
In conclusion, current cognitive abilities of subjects who smoked cannabis are 
reliable only if assessed after a prolonged time of abstinence. Eventual long-term 
impairment observed after this period could reflect the consequence of a complex 
premorbid gene-early environmental predisposition.  
This predisposition can influence the initial contact with the substance and a 
particular pattern of cannabis use, moderated by other environmental factors. This 
could be true even for clinical samples since, according to the neurodevelopmental 
theory of schizophrenia (Murray & Lewis, 1987), the neurocognitive impairment in 
psychosis remains stable after the onset of the illness (Bora & Murray, 2014). 
Similarities between clinical and non-clinical samples are also given from the fact 
that patients with psychosis use cannabis for the same reasons the general 
population does, to “get high”, relax and have fun (Kolliakou, Joseph, Ismail, 
Atakan, & Murray, 2011), but also for affect regulation and socialization (Dekker, 
Linszen, & De Haan, 2009; B. Green et al., 2004).  
Some of these points will be taken into account and further examined by 
generating the hypothesis of this work of thesis in the next chapter. 
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Chapter 2 
Aims and Hypotheses  
 
 
 
1. Introduction  
 
Following on the literature just reviewed, studies on cannabis use and cognitive 
impairment associated with schizophrenia have mostly reported better cognitive 
performance among patients with psychosis who have used cannabis than in those 
who have not.  
The main objective of the work presented in this thesis is to explore this 
association in an epidemiologically-derived case-control study in a sample derived 
from The European Network of National Schizophrenia Networks Studying Gene-
Environment Interactions (EU-GEI) and to address some unresolved issues.  
I will now clarify the hypotheses and the aims of my Thesis.  
 
 
2. Thesis Aims and Hypotheses  
 
As discussed in the previous chapter, two different explanations have been 
advanced for this counterintuitive finding: a “premorbid-driven hypothesis” and a 
“neuroprotective-derived hypothesis”.  
In this work of Thesis, I am going to test the first of these two hypotheses, with 
the aim of exploring IQ and premorbid conditions and how they are related to 
cannabis use in patients at their first episode of psychosis (FEP), by comparing 
those cannabis using patients to non-users and to their respective healthy controls.  
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The main hypothesis is that psychotic patients who used cannabis in their 
lifetime have higher IQ scores and	  better premorbid adjustment than those who do 
not, depending from their pattern of cannabis use, as is better listed below.  
 
2.1. Data derived from different Countries 
 
Given that the prevalence, and patterns, of cannabis use are culturally driven, I 
wanted to study FEP cannabis-using and non-using cases and controls coming from 
different European countries (United Kingdom, Italy, Spain, France, Netherlands) 
as part of the EU-GEI study. I expect that “Country” will significantly affect the 
relationships between the variables of interest. 
 
2.2. Cognition and premorbid adjustment of cases compared to controls 
 
To compare IQ scores in cases and controls. I expect that cases will show a 
greater cognitive impairment (i.e. lower IQ) than controls overall, independent of 
potential confounders and across all countries. 
To analyse the main two components of the premorbid adjustment scores 
(Premorbid Social Adjustment and Premorbid Academic adjustment) (D. N. Allen 
et al., 2001; Barajas et al., 2013), i.e. the Premorbid Academic Factor (PAF) and the 
Premorbid Social Factor (PSF) and to compare them in cases and controls.  
I expect that cases will be more socially and academically impaired in their 
premorbid period (i.e. before 16 years) than controls overall, independent of 
potential confounders and across all countries. 
 
2.3. Pattern of cannabis use of cases compared to controls 
 
To compare pattern of cannabis use (i.e. lifetime prevalence, frequency, age at 
first use, current use, mode of use, etc.) of cases and controls.  
I expect that cases will be more likely to have smoked high potency cannabis, 
starting at an earlier age and with a higher frequency overall (Di Forti et al., 2014). 
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2.4. IQ and premorbid adjustment in cases that used cannabis in their lifetime 
compared to those who did not and to their respective healthy controls 
 
To compare the main effects and interaction terms of lifetime cannabis use 
(yes/no) and group belonging (cases or controls) on IQ, PAF and PSF scores (i.e. 
three different ANCOVAs).  
I expect that cases who used cannabis in their lifetime will be less cognitively 
impaired (i.e. higher IQ) than those who did not, independent from potential 
confounders. I also expect that they will show a better premorbid adjustment.  
 
2.5. Premorbid adjustment and IQ in cases who never used cannabis in their 
lifetime compared to those who used cannabis on a daily basis or less than 
everyday and to their respective healthy controls 
 
To cluster the sample according to “frequency of cannabis use”. 
To compare the main effects and the interactions terms of cannabis use, by 
frequency (never, less frequently than everyday and everyday) and group (case or 
controls) on IQ, premorbid social (PSF) and academic adjustment (PAF) scores (i.e. 
one MANOVA with three outcomes, controlled for sociodemographic main 
variables and Country). I expect to find a better premorbid adjustment (both social 
and academic) in cases who smoked cannabis in their lifetime “less frequently than 
everyday”, compared to people who smoked cannabis “everyday” and to people 
who did not smoke cannabis at all in their lifetime. 
 
The final aim of this work is to identify the relationship between IQ, premorbid 
social and academic adjustment with cannabis use in psychotic patients, compared 
to healthy controls, in order to be able to explain in which cases you can expect a 
better IQ and a better premorbid adjustment and why.  
I hypothesize a subgroup of patients with a recreational use of cannabis, who are 
less cognitively impaired at the onset and less socially withdrawn in the premorbid 
period than other patients. 
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Chapter 3 
Methods and Statistical Analyses 
 
 
 
1. Introduction  
 
In this chapter I will outline the general methodology for the study, run in 
different European Countries, where patients and controls were recruited from the 
1st of May 2010 to 30th of June 2015. This work was born because of the interest in, 
and thanks to the collaboration with two research studies conducted at the Institute 
of Psychiatry, Psychology and Neurosceince, King’s College of London: Genetic 
and Psychosis (GAP) study and The European Network of National Schizophrenia 
Networks Studying Gene-Environment Interactions (EU-GEI) project. Both these 
studies have been also conducted in Palermo, in which I had the opportunity to be 
involved, as part of the research team. In 2008, the Psychiatric Section of Palermo 
University Department of “Biomedicina Sperimentale e Neuroscienze Cliniche” 
(Bionec), started the Sicilian Genetic and Psychosis (SGAP) project, an incidence 
and a case control study aimed at: a) collecting epidemiological data on the 
incidence of psychotic disorders in Palermo and at b) identifying the role of putative 
environmental and genetic risk factors in the risk of developing psychoses. In 2010 
the Palermo research team joined the EU-GEI, one of the largest European first 
episode psychosis studies, investigating the interaction between genetic and 
environmental factors potentially involved in increasing the risk of psychotic 
disorders (www.eu-gei.eu). The pilot study (Chapter 4) was framed into the first of 
these two studies (SGAP), while the present work of thesis forms part of the EU-
GEI study, which will be presented in the next paragraph. 
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2. The European Network of National Schizophrenia Networks Studying Gene-
Environment Interactions Project (EU-GEI)  
 
The aim of EU-GEI is to identify, over a 5-year period, the interactive genetic, 
clinical and environmental determinants involved in the development, severity and 
outcome of schizophrenia. EU-GEI has employed family-based, multidisciplinary 
research paradigms. The overall aim of EU-GEI is the identification and 
translational application of clinical, genetic, and environmental interactions in the 
development, severity, and course of schizophrenia in patients and their families.  
To this end, several work packages have been established, and expertise from 
multiple disciplines has been focussed on addressing contemporary challenges in G 
× E research (European Network of National Networks studying Gene-Environment 
Interactions in Schizophrenia (EU-GEI) et al., 2014) (see Figure 9).  
 
Figure 9. General Approach and Overview of the EU-GEI project. 
 
Legend: the red square identifies the Work Package in which is framed the aim of this work of thesis 
(European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-
GEI) et al., 2014) 
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In order to reach these goals, EU-GEI has assembled a multidisciplinary team of 
top schizophrenia researchers (by a Consortium Agreement), who have the range of 
skills required to deliver a program of research and who have access to collect a 
number of unique European samples. (Project Final report, version 30.06.2015, in: 
www.eu-gei.eu). The project was organized and coordinated by Professor Jim Van 
Os (University of Maastricht). The partners in EU-GEI represent the nationally 
funded schizophrenia/mental health networks of more than 15 European and non-
European countries (EU-GEI affiliated centers) (see Figure 10).  
   
Figure 10. Map of Partners in EU-GEI project. All Work Packages. 
 
Legend: P1 - Universiteit Maastricht / MUMC Prof. Jim van Os (Coordinator) Dr. Bart Rutten (Vice-Coordinator); P2 - King’s 
College London / IoP Prof. Philip McGuire (WP5 leader) Craig Morgan (WP2 leader); P3 - Cardiff University / CU Prof. Michael 
O’Donovan (WP3 leader); P4 - Central Institute of Mental Health / CIMH Prof. Andreas Meyer-Lindenberg (WP4 leader); P5 - 
Ankara Universitesi / AU Prof. Meram Saka (WP6 leader); P7 - Servicio Madrileño de Salud / SERMAS Dr. Celso Arango (WP10 
leader); P8 - Academisch Medisch Centrum – Universiteit van Amsterdam / AMC Prof. Lieuwe de Haan (WP11 leader); P9 - 
Institut National de la Santé et de la Recherche Medicale / INSERM Prof. Marion Leboyer; P10 - Katholieke Universiteit Leuven / 
KU Leuven Prof. Marc De Hert; P11 - University Mental Health Research Institute / UMHRI Prof. Nicholas Stefanis; P12 - 
Medizinische Universität Wien / MUW Prof. Gabriele Sachs; P13 - Universität Basel / UB Prof. Anita Riecher-Rössler; P14 - 
Universität zu Köln – Universitätsklinikum / UK Prof. Joachim Klosterkötter; P15 - SERMES Planificacion / SERMES Dr. Antonio 
Berlanga; P17 - Wingz b.v. / WINGZ John Veeren; P18 - E.C.S. International BV / EIB Peter Emonds; P19 - Omega Pro Proje 
Arastirma Gelistirme ve Danismanlik Ltd Þti / Omega Pro Dr. Murat Hayran; P20 - Mediamens B.V. / Mediamens Daniëlle 
Dohmen; P21 - The University of Hong Kong / UHK Prof. Pak Chung Sham (WP8 leader); P22 - Universidad del Pais Vasco / UPV-
EHU Dr. Aitzibar Emaldi (WP9 leader); P23 - The Chancellor, Masters and Scholars of the University of Cambridge / CMSUC 
Prof. Peter Jones, Dr James Kirkbirde; P24 - Royal College of Surgeons in Ireland / RCSI Prof. Mary Cannon; P25 - Ludwig-
Maximilians-Universität München / LMU Prof. Dan Rujescu; P26 - Alma Mater Studiorum – Universita di Bologna / UNIBO 
Prof. Ilaria Tarricone; P27 - Universita Degli Studi di Palermo / UNIPA Prof. Daniele La Barbera; P28 - University of Melbourne / 
UOM Prof. Patrick McGorry. Project Final report, version 30.06.2015, in: www.eu-gei.eu. 
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The project was funded by the European Community’s Seventh Framework 
Programme, under grant agreement No. HEALTH-F2-2010-241909 (Project EU-
GEI). The specific outline of the project is shown in Figure 11: it is focused on the 
effects of gene-environment interactions on brain pathways and psychological 
vulnerability, and how these cerebral and psychological pathways mediate subtle, 
but measurable, behavioural expressions of vulnerability for psychotic disorder.  
 
Figure 11. Outline of the EU-GEI project. 
 
 
(EU-GEI general press, in www.eu-gei.edu) 
 
An important aspect of the project is the development of tools that allow for the 
actual measurement of the behavioural expression of vulnerability that is caused by 
gene-environment interactions. This makes it possible to monitor, and possibly 
modify, vulnerability at the behavioural level, thus preventing transition to overt 
illness. For example, European enterprises and start-ups in EU-GEI are working on 
new technologies (i.e. PSYMATE) allowing for momentary assessment of subtle 
alterations in mood, thinking, perception and volition in response to small stressors 
in the flow of daily life for patients. (EU-GEI, 2009-gei.edu). 
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3. Study design  
 
This is a case-control design where cases are individuals with a first episode of 
psychosis (FEP) and controls are individuals without psychosis recruited from the 
same geographical area as the cases.  
This work of this Thesis framed into the Work Package 2 of the project, the 
“Functional Enviromics” that was specifically designed to generate, in each site, 
samples of first episode cases and of population based controls with extensive 
information on exposure to a full range of environmental factors, and their 
interaction across the life course on odds (risk) of psychotic disorder. It has 
developed and applied methods for the detailed assessment of candidate, individual- 
and area-level environmental exposures of public health relevance.  
This work package further aims, together with “Discovery Genetics” and “G × E 
Data & Statistics,” to examine evidence for hypothesized genes x environment G × 
E and environment × environment (E × E) interactions, the latter being the 
framework for this work (see Figure 9) (European Network of National Networks 
studying Gene-Environment Interactions in Schizophrenia (EU-GEI) et al., 2014).  
2,553 incident cases were identified across all sites. This constitutes the largest 
and most extensive case-control study of first episode psychosis ever conducted 
(Project Final report, version 30.06.2015, in: www.eu-gei.eu). 
For the purpose of this study, the main analyses are conducted firstly on cases 
and controls exposed or not exposed to the risk factor of cannabis use and secondly 
on cases and controls separated according with different pattern of frequency, as is 
shown in Figure 12.  
Premorbid adjustment and IQ were considered as continuous measures, that 
result from a Gene-Environment Correlation – rGE (Jim van Os, Rutten, & Poulton, 
2008) and therefore have been used as main outcomes of this model. 
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Figure 12. Study Design. 
 
 
 
 
 
 
 
 
Legend: The figure describes the study design, a case control study where firstly patients and controls 
exposed vs. not exposed to the risk-factor of cannabis use are compared each other and secondly, different 
levels of cannabis exposure are considered in this comparison. 
 
 
4. Cases  
 
Cases were defined as people resident within a clearly defined catchment (study) 
area for a period of at least 6 months, aged 18-64 years and affected by a first 
episode of psychosis (even if long-standing) with a diagnosis of schizophrenia 
(F20); other non-affective psychoses (Schizophreniform disorder - F21; Delusional 
disorder - F22; Brief psychotic disorder - F23; Schizoaffective disorder - F25; 
Psychotic disorder not otherwise specified - F28, F29) or affective psychosis 
(Bipolar disorder with psychotic features - F312, F315; Major depressive disorder 
with psychotic features - F323, F333) (World Health Organization, 1992) during the 
study period. We excluded subjects with evidence of psychotic symptoms 
precipitated by an organic cause or transient psychotic symptoms resulting from 
acute intoxication as defined by ICD-10, illegal migrant or people who have 
received a treatment with anti-psychotic medication for an episode of psychosis 
outside of the study period (See Table 5). Age at first onset was defined as the age 
the subject had at the time of the first access to psychiatric services. 
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Table 5. Inclusion and Exclusion Criteria for Cases. 
Cases Inclusion 
1. Age 18 to 64.  
2. Resident within a clearly defined catchment (study) area for a period of at least 6 months.  
3. Presence of an untreated first episode of psychosis (even if long-standing) (ICD-10: F20-29; F30-33 
[psychosis codings]) during the study period.  
Cases Exclusion 
1. Age under 18 or over 64  
2. Resident within a clearly defined catchment (study) area for a period of less than 6 months.  
3. Treatment with anti-psychotic medication for an episode of psychosis outside of the study period.  
4. Evidence of psychotic symptoms precipitated by an organic cause.  
5. Transient psychotic symptoms resulting from acute intoxication as defined by ICD-10. 
6. Illegal migrant (i.e., no legal right to remain in country). 
Project Final report, version 30.06.2015, in: www.eu-gei.eu. 
 
A screening was run on all the subjects aged 18 to 64 years old with a first 
episode of psychosis (defined as the first contact with any psychiatrist) presenting 
from the 1st of May 2010 to 30th of June 2015 at the mental health services of each 
catchment area. For example, the catchment area in Palermo was the whole city. All 
inpatient units (five), private psychiatric hospitals (four) and outpatient services 
(five) were examined through a weekly contact. 
The five inpatients and the five outpatients units in Palermo are part of the public 
regional mental health service system (Azienda Sanitaria Provinciale of Palermo, 
Azienda Ospedaliera Universitaria Policlinico, Azienda Ospedale Civico ARNAS, 
Azienda Ospedali Riuniti Villa Sofia e Ospedale Cervello) while four private 
hospitals (Villa Margherita, Villa Serena, Casa di Cura d’Anna, Casa di Cura 
Stagno) are private psychiatric clinics which are in the network of the regional 
public mental health system. All people can receive care in both public and private 
units because they don’t have to pay to receive psychiatric care. 
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5. Controls  
 
During the same study period, a control group of healthy volunteers was 
recruited from the local population living in the same catchment area, through a 
quota sampling able to collect a control group rapresentative of the general 
population in that area. 
Controls were aged 18 to 64, resident within a clearly defined catchment (study) 
area for a period of at least 6 months (the same as the cases) and had not evidence 
of current or past psychosis (including treatment with antipsychotic medication), 
otherwise they were excluded (See Table 6). 
 
Table 6. Inclusion and Exclusion Criteria for Cases. 
Controls Inclusion  
1. Age 18 to 64.  
2. Resident within a clearly defined catchment (study) area for a period of at least 6 months.  
3. No evidence of current or past psychosis (including treatment with antipsychotic medication).  
Exclusion  
1. Age under 18 or over 64.  
2. Resident within a clearly defined catchment (study) area for a period of less than 6 months.  
3. Current or past psychotic disorder (or treatment within antipsychotic) (including diagnosis or treatment 
within time frame of the study). 
4. Illegal migrant (i.e., no legal right to remain in country). 
Project Final report, version 30.06.2015, in: www.eu-gei.eu. 
 
The recruitment of controls was advertised through Internet, newspaper 
advertisements, leaflets placed in churches, gyms, private residences (by local 
community survey, using publicly available household lists as sampling frames) and 
previous databases of volunteers, using quota sampling to ensure they were broadly 
representative of the population at risk in terms of age, gender, migrant status, level 
of education and employment status.  
Quota sampling basically segments the catchment (study) area population (using 
population statistics) to determine the proportion of the local population in certain 
categories (e.g. gender, age, etnicity). This is then used to set quotas for the number 
of controls to be recruited in each category.  
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6. Methods and Instruments  
 
The assessment was translated in the appropriate language for each Country and 
delivered in a proper private setting. Instruments were distributed online on the 
interactive official website (www.eu-gei.eu) for each Country and interrater 
reliability videos and tools were available at regular times (i.e. once a year or more 
frequently), in conjunction with Work Package 9 (dedicated to the Training) and a 
Kappa >70 was considered acceptable.  
When a subject satisfying the inclusion criteria was identified, he/she was invited 
to be enrolled in the study and after signing a consent form he/she went through the 
whole assessment. When the subject didn’t give the consent to be enrolled or he/she 
was unavailable to be asked for consent, his/her main clinical and socio-
demographic data were still recorded anonymously in a specific form (e.g. in 
Palermo, it was done according to the Italian law about the general authorization to 
process personal data for scientific research purposes) (Gazzetta Ufficiale della 
Repubblica Italiana, n° 72, 26 March 2012). Medical records were checked in detail 
to collect clinical and socio-demographic information for those who didn’t go 
through the whole assessment and subsequently included into the incidence group.  
The instruments used for the assessment are described below. 
 
6.1. Modified version of the Medical Research Council Scale (MRC) 
 
The Modified version of the Medical Research Council (MRC) socio-
demographic scale (Mallett, Leff, Bhugra, Pang, & Zhao, 2002) was used to collect 
the main socio-demographic data (such as age, gender, ethnicity, place of birth, 
housing and living circumstances, level of education, years of education, occupation 
etc.) (See Appendix I). 
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6.2. Operational Criteria Checklist for Psychotic and Affective Illness 
(OPCRIT) 
 
Diagnoses, first ascertained by clinicians, were operationalized trough the 
OPCRIT system (McGuffin, Farmer, & Harvey, 1991) (see Appendix II) a 90-item 
operational criteria checklist for psychosis and a computer program designed for the 
usage in conjunction with it. It includes a structured clinical interview with 
questions and optional probes derived from the World Health Organization 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN, version 2.1). 
This provides a simple and reliable method of applying multiple operational 
diagnostic criteria in studies of psychotic and affective diseases to facilitate a 
polydiagnostic approach to mental illness.  
 
6.3. Cannabis Experience Questionnaire modified version (CEQmv) + CIDI  
 
Detailed data on cannabis and other illicit drugs consumption were collected by 
the Cannabis Experience Questionnaire modified version, CEQmv (Di Forti et al., 
2009) to investigate qualitative and quantitative information on cannabis (age at 
first use, frequency, duration of use in years, current or past use etc.) including a 
section from Composite International Diagnostic Interview (CIDI) on other 
substances of abuse, and tobacco and alcohol use (Kishore, Kapoor, & Reddaiah, 
1999) (see Appendix III).  
 
6.4. Wechsler Adult Intelligence Scale (WAIS) – abbreviated version  
 
An abbreviated version of the WAIS, adapted from the most recent version 
available in each country from Ryan et al. (1998) was used in cases and controls in 
order to estimate IQ scores. All versions included Digit Symbol substitution, 
Arithmetic, Block Design and Information subtests from which raw and scaled 
scores were derived. An estimated sum of scaled scores was calculated from the 
sum of scaled scores (11/4* sum of scaled scores) and then converted to IQ (see 
Appendix IV). 
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6.5. Premorbid Adjustment Scale (PAS) – reduced version  
 
An abbreviated version of the Premorbid Adjustment Scale (Cannon-Spoor et al., 
1982) was adapted in each language. The scale was divided into two distinct 
developmental age periods: childhood to age 11 and early adolescence (i.e. 12 to 
age 16). Individual items in the childhood and adolescence categories assess 
premorbid adjustment by asking about sociability and social withdrawal, peer 
relationships, scholastic performance, adaptation to school, and ability to form 
socio-sexual relationships (after 16 years). Rating was from 0 (not withdrawn) to 6 
(withdrawn) for a total of 9 different scores (see Appendix V). 
 
 
7. Data manipulation 
 
SPSS (version 22) was used to build the dataset including all the variables of 
interest for the analyses. All statistical analyses were conducted using SPSS 22 and 
STATA 14. 
First of all, a reverse-score of Premorbid Adjustment Scale (PAS) was obtained, 
in order to have higher scores for better adjustment, thus having measures 
comparable to IQ scores from WAIS. Then, an exploratory analysis on the nine 
subscales of PAS was performed, and a principal-component analysis (PCA) was 
run. The Kaiser-Mayer-Olkin measure for the sampling adequacy and Bartlett’s test 
of sphericity were calculated. Scree-plot and Kaiser’s criterion were used to extract 
principal factors. We used orthogonal rotation to discriminate between factors and 
then we calculated Cronbach’s alpha to check the reliability of the scales. Then, IQ 
was standardized in z-scores, in order to obtain mean 0 and standard deviation 1 for 
each of the scales. Secondly, PAS was also stratified by age-range (i.e. <12 years 
and between 12-16 years) and another PCA with the same abovementioned 
criterions was performed, for the purpose of the exploratory analyses.  
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8. Statistical analysis 
 
To compare socio-demographic, cognitive, premorbid characteristics and pattern 
of cannabis use between case and control group a univariate analysis was performed 
using t-test or Welch test for quantitative variables and Pearson 2 test for qualitative 
variables. The latter test was also used to compere clinical characteristics (i.e. 
diagnoses) in case group. Bivariate correlations between IQ and PAF and PSF 
scores were controlled by using Pearson’s Test. 
To study the possible aggregation of categories of level of education, relationship 
status, occupational status, living status and frequency of cannabis use, logistic 
regressions were computed using group as dependent variable in order to predict 
which groups (case or control) a person is likely to belong to given certain 
information. 
To compare the main effects and interaction terms of lifetime cannabis use (yes 
or no) and group belonging (cases or controls) on Premorbid Social Factor (PSF), 
Premorbid Academic Factor (PAF) and IQ scores, I used 3 ANCOVA models. 
“Country” was included in the model as fixed factor and the model was adjusted by 
age, gender and ethnicity and, additionally, by occupation and education for IQ. 
To compare the main effects and the interactions terms of cannabis use, by 
frequency (never, less frequently than everyday and everyday) and group (case or 
controls) on IQ, premorbid social and academic adjustment scores a MANOVA 
with these three outcomes (manipulated as abovementioned) was performed, 
controlled for sociodemographic main variables (i.e. age, gender, ethnicity) and 
country. Box’s M resulted significant but this test is highly sensitive. Because we 
can consider equal sample sizes, heterogeneity is not an issue (Tabachnick & Fidell, 
2001).  
Moreover, I wanted to use a MIXED ANCOVA model to study the difference on 
PAF and PSF between the two ranges of age (i.e. time before 12 years and between 
12 and 16 years) controlling for gender, ethnicity and country.  
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I used group (case or control), time of PAS (12 or 16 years) and frequency of 
cannabis use as independent variables and a casual effect for id-patient to take into 
account the repeated measures (12 or 16 years) for each patient.  
To study the main effect and interaction terms of diagnosis and frequency of 
cannabis use on IQ, an ANCOVA model was fitted controlling for gender, age and 
ethnicity on patients’ group only.  
A multinomial regression was used in order to compare the risk to everyday user 
or less than everyday user, rather than never users, taking into account WAIS 
subscales, PAF and PSF as predictors, along with other variables. This analysis was 
preferred, instead of an ordered logistic regression, because it permits a comparison 
between all categories (i.e. less than everyday vs never, everyday vs never and less 
than everyday vs everyday). Due to the large number of potential interactions 
among indipendent varaibles in both analisys, it is not possible to estimate a 
saturated model and then I applied a backward and forward approach, where 
interactions of second and third order for each variable of interest were entered and 
then a F test was used to remove not significant variables. In order to look at other 
variables of interest in terms of different patterns of cannabis use (i.e. current use, 
age at first use, % of THC), a logistic regression was computed, using frequency of 
cannabis use as an outcome variable to estimate the risk to be everyday user or less 
than everyday user, taking into account a list of predictors.  
The assumption of normality of the data that underlies statistical parametric 
approach is considered verified because a large sample is used, as suggested in the 
central limit theorem. P-values <0.05 were considered statistically significant and 
further corrected by Bonferroni. 
 
 
9. Justification of sample size: power calculation 
 
The EU-GEI study proposed a sample size for each Country. It used a 
hypothesised interaction between childhood abuse and the COMT genotype. The 
following assumptions were made: 1) a allele prevalence of 25% met/met, 50% 
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val/met and 25% val/val (based on Caspi et al., 2005); and 2) an overall prevalence 
of abuse of 15% (based on May-Chahal & Cawson, 2005). In a restricted analysis of 
cases (n = 500) and siblings (n = 500), the study would have 99% power to detect 
the following interaction effect: a difference in proportions exposed to abuse 
between cases and controls of 0 in the met/met group (OR=1), of 0.15 in the val/met 
group (OR=2.4) and of 0.32 in the val/val group (OR=5.0). This is a smaller effect 
than that found by Caspi et al (2005) for adolescent cannabis use and COMT. This 
is illustrative and indicates high levels of statistical power to detect gene x 
environment effects in case-control analyses. 
 
 
10. Ethics 
  
In order to make sure that ethical issues would be dealt with appropriately, EU-
GEI opted for the institution of a specific ethics work package. The goal of this 
work package is to continuously inspect and comment on ethical issues in EU-GEI, 
raise awareness and remedy any problems that might arise.  
All core partners have to get ethical approval from their ethical committees prior 
to starting the research, e.g. the study was approved by the Ethical Committee of the 
Palermo University Medical School in 2010 and the data collection in the mental 
health services has been authorized by the Department of Mental Health of Palermo 
which is the coordinator of all the psychiatric services in the catchment area 
involved in the study.  
During recruitment, the subjects received background information on the study 
and signed their consent. An important first step in the study was confirming that 
the potential participants were capable of making an informed decision. Subjects 
were explicitly told that they could stop at any time without consequences. Data 
(genetic variation, environmental exposures, clinical and demographic measures, 
patient status) were stored anonymously.  
In principle, all projects follow the guideline “Ethics for researchers” 
ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethics-forresearchers.pdf.  
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The ethics work package will see to it that research is conduced in accordance 
with the following sources:  
 
•   UNESCO International Declaration on Human Genetic Data. 2003;  
•   UNESCO Universal Declaration on Bioethics and Human Rights. 2005;  
•   EU Directive 95/46/EC of the European Parliament and of the Council of 24 
October 1995 on the protection of individuals with regard to the processing 
of personal data and on the free movement of such data;  
•   EU Directive 2001/20/EC on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on 
medicinal products for human use;  
•   Council of Europe. Convention for the Protection of Human Rights and 
Dignity of the Human Being with regard to the Application of Biology and 
Medicine: Convention on Human Rights and Biomedicine.1997; 
•   Council of Europe. Recommendation Rec (2006) on research on biological 
materials of human origin; 
•   Council of Europe Additional Protocol to the Convention on Human Rights 
and Biomedicine, concerning Biomedical Research. 2005; 
•   Council of Europe. Additional Protocol to the Convention on Human Rights 
and Biomedicine concerning Genetic Testing for Health Purposes. 2008. 
 
Previously collected data that have been used in EU-GEI have undergone the 
required evaluation by local ethics committees and obtained all the required 
permissions (e.g. SGAP and GAP study).  
Data protection includes the strict separation of information identifying the 
subjects, such as name, address, site of residence, from the diagnostics, 
determinants or outcomes. Human data have been stored in a separate locked 
compartment, which is accessible only for staff working on the project and the local 
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investigator. All staff working on the project have to sign confidentiality documents 
before getting access to human data.  
 
11. Statment of contribution to the investigations 
 
My work has been inspired and guided by my supervisors: Prof. Daniele La 
Barbera, Prof. Robin Murray and Prof. Marta Di Forti who gave me the opportunity 
to be involved in the GAP and SGAP studies first and in the EU-GEI study from its 
start. I have been actively involved in the recruitment of both cases and controls and 
in the participants’ assessment and in the retrospective study on clinical notes. 
I was part of the Sicilian Genetic and Psychosis study (S-GAP) and EU-GEI 
research team of psychologists and psychiatrists in training who performed the 
screening in the mental health services together with me from the start to the 
conclusion (i.e. from 2008). I carried out the clinical assessment on a large 
proportion of the cases and controls recruited in Palermo, especially for the 
neuropsychological part of the assessment (including WAIS). In 2011, I spent one 
year in the GAP study, at the Department of Psychosis Studies (King’s College – 
London), where I helped with data screening, collecting and analyzing for the pilot 
study described in Chapter 4. I first started at King’s my involvment in EU-GEI 
project, taking part at the assessment of some patients and controls for the 
neuropsychological battery, after a training with Prof. Craig Morgan.  
In 2016 I had again the opportunuty to spend a period of few months at the 
Department of Psychosis Studies, being involved in data cleaning and project’s 
initial database and where I could write this work of thesis, supervised by Prof. 
Robin Murray and Prof. Jim Van Os. During this period of time, I was also in 
charge for the data cleaning-up for WAIS, PAS and some MRC variables for the 
entire database (e.g. data from all Countries).  
I finally organised the project’s initial database in (SPSS 22) and I built the 
variables relevant to my thesis, to perform the analyses.  
My work was only a little part of a greater and hard working team, without 
whom I would not have been able to develop the present project. 
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Chapter 4 
Pilot study  
 
 
 
1. Introduction  
 
In this chapter I am going to describe the pilot study, conducted in 2011 at 
King’s College on a sample collected as part of the GAP study.  
This section of the Thesis is adapted from the paper published in Schizophrenia 
Research in 2013, with the title “Cannabis users have higher premorbid IQ than 
other patients with first onset psychosis”, thanks to the supervision of Prof. Robin 
Murray and Prof. Marta Di forti and the following co-authorship: Laura Ferraro, 
Manuela Russo, Jennifer O’Connor, Benjamin D.R. Wiffen, Maria Aurora Falcone, 
Lucia Sideli, PoonamGardner-Sood, Simona Stilo, Antonella Trotta, Paola Dazzan, 
Valeria Mondelli, Heather Taylor, Bess Friedman, Hannah Sallis, Caterina La 
Cascia, Daniele La Barbera, Anthony S. David, Abraham Reichenberg, Robin M. 
Murray and Marta Di Forti (Ferraro et al., 2013, see Appendix VI). 
 
 
2. Aims and Hypotheses 
 
We set out this study to test the hypothesis that patients who have smoked 
cannabis show a higher premorbid IQ compared to those who did not in a 
representative group of FEP patients, including those with affective psychosis, and a 
matched control group, whilst controlling for important social and demographic 
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variables. We did not expect to find any such relationship between cannabis use IQ 
and premorbid IQ in controls.  
 
 
3. Methods 
 
3.1. Sample 
 
Our data were derived from the Genetics and Psychosis (GAP) study (Aas et al., 
2011; Di Forti et al., 2009, 2012; Mondelli et al., 2010; O’Connor et al., 2012) a 
case–control study of first-episode psychosis, conducted in consenting patients aged 
18–65 years admitted to the South London and Maudsley Mental Health NHS 
Foundation Trust (SLaM). This study was supported by the UK National Institute 
of Health Research Biomedical Research Centre grant (NIHR-BRC, SLAM) and 
Palermo University (Italy) founded my Research Felloship. 
We collected data on cannabis consumption and neuropsychological performance 
from 279 subjects (119 patients and 160 healthy controls). All subjects underwent 
an extensive assessment which included collecting information about their socio-
demographic characteristics and lifetime substance use. Subjects were administered 
tests of premorbid (WTAR) and present intellectual level (WAIS-III), as soon as 
possible, based on their compliance and within the first six months after their 
admission. 
 
3.1.1. Patients  
119 patients met ICD-10 criteria for psychosis (F10–19, F20–F29 and F30–F33) 
(World Health Organization, 1992); 33 of them had a diagnosis of affective 
psychosis, while 86 were diagnosed as non-affective psychosis. Exclusion criteria 
were applied as follows: organic psychosis, acute intoxication (F1x.0), learning 
disabilities, history of traumatic brain injury and lack of English fluency. 
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3.1.2. Controls  
Healthy controls were recruited from the same catchment area as the patients, 
through local newspapers and internet advertising, job centers, hospitals and a pre-
existing volunteer database. They were representative of the general population in 
age, gender, ethnicity and employment status (Di Forti et al., 2009) and the 
Psychosis Screening Questionnaire (PSQ) (Bebbington & Nayani, 1995) was 
administered to exclude subjects who had any psychotic symptomatology. 
 
3.2. Assessment  
 
A modified version of the Medical Research Council (MRC) Sociodemographic 
Schedule (Di Forti et al., 2009) was administered to all subjects. Ethnicity was self-
ascribed during the interview and grouped into “white”, “black” and “other”. 
Diagnoses for patients were established using the Operational Criteria Checklists 
(OPCRIT) (McGuffin et al., 1991). Levels of positive and negative symptoms were 
assessed by administering the Positive and Negative Syndrome Scale (PANSS), thus 
deriving scores for positive, negative and general symptoms (Kay, Opler, & 
Lindenmayer, 1989). By using the Cannabis Experience Questionnaire (modified 
version) (Di Forti et al., 2009), all subjects were assessed for lifetime cannabis use 
(used at least once), age at first use in years (then dichotomized according to mean 
age at first use), type of cannabis used most often (hash/imported herbal cannabis or 
– alternatively – skunk, high potency cannabis), frequency of use (everyday/less 
frequently), current use (customarily smoking cannabis/no), mode of use 
(social/isolated), self-estimated number of times that they used cannabis over the 
lifetime (operationalized as described in Table 8) and lifetime use of other drugs 
(yes/no). Current IQ was estimated based on five subtests (Information, Digit Span, 
Matrix, Block Design and Digit Symbol) of the Wechsler Adult Intelligence Scale—
Third Edition (WAIS-III) (Wechsler, 1997). Premorbid IQ was estimated using the 
Wechsler Test of Adult Reading (WTAR), a reading test normed with the WAIS-III, 
which is able to provide a broad estimate of general ability before the illness 
(Holdnack, 2001). 
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3.3. Statistical analyses  
 
Chi-square (χ2) tests and t-tests were used where appropriate to compare socio-
demographic characteristics between cases and controls. Equality of variance was 
tested using Levene’s test. A significance level of 5% (two-tailed) was initially 
specified; this was adjusted using a Bonferroni correction in the analysis of 
covariance (ANCOVA).  
Estimated current IQ (WAIS) and premorbid IQ (WTAR) scores were compared 
between the groups, first using a t-test and then using ANCOVA to adjust for 
confounders in order to check if cases were lower in IQ and premorbid IQ than 
controls. Potential confounders were selected a priori based on the literature.  
In order to avoid overfitting the model, significance tests (Pearson correlations, t-
tests and chi-squared tests) were used to select which of these to include in the 
ANCOVA. These included: gender, mother tongue, ethnicity and years of education 
(years attended school). Next, we stratified by group and used an independent two-
tailed t-test to compare mean IQ and premorbid IQ between people with any 
lifetime cannabis use and those without, and also between different patterns of 
cannabis use (Table 8).  
This analysis was carried out in order to test the specific hypothesis that patients 
with lifetime cannabis use were better in their premorbid IQ. A 2 factorial 
ANCOVA was run (groups [cases, controls] x cannabis [cannabis yes, cannabis 
no]) controlling for covariates as specified previously; the inclusion of a cannabis 
by group interaction term formally tested whether the relationship between cannabis 
and IQ and premorbid IQ differed in cases and controls. Finally, a score measuring 
the difference between current IQ and premorbid IQ (current IQ minus premorbid 
IQ) was calculated for the patient group only. We then carried out an ANCOVA 
using this score as the dependent variable and lifetime cannabis use [yes, no] as 
fixed factor, whilst additionally controlling for years of education and mother 
tongue (dichotomized as English vs. Not English first language), which a 
preparatory analysis showed to be related to differences between IQ and premorbid 
IQ. This analysis tested the hypothesis of a smaller difference between IQ and 
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premorbid IQ in patients with cannabis use, compared with patients without any use 
of cannabis. Statistical analyses were carried out using SPSS 15.0 for Windows 
(SPSS, 1994). 
 
 
4. Results  
 
4.1. Socio-demographic characteristics 
 
Table 7 shows socio-demographic characteristics of patients and controls. There 
were no differences in mean age at assessment between cases and controls. 
Statistically significant differences emerged between patients and controls in gender 
(higher percentage of males in cases than in controls), ethnicity (higher percentage 
of black and other ethnic minority groups among cases) and years of education 
(fewer years of education among cases). The case group also contained a greater 
percentage of unemployed people at the time of assessment. All of these differences 
were expected (see also Di Forti et al., 2009) and, therefore, used as covariates. 
 
Table 7. Socio-demographic characteristics (Pylot Study). 
 
Abbreviation: df=degree of freedom. 
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4.2. Pattern of cannabis use  
 
Table 8 reports patterns of cannabis use by group. All patients who reported use 
of cannabis in their lifetime started using cannabis prior to the onset of psychosis.  
 
Table 8. Patterns of Cannabis Use by Group (Pylot Study). 
 
Abbreviation: df = degree of freedom. a In those who had ever used cannabis. Ferraro et al. 2013 
 
There were no significant differences in ever having used cannabis or other illicit 
drugs between cases and controls. Among those who had used cannabis, there were 
no significant differences between cases and controls in age of first use, current 
cannabis use, context of use (isolated or social), or the number of times that they 
had used cannabis. Statistically significant differences between cases and controls 
were, however, found in the type and the frequency of cannabis used.  
Cases were more likely than controls to have preferentially smoked “skunk” 
which has a relatively high concentration of Δ9-THC (12–18%) (Potter, Clark, & 
Brown, 2008), and were more likely to have used cannabis everyday than controls. 
There were no significant differences between cases who used cannabis and those 
who did not in gender, age, ethnicity, years of education, mother tongue nor in any 
of the PANSS subscales: negative (t (111) = −1.187, p = .238), positive (t (111) = 
.677, p = .500) and general psychopathology (t (111) = −.386, p = .700) scores (data 
not shown in tables).  
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4.3. Current IQ and premorbid IQ in cases and controls  
 
Differences between cases and controls emerged in terms of current IQ (t (247) = 
8.99, p <0.001) and premorbid IQ (t (181) = 10.81, p <0.001). Cases had a mean 
current IQ of 87.9 (16.2) and controls of 106.6 (16.2); cases had a mean premorbid 
IQ of 91.2 (11.3) compared with 102.0 (10.5) in controls.  
ANCOVAs were subsequently carried out adjusting for gender, years of 
education, mother tongue and ethnicity. Age was not included since WAIS scores 
and WTAR already take this into account. After adjusting for the above covariates, 
patients still performed significantly worse than controls in IQ (F (1,233) = 53.1, 
adjusted p <0.001, η2 = 0.186) and premorbid IQ (F (1,169) = 27.0, adjusted p 
<0.001, η2 = 0.138). 
 
4.4. Association of IQ and premorbid IQ with cannabis use when stratifying by 
case/control groups 
 
In cases, IQ (t (104) = 3.6, p <0.001) and premorbid IQ (t (81) = 2.9, p = 0.004) 
were significantly higher among patients who had used cannabis compared with 
those who had never used it (Table 9). In contrast, in the controls there were no 
statistically significant differences either in IQ (t (141) = −0.2, p = 0.757) or in 
premorbid IQ (t (98) = 0.6, p = 0.156) scores between those who did or did not use 
cannabis.  
ANCOVAs adjusting for gender, education, mother tongue and ethnicity, still 
gave similar results in the case group for both IQ (F (1,86) = 21.6, adjusted p 
<0.001, η2 = 0.201) and premorbid IQ (F (1,66) = 10.6, adjusted p = 0.002, η2 = 
0.139) (not shown in table). We did not find any such significant differences when 
analysing the control group (all p >0.05). 
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Table 9. Comparing IQ and premorbid IQ across different patterns of cannabis use (Pylot Study). 
a In those who had ever used cannabis. 
Ferraro et al., 2013. 
 
4.5. Patterns of cannabis use and IQ 
 
T-tests in the group of lifetime cannabis users were only performed to establish 
whether current cannabis use, type of cannabis used, frequency of use, mode of use, 
number of times used or age at first use were associated with IQ or premorbid IQ. 
None of these variables were found to have a significant association with either IQ 
or premorbid IQ among cases or controls (all p >0.05). We only found that controls 
who had smoked cannabis after age 16, had higher IQ than controls that had smoked 
cannabis earlier in life (p = 0.016) (see also Meier et al., 2012) (Table 9). 
 
4.6. IQ and premorbid IQ scores association with cannabis use: Case–control 
comparisons 
 
4.6.1. IQ 
Factorial ANCOVA confirmed a significant main effect of the group 
(case/control) on IQ scores (F (1,222) = 53.3, p < 0.001, η2 = 0.205). There was also 
a significant main effect of cannabis use (F (1,222) = 8.1, p = 0.005, η2 = 0.036). 
The interaction effect between cannabis use and the group was significant (F 
(1,222) = 13.7, p <0.001, η2 = 0.058), indicating that the IQ of cases and controls 
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was related differently to cannabis use. Specifically, the IQ of patients was 
significantly related to cannabis use (F (1,86) = 21.6, p <0.001, η2 = 0.201), whilst 
the IQ of the controls was not (F (1,132) = 0.7, p = 0.399). 
 
4.6.2. Premorbid IQ 
A factorial ANCOVA showed a significant main effect of the group 
(case/control) on premorbid IQ scores (F (1,161) = 34.3, p <0.001, η2 = 0.176), a 
main effect of cannabis (F (1,161) = 6.2, p = 0.013, η2 = 0.038), and a significant 
interaction between cannabis and the group (F (1,161) = 3.9, p = 0.048, η2 = 0.024) 
indicating that premorbid IQ of cases and controls was related differently to 
cannabis use. Whilst premorbid IQ of patients was significantly related to cannabis 
use (F (1,66) = 10.6, p = 0.002, η2 = 0.139), premorbid IQ of the controls was not (F 
(1,91) = 0.1, p = 0.730).  
 
4.6.3. Difference between IQ and premorbid IQ 
A difference score was calculated (IQ minus premorbid IQ) for each of the 
patients. Those in the non-cannabis group were found to have a difference between 
premorbid IQ and IQ of 6.1 points greater (95% CI: 0.3, 11.7; p = 0.037) than that 
of patients who had used cannabis (F (1,75) = 6.6, adjusted p = 0.012, η2 = 0.081). 
Diagnosis had no effect. 
 
 
5. Discussion 
 
The aim of this study was to test the hypothesis that among psychotic patients, 
those who had smoked cannabis would have a higher premorbid IQ than those who 
had not. Our main finding was in line with this hypothesis and showed that patients 
who had used cannabis in their lifetime had higher scores in both IQ and premorbid 
IQ compared to those patients who had never used cannabis. 
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5.1. Why is lifetime cannabis use associated with better premorbid IQ? 
 
In our sample of cases, any lifetime use of cannabis was associated with a better 
premorbid cognitive performance, in line with reports by Yücel et al. (2012), Meijer 
et al. (2012), Rabin et al. (2013) and Schnell et al. (2012). Cognition has been 
established as a predictor of real world community functioning in schizophrenia 
(Green et al., 2000; Evans et al., 2003) and 69% of our sample of psychotic 
cannabis users reported a social use of cannabis, a similar proportion as in controls.  
Thus, our findings are compatible with the view that, among psychotic patients, 
the better premorbid cognition of the group who had smoked cannabis is likely to 
have facilitated their use of the drug in a normal recreational way, sharing it with 
their friends. The findings are also compatible with the view that patients that used 
cannabis were less neurodevelopmentally impaired than those who did not. Other 
studies compatible with this latter view have reported that patients at their first 
episode who have used cannabis have fewer neurological soft signs signs (Ruiz-
Veguilla, F. Callado, & Ferrin, 2012) and less abnormal MRI scans (Cunha et al., 
2013) than those who have not. 
 
5.2. Are IQ and premorbid IQ of patients and controls different in relation to 
cannabis use? 
 
Looking at differences between cases and controls, we found, as expected, 
significantly lower current and premorbid IQ in patients on the overall. We also 
expected that cannabis use would be associated differently with IQ and premorbid 
IQ in patients and controls. Among cases, cannabis use was associated with a higher 
IQ and premorbid IQ, whilst among the controls, there was no significant 
difference. Previous studies compared cases and controls who used cannabis at age 
16 or before and their performance in single tests: Jockers-Scherübl et al. (2007) 
found an interaction effect of group and cannabis on the “digit symbol” subtest from 
WAIS-R. Yücel et al. (2012) reported that “visual memory”, “working memory”, 
and “executive functioning” were better in patients who used cannabis, but no 
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interaction analysis was made with a corresponding control group. Meijer et al. 
(2012) found that lifetime cannabis use was associated with better performance on 
acquired knowledge, facial affect recognition and face identity recognition, but  
they did not find any interaction effect with group status (patients, siblings and 
controls). To our knowledge, this is the first study that has investigated and found a 
relationship between IQ, premorbid IQ and cannabis use in cases but not in a 
comparison group of controls. 
 
5.3. Difference between IQ and premorbid IQ in relation to cannabis use  
 
As expected, the current IQ of patients was lower than their premorbid IQ on 
average (see also Dazzan et al., 2008). We calculated a difference score (IQ minus 
premorbid IQ) in order to see whether the estimated deterioration was associated 
with cannabis use (see also Leeson, Harrison, et al., 2011), and found this to be the 
case. This raises the possibility of a neuroprotective action of cannabis. However, 
those who used cannabis daily were neither less, nor more impaired than less 
frequent users; this was also the case when we compared patients that had started 
smoking cannabis at 16 or earlier (our mean age for cannabis use onset — the 
lowest age of first use in our sample was 5 years), and also when we compared 
patients that had smoked cannabis more or less than 200 times in their life, or 
patients that were currently smoking cannabis or not. Thus, we cannot make a 
definite statement on the question of any protective effect of cannabis use. 
 
4.4. Limitations and strengths  
 
We examined patients at their first episode of psychosis, which minimizes the 
influence from variables inherent to those with chronic illness and/or the effects of 
continuous pharmacological treatment on cognition. However, patients were not 
medication naïve and, as is well known, medication could have affected current 
neuropsychological performance (i.e. IQ) even in the short period between initial 
contact with the services and our cognitive testing. On the other hand, as already 
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mentioned, WTAR – our main measure of interest – is also robust in patients 
exerting suboptimal effort due to medication effects. 
The inclusion of a control group was another strength of our study, but, as some 
demographic differences show, our strategy of recruiting controls representative of 
the local population could have biased our findings. However, we corrected our 
analysis for these characteristics and differences in neuropsychological 
performances stayed significant. Otherwise, as already discussed in Di Forti et al. 
(2009), it seems unlikely that the difference in frequency and type of cannabis used 
between cases and control group was driven by a recruitment bias. Cannabis use 
was self-reported but we measured the reliability of the self-reported data on current 
users in a random sample of 56 cases from the GAP sample, by carrying out a 
urinary drug screening (UDS). 
Of the 56 cases tested, 34 had reported they were not current users; 32 of these 
(88%) had a negative UDS, only 2 tested positive. Thus, the accuracy of self-report 
data on current use in our sample is high. For obvious reasons, a history of 
lifetimeuse of cannabis cannot be assessed by a biological test. Finally, we are 
aware that reading-based tests have some limitations as a measure of premorbid IQ 
(O’Connor et al., 2012; Russell et al., 2000). However, WTAR is thought to be a 
more reliable measure of pre-morbid IQ (R. E. A. Green et al., 2008) compared to 
other tests like the NART (National Adult Reading Test) (Nelson and Willison, 
1991) and is able to indicate a “hold” intellectual capacity (Horn & Cattell, 1966). 
 
 
6. Conclusions 
 
Our findings are in line with the hypothesis that among psychotic patients, 
cannabis users had a higher premorbid IQ than non-users (an association not 
witnessed among controls). Our cannabis-using patients also had a smaller 
difference between current IQ and premorbid IQ than non-using patients. Kremen et 
al., (2008) point out that premorbid estimates should be understood as a measure of 
“potential” had a given subject not been destined to develop schizophrenia. Thus, 
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individuals with a high premorbid IQ could be seen as less predisposed. Taking 
these findings together with the substantial evidence that cannabis use is a risk 
factor for psychosis, we suggested in this study that cannabis may play a role in 
provoking psychosis in people who were less neurodevelopmentally impaired than 
is generally the case in psychosis.  
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Chapter 5 
Results 
 
 
 
1. Introduction 
 
In this section I am going to summarize the results of the study. In the first part I 
will be described the sample and its distribution by Country, socio-demographic 
characteristics, cognitive and premorbid characteristics, pattern of cannabis-use, 
other drug-use and clinical characteristics of case group. In the second part, I will 
describe the Principal Component Analysis for PAS factors and other data 
manipulations and in the third part I will show the progression of the model by 
frequency of cannabis use. The last part of the chapter will be dedicated to further 
exploratory analyses. 
  
 
2. Descriptive Characteristics  
 
2.1. Sample Characteristics  
 
Across all sites, 1,168 cases were assessed in detail and form the case sample for 
case-control analyses. Across all sites 1,855 controls were recruited and assessed. 
Patients recruited were those who accepted to be enrolled, while patients who 
weren’t involved in the study, either because they refused to be interviewed or 
because they had been screened and identified retrospectively by the leakage study, 
were entered as part of the incidence sample (1,338 psychotic subjects).
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Complete case analysis deletes all units with incomplete data and the final 
sample of the present study therefore included 1,895 subjects (834 cases and 1,061 
controls), with complete information about cannabis use (CEQ) and premorbid 
adjustment (PAS) at least, distributed by site and Country as described in Table 10. 
 
Table 10.  Sample Distribution by Site and Country.  
Country  Cases Controls TOT, % 
United Kingdom  215 345 560 (29.5) 
   London 173 239 412 
   Cambridge 42 106 148 
Holland  193 220 413 (21.8) 
   Amsterdam 94 104 198 
   Leiden 99 116 215 
Spain 202 217 419 (22.1) 
   Madrid 60 76 136 
   Barcelona 29 37 66 
   Oviedo 39 35 74 
   Valencia 49 32 81 
   Galicia 25 37 62 
France 102 144 246 (13.0) 
   Paris 87 99 186 
   Puy de Dome 15 45 60 
Italy  122 135 257 (13.6) 
   Palermo  56 94 150 
   Bologna 66 41 107 
TOTAL 834 1,061 1,895 (100) 
 
2.2. Socio-Demographic Characteristics  
 
The most relevant socio-demographic characteristics of the sample by cases and 
control status are described in the next tables. 
As expected, the case group shows a greater percentage of males (63.1%) 
compared to control group (p<0.001). Cases are generally younger than controls 
(p<0.001) and include a greater percentage of black and people of other ethnicity 
than controls (p<0.001) (Table 11).  
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Table 11.  Socio-demographic Characteristics of the Sample by Cases and Controls. 
Variables  Cases    N Controls N χ2 or t-test df p-value 
Gender  834  1,061 45.6 1 <0.001 
   Male, N (%) 526 (63.1)  504 (47.5)     
   Female, N (%) 308 (36.9)  557 (52.5)     
Age, Mean (SD) 30.2 (10.4) 833 36.7 (13.3) 1,059 11.8 1,890 <0.001 
Ethnicity   831  1,050  54.5 2 <0.001 
   White, N (%) 536 (64.5)  837 (79.7)     
   Black, N (%) 141 (17.0)  104 (9.9)     
   Other, N (%) 154 (18.5)  109 (10.4)     
Legend: SD=standard deviation; df=degree of freedom. 
 
Controls have more years of education (p<0.001) and they achieved higher levels 
of education than cases (p<0.001). Cases are more likely to be unemployed than 
controls (p<0.001) at the moment of the interview (Table 12) as well as 5 years 
before (p<0.001) (data not shown in table).  
 
Table 12.  Characteristics of the Sample by Cases and Controls: Education and Work. 
Variables  Cases    N Controls N χ2 or  
t-test 
df p-
value 
Education   832  1,061 200.9 5 <0.001 
   No qualification, N (%) 113 (13.6)  30 (2.8)     
   Compulsory education, N (%) 217 (26.1)  142 (13.4)     
   1st level non-compulsory, N (%) 183 (22.0)  247 (23.3)     
   Job-related education, N (%) 173 (20.8)  205 (19.3)     
   University 1st degree, N (%) 100 (12.0)  250 (23.6)     
   University degree, (N, %) 46 (5.5)   187 (17.6)     
Years of education,  Mean (SD) 13.5 (3.9) 830 15.4 (3.8) 1,061 10.6 1,889 <0.001 
Occupational status  819  1,012 220.1 5 <0.001 
   Unemployed, N (%) 324 (39.6)  153 (15.1)     
   Economically inactive, N (%) 145 (17.7)  107 (10.6)     
   Student, N (%) 123 (15.0)  169 (16.7)     
   Part-time employee, N (%) 72 (8.8)  142 (14.0)     
   Full-time employee, N (%) 123 (15.0)  382 (37.7)     
   Self-employed, N (%) 32 (3.9)  59 (5.8)     
Legend: SD=standard deviation; df=degree of freedom. 
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With respect to the relationship and living status, cases are more likely to be 
single and to not ever have had a long-term – more than 1 year – relationship in 
their lifetime than controls (all p<0.001). They are also less likely to have lived 
alone than controls (p<0.001), probably because they are still living with their 
parents more frequently than controls (p<0.001) (Table 13). 
At this point it is important to remember that the control group was selected to be 
representative of the general population of each area and not to be matched with the 
case group. 
 
Table 13.  Characteristics of the Sample by Cases and Controls: Relationship and Living Status. 
Variables  Cases    N Controls N χ2 df p-value 
Relationship status  822  1,011 262.3 4 <0.001 
   Single N (%) 551 (67.0)  313 (31.0)     
   Married, living together, N (%)    
   In a steady relationship, N (%) 
   Divorced, separated, N (%) 
   Widowed, N (%) 
127 (15.5) 
92 (11.2) 
48 (5.8) 
4 (0.5) 
 426 (42.1) 
216 (21.4) 
47 (4.6) 
9 (0.9) 
    
Long-term relationship lifetime  815  1,011 122.8 1 <0.001 
   Yes, N (%) 529 (64.9)  878 (86.8)     
   No, N (%)  286 (35.1)  133 (13.2)     
Living status   818  1,010 246,5 7 <0.001 
   Alone, N (%) 139 (17.0)  159 (15.7)     
   Alone, with children, N (%) 
   Partner, N (%) 
   Partner, with children, N (%) 
   Parents, N (%) 
   Other family, N (%) 
   Friends, N (%) 
   Other (e.g. hostels, hall of 
residence), N (%) 
31 (3.8) 
70 (8.6) 
77 (9.4) 
336 (41.0) 
64 (7.8) 
40 (4.9) 
61(7.5) 
 48 (4.8) 
219 (21.7) 
267 (26.4) 
187 (18.5) 
19 (1.9) 
68 (6.7) 
43 (4.3) 
    
Since leaving your parent’s home, 
have you lived with others? 
 746  959 55.5 1 <0.001 
   Yes, N (%) 495 (66.4)  787 (82.1)     
   No, N (%)  251 (33.6)  172 (17.9)     
Legend: SD=standard deviation; df=degree of freedom. 
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2.3. Cognitive Characteristics 
 
Across all sites, 705 cases and 1,034 controls were assessed with WAIS, in order 
to obtain four scaled scores (Ss) to estimate the IQ, as it is showed in Table 14, 
8.2% of the sample was missing for these values.  
As expected, patients performed worse than controls in all cognitive domains and 
in general IQ (all p<0.001) and these differences stayed significant even after 
controlling for gender, ethnicity and level of education (all p<0.001). Age was not 
used as covariate because it is already taken into account in IQ calculation. 
 
Table 14.  Cognitive Characteristics of the Sample by Cases and Controls from WAIS Scores. 
Variables  Cases N Controls N t-test df p-value  Adj  
p-value* 
Digit Symbol - Ss  
   Mean (SD) 
 
6.6 (3.0) 
708  
10.4 (3.1) 
1,034 25.4 1,740 <0.001 <0.001 
Arithmetic - Ss 
   Mean (SD) 
 
7.7 (3.5) 
707  
10.0 (3.5) 
1,039 13.4 1,744 <0.001 <0.001 
Block Design - Ss 
   Mean (SD) 
 
7.6 (3.8) 
705  
10.3 (3.7) 
1,037 14.3 1,740 <0.001 <0.001 
Information - Ss 
   Mean (SD) 
 
8.9 (4.0) 
706  
10.8 (3.7) 
1,039 9.9 1,743 <0.001 <0.001 
Total IQ 
   Mean (SD) 
 
84.5 (19.2) 
705  
103.9 (18.5) 
1,034 20.2 1,737 <0.001 <0.001 
Legend: Ss= Scaled scores; SD=standard deviation; df=degree of freedom;  
* Adjusted for gender, ethnicity and level of education. 
 
2.4. Premorbid characteristics  
 
Across all sites, the differences between cases and controls in all the measures of 
premorbid adjustment were statistically significant (all p<0.001). Cases were less 
sociable, they had less peer relationships, they had a worse scholastic performance 
and a worse adaptation to school, both in childhood (<12 years) and in early 
adolescence (12-16 years). Cases were also more impaired in their socio-sexual 
aspects in early adolescence. All these differences remained significant after 
adjusting for age, gender and ethnicity (all p<0.001) (Table 15).  
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Table 15.  Premorbid Characteristics of the Sample by Cases and Controls from PAS Scores. 
Variables Cases N Controls N t-test df p-value Adj  
p-value* 
1 –Sociability and 
withdrawal – 
Childhood (Soc<12),  
Mean (SD) 
 
 
1.6 (1.5) 
834  
 
1.1 (1.3) 
1,061 -7.3 
** 
1,639 <0.001 <0.001 
2 – Sociability and 
withdrawal – Early 
Adolescence (Soc 16),  
Mean (SD) 
 
 
1.7 (1.5) 
834  
 
1.1 (1.2) 
1,061 -9.7 
** 
1,574 <0.001 <0.001 
3 –Peer Relationships – 
Childhood (Peer<12), 
Mean (SD) 
 
 
1.6 (1.3) 
832  
 
1.1 (1.1) 
1,061 -9.1 
** 
1,641 <0.001 <0.001 
4 –Peer Relationships – 
Early Adolescence, 
(Peer 16), Mean (SD) 
 
 
1.7 (1.4) 
833  
 
0.1 (1.1) 
1,061 -12.3 
** 
1,581 <0.001 <0.001 
5 –Scholastic 
Performance – 
Childhood (Schol<12), 
Mean (SD) 
 
 
 
2.7 (1.5) 
830  
 
 
1.9 (1.4) 
1,061 -11.6 
** 
1,715 <0.001 <0.001 
6 –Scholastic 
Performance – Early 
Adolescence (Schol 16), 
Mean (SD) 
 
 
 
3.2 (1.5) 
822  
 
 
2.2 (1.5) 
1,056 -13.7 1,876 <0.001 <0.001 
7 –Adaptation to 
School – Childhood,  
(Adap<12), Mean (SD) 
 
 
1.3 (1.3) 
831  
 
0.6 (0.9) 
1,061 -12.3 
** 
1,459 <0.001 <0.001 
8 –Adaptation to 
School – Early 
Adolescence, 
(Adap 16), Mean (SD) 
 
 
 
1.9 (1.5) 
821  
 
 
1.1 (1.3) 
1,056 -12.6 
** 
1,611 <0.001 <0.001 
9 –Socio-Sexual Aspects 
During Early 
Adolescence, (Sex 16),  
Mean (SD) 
 
 
 
1.1 (1.5) 
828  
 
 
0.8 (1.2) 
1,059 -5.4 
** 
1,544 <0.001 <0.001 
Legend: SD=standard deviation; df=degree of freedom;  
* Adjusted for gender, age, ethnicity and level of education;  **Levene’s test <0.05. 
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2.5. Pattern of Cannabis Use 
 
Figure 13 shows the distribution of cannabis use across different countries. 
Holland and UK have the higher percentages of cannabis smokers in case group and 
overall, compared to other countries. 
 
Figure 13. Distribution of Cannabis Use Across Different Countries.  
Legend: this histogram displays on the Y axis the percentages of cases and controls who smoked cannabis 
in their lifetime (in red) distributed by country. 
 
Table 16 shows some aspects of pattern of cannabis use, by comparing them 
between cases and controls. Cases were more likely to have used cannabis in their 
lifetime (p<0.001) and to currently use cannabis (p<0.001). Among cases who 
smoked cannabis, a greater percentage of them used cannabis everyday (p<0.001) 
and they started the consumption at an earlier age, compared to controls (p<0.001). 
More cases than controls declared that they had increased the amount of cannabis 
used due to tolerance induced by the substance (<0.001). 
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Table 16. Pattern of Cannabis Use of the Sample by Cases and Controls from CEQ. 
Variables  Cases N Controls N t-test 
or χ2 
df p-
value 
Cannabis Use Lifetime   834  1,061 32.1 1 <0.001 
   Yes, N (%) 571 (68.4)  591(55.7)     
   No, N ( %) 263 (31.5)  470 (44.3)     
Current Cannabis Use  
   Yes, N (%) 
   No, N, (%) 
 
202 (24.3) 
628 (75.7) 
830  
141 (13.3) 
918 (86.7) 
1,059 38.0 1 <0.001 
Age at First Use  
   (mean, SD)** 
 
16.9 (4.7) 
565  
17.8 (4.5) 
591 -3.5 1,154 <0.001 
Frequency of use** 
   Everyday, N (%) 
   (More than) once a week 
   A few times each month 
   A few times each year 
   Only once or twice 
 
256 (45.5) 
96 (17.1) 
56 (9.9) 
58 (10.3) 
97 (17.2) 
563  
81 (13.8) 
89 (15.1) 
92 (15.6) 
108 (18.3) 
219 (37.2) 
589 161.5 4 <0.001 
Tolerance increased amount**  237  904 71.5 1 <0.001 
   Yes, N (%) 173 (31.2)  64 (27.0)     
   No, N, (%) 381 (68.8)  523 (89.1)     
Mode of use** 
   Socially (N, %) 
   On my Own (N, %)  
 
365 (69.1) 
163 (30.9) 
528  
518 (90.7) 
53 (9.3) 
571 80.9 1 <0.001 
Type of cannabis used** 
   Low-THC cannabis (N, %) 
   High-THC cannabis (N, %) 
 
164 (34.2) 
350 (31.9) 
514  
253 (46.4) 
292 (68.1) 
545 23.3 1 <0.001 
Cannabis is mostly used**  
   In a joint with tobacco (N, %) 
   In a joint without tobacco (N, %) 
   Using a bong (N, %) 
   Ate or drank (N, %) 
   Other (N,%) 
 
488 (91.2) 
26 (4.9) 
8 (1.5) 
4 (0.7) 
9 (1.7) 
535  
492 (7.9) 
41 (7.3) 
9 (1.6) 
7 (1.3) 
11 (2.0) 
560 3.8 4 0.422 
Legend: ** among those who used cannabis. 
 
As is shown in Table 16, a greater percentage of cases (69.1%) and controls 
(90.7%) declared that they smoke cannabis socially, more than on their own, but 
this percentage was greater in controls than in cases (p<0.001). As expected, cases 
were also more likely to have used high potency cannabis, which means with total 
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levels of THC ≥10%. The Eu-GEI team, coordinated by Prof. Marta Di Forti, 
decided to initially establish this conservative cut-off of 10% THC concentration; if 
anything, this cut-off may underestimate the effect of high potency cannabis. There 
were no differences between cases and controls in the mode of cannabis use 
(p=0.422), cannabis was mostly used in a joint with tobacco. 
Starting from data available from the European Monitoring Centre for Drugs and 
Drug Addiction and Europol (2016) and other reports (European Monitoring Centre 
for Drugs and Drug Addiction, 2016; European Monitoring Centre for Drugs and 
Drug Addiction - Ministerio de Sanidad Servicios Sociales e Igualidad, 2013; R. 
Niesink & Rigter, 2013; Observatoire Francais des Drogues et des Toxicomanies 
(OFDT), 2015; Potter et al., 2008), the distribution of cannabis use across all 
Countries was grouped as follows (Table 17).  
 
Table 17.  Distribution of drug use across all Countries according THC-absolute concentration. 
Country THC<10% N (%) THC≥10% N (%) 
United 
Kingdom 
Hash  108 (34.2) Home-grown Skunk/Sensimilla 98 (31.0) 
Imported herbal cannabis  78 (24.7) Super skunk 23 (7.3) 
Geimporteerde Wiet 1 (0.3)   
Unknown 8 (2.5)  
Holland Hash   2 (0.8) Home-grown Skunk/Sensimilla 4 (1.5)  
Imported herbal cannabis  1(0.4) Nederwiet 174 (66.4) 
Geimporteerde Wiet 7 (2.7) Nederhasj 29 (11.1) 
Geimporteerde Hasj 21 (8.0) 
Unknown 24 (9.2)  
Spain Imported herbal cannabis  
Geimporteerde Wiet 
83 (33.9) 
1 (0.4) 
Hash   
Home-grown Skunk/Sensimilla 
140 (57.1) 
15 (6.1) 
Unknown 6 (2.4)  
France Imported herbal cannabis  
 
28 (26.9) Hash   
Home-grown Skunk/Sensimilla 
Super Skunk 
61 (58.7) 
5 (4.8) 
1 (1.0) 
Unknown 9 (8.7)  
Italy Hash  
Imported herbal cannabis  
53 (39.8) 
67 (50.4) 
Home-grown Skunk/Sensimilla 
Super skunk 
9 (6.8) 
2 (1.5) 
Unknown 2 (1.5)  
TOTAL  429 (42.4)   582 (57.6) 
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Across all countries, the favorite substance used is hash, even though the 
varieties used have different potencies. In Holland 66.6% of the sample preferred 
Nederwiet, that is the local herbal variety. The 57.6% of the sample, considering 
cases and controls together, smoked cannabis with an absolute percentage of 
THC>10%. 2.6% of the sample declared that they were unaware of the type of 
cannabis they smoked (Table 17).  
At this stage, I would acknowledge that there are not botanical reasons for 
dividing the cannabis populations either side of 10% THC, but it is probably the 
most pragmatic way of dividing the sample, according to the Potter et al. study 
(2008), which is relevant to the time of our data collection, all resin and imported 
herbal samples in UK showed a below 10% THC-absolute concentration, while 
over 80% of sinsemilla samples were above 10% THC. 
Table 18 shows that both cases (77.8%) and controls (84.4%) mostly declared 
that they smoked cannabis because their friends were using it, but this was more 
common in controls than in cases (p=0.004). A small proportion of cases (9.8%) 
and controls (6.6%) declared they first tried cannabis because their family members 
were using it, but this was a little more present in cases (p=0.05). Cases were also 
more likely to report to have used cannabis in order to feel better, compared to 
controls (p<0.001). 
 
Table 18.  Motivations for First Cannabis Use of the Sample by Cases and Controls.  
Variables  Cases N Controls N t-test 
o χ2 
df p-value 
Friends were using it 
   Yes (N, %) 
   No (N, %) 
 
425 (77.8) 
121 (22.2) 
546  
494 (84.4) 
91(15.6) 
585 8.1 1 0.004 
Family members were using it 
   Yes (N, %) 
   No (N, %) 
 
52 (9.8) 
479 (90.2) 
531  
37 (6.6) 
527 (93.4) 
564 3.8 1 0.050 
To feel better 
   Yes (N, %) 
   No (N, %) 
 
86 (16.2) 
444 (83.8) 
530  
21 (3.7) 
543 (96.3) 
564 48.4 1 <0.001 
Legend: degree of freedom. 
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Table 19 shows that both cases and controls, among those who were currently 
cannabis users (i.e. in the last 12 months) at the time of the interview (i.e. the onset 
for cases), smoke cannabis because they like its effect, without any difference 
between the two groups (p=0.500).  
 
Table 19.  Motivations for Current Cannabis Use of the Sample by Cases and Controls 
Variables  Cases N Controls N t-test o 
χ2 
df p-
value 
Like effect 
   Yes (N, %) 
   No (N, %) 
 
109 (58.9) 
76 (41.1) 
185  
75 (55.1) 
61 (44.9) 
136 0.45 1 0.500 
Feel relaxed 
   Yes (N, %) 
   No (N, %) 
 
150 (81.1) 
35 (18.9) 
185  
98 (71.5) 
39 (28.5) 
137 4.1 1 0.044 
Feel less nervous 
   Yes (N, %) 
   No (N, %) 
 
91 (50.0) 
91 (50.0) 
182  
38 (27.7) 
99 (72.3) 
137 16.1 1 <0.001 
Being more sociable 
   Yes (N, %) 
   No (N, %) 
 
62 (34.1) 
120 (65.9) 
182  
30 (22.1) 
106 (77.9) 
136 5.4 1 0.019 
Do you think to stop cannabis one 
day? 
   Yes (N, %) 
   No (N, %) 
 
149 (71.6) 
59 (28.4) 
208  
73 (49.0) 
76 (51.0) 
149 18.9 1 <0.001 
Legend: df=degree of freedom. 
 
Cases are more likely than controls to smoke cannabis in order to feel relaxed 
(0.044), less nervous (<0.001) and more sociable (0.019). In spite of this, cases are 
also more likely to want to stop cannabis use one day (<0.001) (Table 20). 
Additionally, cases also declared they had unpleasant effects from cannabis (i.e. 
to feel fearful, mad, nervy, suspicious, to hearing voices, to have visions) more 
often than controls (all p<0.001); however they declared also that they feel full of 
plans and ideas and better in understanding the world, more often than controls (all 
p<0.001), while controls are more likely to refer to feel happy after smoking 
cannabis, with respect to cases (p=0.004) (data not shown in tables). 
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2.6. Other Drug Use 
 
Table 20 shows that cases are more likely to have smoked tobacco in the last 12 
months (p<0.001) and in a larger amount than controls (p=0.008). Cases were also 
more likely to have used other illegal drugs (p<0.001), while controls were more 
likely to have used alcohol in the last 12 months (p<0.001). 
 
Table 20.  Pattern of Tobacco and Other Drug Use of the Sample by Cases and Controls.  
Variables  Cases N Controls N t-test 
o χ2 
df p-value 
Tabaco use - past 12 months 
   Yes (N, %) 
 
477 (59.0) 
809  
254 (25.2) 
1,008 212.7 1 <0.001 
Cigarette/day - past 12 moths 14.8 (16.9) 469 11.7 (10.7) 257 2.6 724 0.008 
Other Drugs Use Lifetime  
   Yes (N, %)  
 
243 (22.9) 
834  
326 (39.1) 
1,061 58.2 1 <0.001 
Alcohol   Yes (N, %) 431 (62.9) 685 649 (75.2) 863 27.3 1 <0.001 
Legend: df=degree of freedom. 
 
Table 21 describes frequencies and percentages of other drug consumption in the 
sample. The sum of percentages is more than 100% because some subjects have 
tried more than one drug in his/her lifetime. The table indicates the answer of the 
568 (325 cases; 243 controls) people of the sample who used other drugs.  
 
Table 21. Other Drugs: Type and Distribution. 
Drug Type Total 
% 
Cases 
N (%) 
Controls 
N (%) 
p-
value 
% Cases 
N=325* 
%Controls 
N=243* 
p-
value 
Cocaine  20.2 222 (26.7) 159 (15) <0.001 68.3 65.4 0.471 
Amphetamines/Stimulants 18.2 187 (22.4) 158 (14.9) <0.001 57.5  65.0 0.060 
Hallucinogens 12.0 114 (13.7) 114 (10.7) 0.052 34.8 46.9 0.003 
Ketamine 5.3 64 (7.7) 37 (3.5) <0.001 19.4  15.2 0.198 
Inhalants 4.6 55 (6.6) 32 (3.0) <0.001 16.6 13.2 0.257 
Sedatives 3.4 40 (4.8) 25 (2.4) 0.004 12.0 10.3 0.523 
Opioids 3.3 42 (5.0) 21 (2.0) <0.001 5.0 2.0 <0.001 
Crack 3.0 37 (4.4) 19 (1.8) 0.001 4.4 1.8 0.001 
Other 3.4 34 (4.1) 30 (2.8) 0.135 10.2 12.3 0.410 
*Among those who used other drugs 
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A part from Hallucinogens and Other substances, cases were more likely to have 
used any kind of other drug than controls. Among those who used other drugs, cases 
and controls did not differ very much in substance preferred, a part from opioids, 
and crack, wich were mostly preferred from psychotic patients, and hallucinogens, 
that were preferred by a higher percentage of controls, than cases. 
103 subjects in total of those who used other illegal drugs declared to have 
abused of at least one of these drugs in their lifetime and this percentage was higher 
for cases (24.3%) than controls (9.5%) (p<0.001). Most of cases abused of one 
other illegal drug (see Figure 14).  
 
Figure 14. Number Of Other Illegal Drugs Abused Lifetime.  
 
Legend: This histogram represents number of subjects (Y axis) who abused of one or more drugs (X axis) 
in their lifetime. 
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2.7. Clinical Characteristics of Cases 
 
Table 22 describes the distribution of the diagnoses in cases.  
 
Table 22.  Clinical Characteristics of Cases. 
Diagnosis according to ICD-10 (N, %) Diagnosis according to DSM-IV-
TR 
(N, %) 
Non-affective Psychosis  517 (74.5) Non affective Psychosis 552 (75.5) 
Schizophrenia (F20) 
Schizoaffective Disorder (F25) 
Delusional Disorder (F22) 
Other Non-Organic Psychosis (F29) 
275 (39.6) 
29 (4.2) 
37 (5.3) 
176 (25.4) 
Schizophrenia 
Schizophreniform Disorder 
Schizoaffective Disorder 
Delusional Disorder 
Psychosis NOS 
216 (29.5) 
152 (20.8) 
37 (5.0) 
26 (3.6) 
121(16.6) 
Affective Psychosis 177 (25.5) Affective Psychosis 179 (24.5) 
Major depressive disorder with 
psychotic features (F323, F333)  
Bipolar disorder with psychotic 
features (F312, F315)  
79 (11.4) 
 
98 (14.1) 
Major Depressive Disorder with 
psychosis 
Bipolar I with psychosis  
89 (12.2) 
 
90 (12.3) 
 
TOT 694  731 
 
517 (74.5%) subjects met criteria for a diagnosis of F20-29 non-affective 
psychosis, 275 (39.6%) of them encountered ICD-10 criteria for the diagnosis of 
F20 schizophrenia.  
The remaining 25.5% of the sample (177 subjects) met ICD-10 criteria for F30-
33 affective psychoses. The proportions were similar using DSM-IV-TR criteria, 
with a 75.5% of the sample meeting criteria for non-affective psychosis and 24.5% 
of its meeting criteria for affective psychosis. As already mentioned, in the EU-GEI 
study we used ICD-10 criteria. 
 
 
3. Principal Component Analysis (PCA) of PAS 
 
PAS scores were manipulated. First of all, a reverse score was calculated in order 
to have higher scores for better adjustment, thus having scores comparable to IQ 
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derived from WAIS. In order to reduce the dimensionality of PAS, a principal-
component analysis (PCA) on its nine scales was run.  
 
 
•   Sociability: Childhood (Soc<12), Early Adolescence (Soc 16); 
•   Peer Relationships: Childhood (Peer<12), Early Adolescence (Peer 16); 
•   Scholastic Performance: Childhood (Schol<12), Early Adolescence (Schol 
16);  
•   Adaptation to School: Childhood (Adap<12), Early Adolescence (Adap 16);  
•   Socio-Sexual Aspects During Early Adolescence (Sex 16). 
 
The Kaiser-Mayer-Olkin measure verified the sampling adequacy for the analysis 
(KMO=0.670) and the Bartlett’s test of sphericity (χ2(36) = 8153,42; p<0.0001) 
indicated that correlations between scales were sufficiently large for PCA. Firstly, 
an oblique rotation (theoretically oriented) was applied, that demonstrated a 
negligible correlation between the extracted factors (rho=0.306). Then the 
orthogonally rotated solution (Pedhazur & Schmelkin, 1991)  was preferred, in 
order to convert this set of possibly correlated variables into a set of linearly 
uncorrelated variables (rho=0) (Table 23; Figure 15).  
 
Table 23.  Principal-Component Analysis.  
 
Components  
Eigenvalues Rotation Sums of Squared Loadings 
Total % of variance % cumulative Total % of variance % cumulative 
1 - Soc<12  3.775 41.945 41.945 3.140 34.894 34.894 
2 – Soc 16  1.874 20.823 62.768 2.509 27.874 62.768 
3 - Peer<12  .815 9.058 71.826 - - - 
4 – Peer 16  .789 8.771 80.598 - - - 
5 - Schol<12  .549 6.097 86.694 - - - 
6 – Schol 16  .493 5.482 92.176 - - - 
7 - Adap<12  .366 4.062 96.238 - - - 
8 – Adap 16  .198 2.198 98.436 - - - 
9 – Sex 16  .141 1.564 100.000 - - - 
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Figure 15. Graph of the Eigen Values (Scree plot). 
 
Legend: Kraiser’s criterion (dashed line). 
 
According to Kraiser’s criterion (see Figure 16), only eigen values >1 were 
considered, so two factors were retained in the final analysis.  
 
Figure 16. Factor loading after rotation 
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The rotated components matrix (Table 24) shows five scales (Sociability in 
Childhood and in Early Adolescence, Relationships with Peer in Childhood and in 
Early Adolescence and Socio-Sexual Aspects of Life During Early Adolescence) 
that cluster on Factor 1, that represents the Premorbid Social Factor (PSF), while 
the other four scales (Scholastic Performance in Childhood and in Early 
Adolescence and Adaptation to School in Childhood and in Early Adolescence) 
cluster on Factor 2, thus representing the Premorbid Academic Factor (PAF). 
 
Table 24. Factor loading after rotation. 
Components 1 2 
1 - Soc<12 .807 .109 
2 – Soc 16 .845 .131 
3 - Peer<12 .824 .142 
4 – Peer 16 .822 .177 
5 - Schol<12 .087 .797 
6 – Schol 16 .039 .855 
7 - Adap<12 .269 .709 
8 – Adap 16 .136 .744 
9 – Sex 16 .567 .072 
 
 
From this analysis we can also derive the information that PSA factor is able to 
explain 34.9% of the variance while PAF factor the 27.9%. This result indicates that 
social adjustment factor is able to explain the greater part of the premorbid 
adjustment in childhood and early adolescence. Finally, the Cronbach-α for PAS is 
0.816, thus indicating a high reliability and it is <0.815 for all the dimensions and 
this suggests that it is not necessary to remove some scales of the PAS in order to 
increase the reliability of the test. 
 
4. Aggregated sociodemographic-categories  
 
Some variables of interest were analyzed using logistic regressions in order to 
predict which of groups (case or control) a person is likely to belong to given 
certain information. 
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4.1. Level of Education 
 
People with higher university degree have the same probability to belong to the 
case group compared to people who achieved a first university degree (p=0.971), 
thus it is possible to aggregate these two categories. Moreover, it is possible to 
aggregate the job-related education and the first level education categories (p=1.00) 
(Figure 17).  
 
Figure 17. Level of Education: Categories Aggregation. 
 
Legend: the graph reports a logistic regression on the “Level of education” variable: on the X axis are 
represented the categories of the variable, on the Y axis is expressed the probability of a person to belong to 
the case group, in terms of percentages. 
 
Thus, the new variable will be constituted of four main categories:  
 
•   Code 0. University education; 
•   Code 1. First Level education; 
•   Code 2. Compulsory Education; 
•   Code 3. No education. 
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4.2. Occupational Status  
 
People unemployed have the same probability to belong to the case group 
compared to people who are economically inactive (p=1.00), thus it is possible to 
aggregate these two categories. Moreover, it is possible to aggregate student, part-
time, full-time employed and self-employed categories (p-range=0.076-1.00) 
(Figure 18).  
 
Figure 18. Occupational Status: Categories Aggregation. 
 
Legend: the graph reports a logistic regression on the “Occupational Status” variable: on the X axis are 
represented the categories of the variable, on the Y axis is expressed the probability of a person to belong to 
the case group, in terms of percentages. 
 
The new variable will be constituted of two only categories:  
 
•   Code 0. Employed-Student; 
•   Code 1. Unemployed-Economically Inactive. 
 
 
.2
.3
.4
.5
.6
.7
Pr
(G
ro
up
)
Unemployed inactive Student Part-­time Full-­time Self-­employed
Occupational  Status
	  
 114 
 
4.4. Living Status  
 
People living with their parents have the same probability to belong to the case 
group compared to people who live with other families or with others (not friends) 
(p-range=0.161-1.00), thus it is possible to aggregate these three categories. It is 
also possible to aggregate the remaining categories (p-range=0.325-1.00) (Figure 
19). Living alone was not aggregated to other categories, given that it was reported 
as a risk factor for psychosis (C Morgan et al., 2008; Stilo et al., 2013). 
 
Figure 19. Living Status: Categories Aggregation. 
 
Legend: the graph reports a logistic regression on the “Living Status” variable: on the X axis are 
represented the categories of the variable, on the Y axis is expressed the probability of a person to belong to 
the case group, in terms of percentages. 
 
The new variable will be constituted of the following three categories:  
 
•   Code 0. Partner, partner with children, friends, alone with children; 
•   Code 1. Alone; 
•   Code 2. Parents, other family and other. 
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4.5. Relationship Status  
 
People married have the same probability to belong to the case group compared 
to people in a steady relationship (p=1.00), thus it is possible to aggregate these two 
categories. It is also possible to aggregate people divorced with people widowed 
(p=1.00) (Figure 20). Being single is not aggregated to other categories (i.e. being 
separated or widowed) for theorical reasons, given that it was reported as a risk 
factor for psychosis (C Morgan et al., 2008; Stilo et al., 2013). 
 
Figure 20. Relationship Status: Categories Aggregation. 
 
Legend: the graph reports a logistic regression on the “Relationship Status” variable: on the X axis are 
represented the categories of the variable, on the Y axis is expressed the probability of a person to belong to 
the case group, in terms of percentages. 
 
The new variable will be categorized as follow:  
 
•   Code 0: Married/in a steady relationship; 
•   Code 1: Divorced/Separated/Widowed; 
•   Code 2: Single. 
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5. IQ and Cannabis Use by Country 
 
I first tried to replicate the analysis performed in my previous study, by 
performing an ANCOVA with IQ as dependent variable and cannabis (Yes/No) and 
subject status (Cases/Controls) as independent variables, along with Country. The 
model was adjusted by age, gender, ethnicity, occupation and education. Cases are 
lower in IQ than controls after controlling for possible confounders (p<0.001). Both 
patients and controls who smoked cannabis in their lifetime have a 2.02 points 
higher IQ than their respective no-cannabis groups (p=0.015) (Table 25). The 
relationship is similar across different countries but shifts (p<0.05). (Figure 21). 
 
Figure 21. IQ Scores in Cases and Controls by Cannabis Use Across Countries.  
 
Legend: This graph describes IQ scores (Y axis) in cases and controls cannabis users and not users across 
different countries (X axis). Adjusted for Country, age, gender, ethnicity, occupation and education. 
Bonferroni. 
 
Table 25. Main Effects of Cannabis Use and Group Belonging on IQ across Different Countries.  
Variables  Coefficient  S.E. t-test p-value 95% C.I. 
Cannabis Yes vs. No 2.014    0.825 2.44 0.015 0.395 3.633 
Group Cases vs. Controls -12.423    0.884         -14.05 <0.001 -14.157 -10.688 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
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6. Premorbid Academic Factor and Cannabis Use by Country 
 
Premorbid Academic Factor (PAF) before 16 years derived from PSA scales, 
was entered as dependent variable in an ANCOVA model with cannabis (Yes/No) 
and subject status (Cases/Controls) as independent variables. Country was included 
in the model as a fixed factor and the model was adjusted by age, gender and 
ethnicity. Education and occupation were not taken into account because they are 
strictly related to and a consequence of premorbid academic adjustment. As is 
shown in Figure 22, cases have a worse PAF scores than controls after controlling 
for possible confounders (p<0.001). PAF results were worst in both patients and 
controls who smoked cannabis in their lifetime than patients who did not (p<0.001) 
(Table 26), and this relationship in relation to cannabis is the same across all 
countries, but shifts, because differences in cases and controls (p<0.05).  
 
Figure 22. PAF Scores in Cases and Controls by Cannabis Use Across Countries. 
Legend: This graph describes PAF scores (Y axis) in cases and controls cannabis users and not users across 
different countries (X axis). Adjusted for Country, age, gender and ethnicity. Bonferroni.  
 
 
Table 26. Main Effects of Cannabis Use and Group Belonging on PAF across Different Countries.  
Variables  Coefficient  S.E. t-test p-value 95% C.I. 
Cannabis Yes vs. No -0.200 0.046     -4.30    <0.001 -0.292     -0.109 
Group Cases vs. Controls -0.600     0.047    -12.55    <0.001 -0.694    -0.506 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
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7. Premorbid Social Factor and Cannabis Use by Country 
 
Premorbid Social Factor (PSF) before 16 years derived from PSA scales, was 
entered as dependent variable in an ANCOVA model with cannabis (Yes/No) and 
subject status (Cases/Controls) as independent variables. Country was included in 
the model as a fixed factor and the model was adjusted by age, gender and ethnicity. 
Cases have a worse PSF than controls once corrected for confounders (p<0.001) 
(Figure 23). Conversely to PAF, PSF results better in patients who smoked 
cannabis in their lifetime than patients who did not (p=0.009), but there are tiny 
differences in controls in PSF scores (p=0.053), according to cannabis use 
(interaction p=0.030) (Table 27). These results are similar across all countries, but 
shift because of differences in cases and controls social behaviour (p<0.05). 
 
Figure 23. PSF Scores in Cases and Controls by Cannabis Use Across Countries.  
Legend: This graph describes PSF scores (Y axis) in cases and controls cannabis users and not users across 
different countries (X axis). Adjusted for Country, age, gender and ethnicity. Bonferroni. 
 
Table 27. Effects of Cannabis Use and Group Belonging on PSF across Different Countries.  
Variables  Coefficient  S.E. t-test p-value 95% C.I. 
Cannabis Yes vs. No 0.159    0.060      -2.62    0.009      0.039     0.278 
Group Cases vs. Controls -0.505    0.106      -4.73    <0.001 -0.715    -0.295 
Cannabis Yes x Group 0.204    0.094      2.17    0.030      0.019   0.390 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
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8. Conclusions About Cannabis Use on IQ, PAF and PSF 
 
These analyses show that, across all European Countries studied, both cases 
(68.4%) and controls (55.7%) that reported a lifetime cannabis use have a higher IQ 
than cases and controls who did not.  
Conversely, both cases and controls that smoked cannabis in their lifetime, 
reported a worse academic adjustment before 16 years and cases, but not controls, 
also reported a better premorbid social adjustment before their 16 years. 
  
 
9. Data Manipulation for a Comprehensive Model 
 
Given these preliminary results, with contradictive findings on IQ and academic 
premorbid adjustment, I wanted to perform a Multivariate Analysis of Variance 
(MANOVA) with IQ, PAF and PSF standardized score as outcomes and group 
(Cases/Controls) and cannabis use (Never/Less Than Everyday/Everyday) as fixed 
factors.  
Country, age, gender and ethnicity were also included as possible confounders. 
In order to construct the model, correlations between these three outcomes and their 
standardization were performed. Different pattern of cannabis use was observed to 
establish which categories could be aggregated. 
 
8.1. Correlation of IQ, PAF and PSF scores and Standardization of IQ 
 
First of all, bivariate correlations between IQ and PAF and PSF scores were 
controlled and, as is shown in Table 28, IQ was related to PAF (rho= 0.46, 
p<0.001) but not to PSF (rho= 0.03, p=0.163), apparently in a counterintuitive 
relationship with my previous results.  
Then, IQ scores were standardized in z-scores, in order to obtain mean 0 and 
standard deviation 1. 
 
 
	  
 120 
 
Table 28. Bivariate Pearson’s Correlations Between IQ, PAF and PSF. 
  IQ PSF PAF 
IQ Pearson Correlation 1 0.034 0.460** 
 Sig. (2-tailed)  0.163 0.000 
 N 1739 1718 1718 
PSF Pearson Correlation 0.034 1 0.000 
 Sig. (2-tailed) 0.163  1,000 
 N 1718 1867 1867 
PAF Pearson Correlation 0.460** 0.000 1 
 Sig. (2-tailed) 0.000 1,000  
 N 1718 1867 1867 
Legend  ** Correlation is significant at the 0.01 level (2-tailed). 
 
 
8.2. Aggregated Categories of Different Patterns of Cannabis Use 
 
I performed a logistic regression on the variable “frequency of cannabis use” in 
order to predict which groups (case or control) a person is likely to belong to given 
certain pattern of cannabis use. Frequency is an indicator of the amount of cannabis 
intake in the period of life in which cannabis was mostly used. 
As is shown in Figure 24, people who smoked cannabis everyday at any time in 
their lifetime, are 3.9 folds more likely to be cases than “never used” group 
(OR=3.9, C.I. 95%=2.87-5.35, p<0.001), i.e. the probability to be cases is equal to 
70% for people who smoked cannabis everyday, while people who never used 
cannabis have only the 39.6% of probability to be cases.  
Everyday use of cannabis was the only category able to be separated from the 
others from a statistical point of view, while we separated “never-users” for 
theoretical reasons. This analysis was adjusted for age, gender and ethnicity. 
The new variable will be categorized as follow:  
 
•   Code 0: Never; 
•   Code 1: Less than everyday; 
•   Code 2: Everyday. 
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Figure 24. Frequency of Cannabis Use: Categories Aggregation. 
 
Legend: the graph reports a logistic regression on the “Frequency of cannabis Use” variable: on the X axis 
are represented the categories of the variable, on the Y axis is expressed the probability of a person to belong 
to the case group, in terms of percentages. Adjusted for age, gender and ethnicity. 
 
 
10. Characteristics of the sample by Frequency of cannabis Use 
 
I first explored the descriptive characteristics of the sample by frequency of 
cannabis use.  
Table 29 describes the frequency of cannabis use by Country and stratified by 
case/control status, that shows evident differences in the distribution of frequent 
users.  
Holland has the highest proportion of everyday users, in the case group, followed 
by Spain (p<0.001). Interestingly, there are no differences in control group by 
frequency of cannabis use (p=0.081). 
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Table 29. Frequency of cannabis use across different Countries. 
Variables Never N Less than 
Everyday 
N Everyday N χ2 df p-value 
C
A
SE
S 
Country, N (%)   263  307  256 41.1 8 <0.001 
   UK 60 (28.6)  94 (44.8)  56 (26.7)     
   Holland 40 (20.8)  73 (38.0)  79 (41.1)    !! 
   Spain 63 (31.3)  70 (34.8)  68 (33.8)    ! 
   France 46 (45.1)  26 (25.5)  30 (29.4)     
   Italy 54 (44.6)  44 (36.4)  23 (19.0)     
C
O
N
T
R
O
L
S 
Country, N (%)  470  508  81 14.0 8 0.081 
   UK 146 (42.3)  169 (49.0)  30 (8.7)     
   Holland 94 (42.7)  108 (49.1)  18 (8.2)     
   Spain 96 (44.2)  105 (48.4)  16 (7.4)     
   France 83 (57.6)  53 (36.8)  8 (5.6)     
   Italy 51 (38.3)  73 (54.9)  9 (6.8)     
Legend: df= degree of freedom 
 
Overall, cannabis users in our sample are generally males and younger than not-
users (data not shown in tables), and Table 30 shows that everyday users have an 
even higher proportion of males and are younger than less than everyday users, both 
in cases and in controls (p<0.001). While in controls less than everyday users are 
mostly white people (p<0.001), this difference is attenuated in cases (0.057).  
Table 31 shows that both cases and controls with a University degree were more 
likely to have used cannabis at least once in their life, but less than everyday 
(p<0.001). Additionally, those with less than everyday cannabis use, have more 
years of education in both cases (p=0.001) and controls (p<0.001). Less than 
everyday users are also more likely to be employed or students in both cases 
(p<0.001) and controls (p=0.014), while everyday users are more likely to be 
unemployed in cases, but not in controls. 
Finally, everyday and less than everyday users are mostly single in cases 
(p<0.001), while in controls they mostly have a partner (p=0.003). Everyday users 
are also more likely to live with their parents or in other families or institutions than 
less than everyday and never users in case group (p<0.001), but not in controls 
(p=0.103) (Table 32). 
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Table 30. Socio-demographic Characteristics of the Sample by Frequency of Cannabis Use.  
Variables Never N Less than 
Everyday 
N Everyday N χ2 or 
t-test 
df p-value 
CASES  
Gender, N (%)  263  307  256 74.5 2 <0.001 
   Male 113 (21.8)  204 (39.3)  202 (38.9)     
   Female 150 (48.9)  103 (33.6)  54 (17.6)     
Age,  
   Mean (SD) 
 
34.8 (12.1) 
263  
29.1 (9.3) 
306  
26.8 (7.7) 
256 45.5 2 <0.001 
Ethnicity, N (%)  262  305  256 9.1 4 0.057 
   White 164 (30.8)  213 (40.0)  156 (29.2)     
   Black 51 (37.2)  46 (33.6)  40 (29.2)     
   Other 47 (30.7)  46 (30.1)  60 (39.2)     
CONTROLS 
Gender, N (%)  470  508  81 23.0 2 <0.001 
   Male 191 (38.0)  258 (51.3)  54 (10.7)     
   Female 279 (50.2)  250 (45.0)  27 (4.9)     
Age,  
   Mean (SD) 
 
39.4 (14.1) 
470  
34.5 (12.5) 
507  
34.6 (11.3) 
80 18.6 2 <0.001 
Ethnicity, N (%)  466  502  80 17.7 4 0.001 
   White 347 (41.6)  426 (51.0)  62 (7.4)     
   Black 58 (55.8)  35 (33.7)  11 (10.6)     
   Other 61 (56.0)  41 (37.6)  7 (6.4)     
Legend: SD=standard deviation; df=degree of freedom. 
 
Table 31. Characteristics of the Sample by Frequency of Cannabis Use: Education and Work. 
Variables Never N Less than 
Everyday 
N Everyday N χ2 
or t 
df p-value 
CASES  
Education, N (%)  262  306  256 22.6 6 0.001 
   No qualification 37 (33.3)  28 (25.2)  46 (41.4)     
   Compulsory Edu. 65 (30.2)  79 (36.7)  71 (33.0)     
   1st Degree Edu. 107 (30.4)  131 (37.2)  114 (32.4)     
   University 53 (36.3)  68 (46.6)  25 (17.1)     
Years of Edu.,  
   Mean (SD) 
 
13.1 (4.1) 
260  
14.1 (4.1) 
307  
13.3 (3.6) 
255 4.5 2 0.001 
Occupation, N (%)  256  303  252 21.7 2 <0.001 
  Uneployed 138 (29.7)  152 (32.8)  174 (37.5)     
  Employed/Student 118 (34.0)  151 (43.5)  78 (22.5)     
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CONTROLS 
Education, N (%)  470  508  81 21.1 6 0.002 
   No qualification 12 (40.0)  12 (40.0)  6 (20.0)     
   Compulsory Edu. 76 (53.5)  52 (36.6)  14 (9.9)     
   1st Degree Edu. 193 (42.8)  218 (48.3)  40 (8.9)     
   University 189 (43.3)  226 (51.8)  21 (4.8)     
Years of Edu.,  
   Mean (SD) 
 
15.0 (3.8) 
470  
15.9 (3.8) 
508  
14.2 (3.4) 
81 9.8 2 <0.001 
Occupation, N (%)  453  483  74 8.5 2 0.014 
  Uneployed 128 (49.2)  106 (40.8)  26 (10.0)     
  Employed/Student 325 (43.3)  377 (50.3)  48 (6.4)     
Legend: df= degree of freedom. Abbreviations: Edu. = Education. 
 
Table 32. Characteristics by Frequency of Cannabis Use: Relationship and Living Status. 
Variables Never N Less than 
Everyday 
N Everyday N χ2  df p-value 
CASES 
Relationship, N (%)  243  277  233 26.6 4 <0.001 
   Single 89 (25.6)  123 (35.3)  136 (39.1)     
   Partner 103 (39.0)  92 (34.8)  69 (26.2)     
   Separated  51 (36.1)  62 (44.0)  28 (19.9)     
Living with, N (%)  257  303  250 24.4 4 <0.001 
   Part./ Friends/ Child 85 (39.9)  90 (42.3)  38 (17.8)     
   Alone 39 (28.3)  53 (38.4)  46 (33.3)     
   Parents/Other 133 (29.0)  160 (34.9)  166 (36.2)     
CONTROLS 
Relationship, N (%)  421  448  66 16.1 4 0.003 
   Single 57 (36.3)  79 (50.3)  21 (13.4)     
   Partner 238 (48.6)  223 (45.5)  29 (5.9)     
   Separated  126 (43.8)  146 (50.7)  16 (5.6)     
Living with, N (%)  453  481  74 7.7 4 0.103 
   Part./ Friends/ Child 286 (47.7)  276 (46.0)  38 (6.3)     
   Alone 59 (37.1)  83 (52.2)  17 (10.7)     
   Parents/Other 108 (43.4)  122 (49.0)  19 (7.6)     
Legend: df= degree of freedom. Abbreviations: Part.= partner. 
 
In terms of pattern of cannabis use, Table 33 describes differences between less 
than everyday users and everyday users.  
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Table 33. Patterns of Cannabis Use by Frequency in Cases and Controls. 
Variables Less than 
Everyday 
N Everyday N χ2 or 
t-test 
df p-value 
CASES 
Current Use, N (%)  305  256 13.4 1 <0.001 
   Yes 88 (44.0)  112 (56.0)     
   No 217 (60.1)  144 (39.9)     
Age at First Use, 
   Mean (SD) 
 
17.5 (5.1) 
306  
16.1 (2.9) 
255 12.5 1 <0.001 
Tolerance Increased Amount, N (%)  289  242  1 <0.001 
   Yes 33 (19.4)  137 (80.6)     
   No 256 (70.9)  105 (29.1)     
Mode of use, N (%)  278  250 71.5 1 <0.001 
   Socially  237 (64.9)  128 (35.1)     
   On my Own  41 (25.2)  122 (74.8)     
Type, N (%) 
   Low-THC <10% 
   High-THC <10% 
 
107 (62.2) 
143 (43.6) 
250  
65 (37.8) 
185 (56.4) 
250 15.6 1 <0.001 
 
 
CONTROLS 
Current Use, N (%)  506  81 8.7 1 0.005 
   Yes 111 (78.7)  30 (21.3)     
   No 395 (88.6)  51 (11.4)     
Age at First Use, 
   Mean (SD) 
 
18.2 (4.6) 
508  
15.6 (2.9) 
81 22.1 1 <0.001 
Tolerance Increased Amount, N (%)  497  75  1 <0.001 
   Yes 27 (43.5)  35 (56.5)     
   No 470 (92.2)  40 (7.8)     
Mode of use, N (%)  491  80 87.9 1 <0.001 
   Socially  468 (90.3)  50 (9.7)     
   On my Own  23 (43.4)  30 (56.6)     
Type, N (%) 
   Low-THC <10% 
   High-THC <10% 
 
223 (86.8) 
210 (82.7) 
433  
34 (13.2) 
44 (17.3) 
78 1.6 1 0.122 
Legend: df= degree of freedom; SD= standard deviation. 
 
Everyday users are more likely to be current users both in cases (p<0.001) and in 
controls (p=0.005), and to have started at a younger age in both groups (p<0.001). 
Cases and controls everyday smokers were also more likely to declare that tolerance 
has increased the amount of cannabis they used (p<0.001), and they were also more 
	  
 126 
 
likely to smoke cannabis alone, while the opposite was true for less than everyday 
smokers, that were more socially smokers (p<0.001). Finally, among cases 
(p<0.001) but not among controls (p=0.122), everyday smokers were also more 
likely to have preferentially chosen high potency cannabis. Everyday users were 
more likely to have used other drugs than less than everyday users in cases 
(p<0.001) but the opposite was true in control group, where less than everyday 
users have used more other illegal drugs than everyday cannabis users (p<0.001) 
(data not shown in tables). Given these differences, I wanted to proceed with the 
analysis on the three different outcomes by frequency of cannabis use. 
 
 
11. Multivariate Analysis of the Variance on IQ, PAF and PSF  
 
Results from MANOVA were derived from 1,739 observations (cases and 
controls with complete information on PAS, CEQ and WAIS). Using Roy’s largest 
root test, there was a significant effect of both group (R = 0.195, F (3, 1689) 
=109.64, p<0.001) and frequency of cannabis use (R = 0.043, F (3, 1690) = 24.05, 
p<0.001) in determining IQ, PSF and PAF scores. There was also a significant 
interaction effect (R = 0.0058, F (3, 1690) = 3.27, p = 0.020) between group and 
frequency of cannabis use. Thus it was possible to look at the separate ANOVAs on 
the outcome variables, corrected by Bonferroni, by including Country, age, gender 
and ethnicity as additional fixed factors. Education and occupation were not taken 
into account because they are related to and/or predicted from PAF.  
 
11.1. IQ and Frequency of Cannabis Use  
 
Regarding IQ, cases are lower in IQ than controls (F (1,1693) = 297.5, p<0.001) 
and there is also an effect of frequency of cannabis use overall (F (2,1693) = 3.98, 
p=0.018), but not interaction effect between cannabis and group (p=0.647). Looking 
at multiple comparisons, adjusted by Bonferroni, both cases and controls who 
smoked cannabis less than everyday have a higher IQ (p=0.026) compared with 
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never users, while there are no differences between everyday users and never users 
(p=1.000) nor between everyday and less than everyday users (0.224) (Table 34).  
 
Table 34. ANOVA on IQ scores, corrected by Bonferroni. 
Variables Contrast SE t-test p-value 95% C.I. 
Group       
Cases vs Controls -0.770 0.044 -17.25 <0.001 -0.858 -0.683 
Frequency of use        
Less everyday vs Never   0.120 0.045 2.63 0.026 0.010 0.229 
Everyday vs Never   0.013 0.062 0.22 1.000 -0.136 0.164 
Everyday vs Less everyday   -0.106 0.059 -1.78 0.224 -0.249 0.036 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
 
11.2. Premorbid Academic Factor and Frequency of Cannabis Use  
 
Regarding Premorbid Academic Factor (PAF), cases score worse in their 
premorbid academic adjustment compared to controls (F (1,1693) = 107.2, 
p<0.001) and there is also a significant effect of cannabis use (F (2,1693) = 23.8, 
p<0.001) but not an interaction effect between cannabis and group (p=0.1843). 
Looking at multiple comparisons, adjusted by Bonferroni, both cases and 
controls everyday smokers score worse in premorbid academic adjustment than 
never users (p<0.001) and less than everyday users (p<0.001). There are no 
differences between less than everyday users and never users in premorbid 
academic adjustment (Table 35). 
Table 35. ANOVA on PAF scores, corrected by Bonferroni. 
Variables Contrast SE t-test p-value 95% C.I. 
Group       
Cases vs Controls -0.507 0.048 -10.36 <0.001 -0.603 -0.411 
Frequency of use        
Less everyday vs Never   -0.107 0.050 -2.15 0.094 -0.228 0.012 
Everyday vs Never   -0.471 0.068 -6.84 <0.001 -0.636 -0.306 
Everyday vs Less everyday   -0.363 0.065 -5.56 <0.001 -0.520 -0.206 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
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11.3. Premorbid Social Factor and Frequency of Cannabis Use  
 
Regarding the Premorbid Social Factor (PSF), cases score worse in their 
premorbid social adjustment compared to controls (F (1,1691) = 81.4, p<0.001) and 
there is also a significant effect of cannabis use (F (2,1691) = 12.7, p<0.001) and an 
interaction effect between cannabis and group (F (2,1691) = 3.06, p=0.047). 
Looking at multiple comparisons, corrected by Bonferroni, cases who never 
smoked cannabis are lower in premorbid social adjustment than cases less than 
everyday users (p=0.002) and everyday users (p<0.001) while there are no 
differences between these two groups (p=1.000). In controls, there are no 
differences in terms of sociability by frequency of cannabis use (all p>0.05).  
Interestingly, there is also no difference between cases who smoked cannabis 
everyday and controls who never smoked cannabis in terms of sociability (p=0.225) 
and there are only modest differences between cases everyday users and controls 
everyday users (p=0.059) (Table 36) while all other differences between cases and 
controls remain significant (all p<0.001 – data not shown in table). 
 
Table 36. ANOVA on PSF scores, corrected by Bonferroni. 
Variables Contrast SE t-test p-value 95% C.I. 
Controls E vs Controls N  0.164 0.119 1.38 1.000 -0.186 0.514 
Controls E Vs Controls L 
Control L vs Control N 
0.027 
0.136 
0.117 
0.063 
0.23 
2.16 
1.000 
0.469 
-0.318 
-0.049 
0.373 
0.323 
Cases N vs Cases L 0.345 0.090 3.80 0.002 0.078 0.612 
Cases E Vs Cases N   
Cases E vs Cases L 
0.494 
0.148 
0.095 
0.087 
5.17 
1.69 
<0.001 
1.000 
0.213 
-0.109 
0.775 
0.407 
Cases E  vs Controls N -0.206 0.084 -2.43 0.225 -0.455 0.042 
Cases E  vs Controls E -0.370 0.128 -2.89 0.059. -0.747 0.006 
Legend: SE= Standard Error; C.I.= Confidence Interval. E=everyday; L=less than everyday; N=never. 
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11.4. Conclusions about Frequency of Cannabis Use on IQ, PSF and PAF 
 
Figure 25 represents predicted values of premorbid school factor (PAF), 
premorbid social factor (PSF) and IQ, according with frequency of cannabis use in 
cases and controls. The higher IQ reported in both cases and controls who smoked 
cannabis in their lifetime is due to the subgroup of those who smoked cannabis less 
than everyday, thus accounting for the higher IQ reported in cannabis users overall. 
Both cases and controls who smoked cannabis less than everyday have a Premorbid 
Academic Factor (PAF) equal to people who never smoked cannabis, while the 
everyday users group accounted for the worse PAF reported in cannabis users. 
Controls show no differences by frequency of cannabis use in their sociability, 
while cases who smoked cannabis less than everyday or everyday had higher 
premorbid sociability scores (PSF) than never users. 
 
Figure 25. IQ, PAF and PSF Scores by Frequency Of Cannabis Use in Cases and Controls. 
Legend: these two graphs represent the predicted values of PAF, PSF and IQ in MANOVA, divided by cases 
and controls. PAF is represented by the green line, PSF is represented in blue and IQ is represented in red. 
On the Y axis are z-scores, on the X axis is represented the predictor “frequency of cannabis use”. 
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In conclusion, the higher IQ recorded in cases cannabis recreational-users, is 
present in people who had a good premorbid social and academic adjustment before 
their 16 years, while in controls the better IQ of cannabis recreational users is only 
associated with a better academic adjustment before 16 years.  
Everyday users were worse at school before 16 years, but they had better 
sociability and this was true in cases more than in controls, where this difference 
was not significant. Cases who never used cannabis were also the most impaired 
group in terms of sociability before their 16 years, despite their better premorbid 
academic adjustment, moreover they have the lowest IQ.  
 
 
12. Exploratory Analyses  
 
12.1. Other Drugs 
  
Previous studies about cognition in psychotic cannabis using patients that did not 
exlude people with other substance abuse, have found similar results (i.e. better IQ 
and cognitive functions in drug users), and cannabis was confirmed as the preferred 
subsance (see meta-analisys by Potvin et al., 2008). However, given the large 
sample size, I wanted to explore other substance use and abuse. 103 subjects in 
total, of those who used other drugs (325 cases and 243 controls), declared to have 
abused of at least one of those drugs in their lifetime.  
I wanted to perform again the MANOVA model with IQ, premorbid sociability 
(PAF) and academic adjustment (PSF) as outcomes, as already described, this time 
by excluding those subjects who have abused of at least one other drug in their 
lifetime. The results did not change, there was a significant interaction between 
cannabis use and group (Roy’s Test F(3,1595)=3.4, p=0.017) due to PSF, that 
resulted higher in everyday and less than everyday cannabis users compared to 
never users, without any differences in control group. PAF of both cases and 
controls resulted worse in cannabis everyday smokers than in less than everyday 
users and never users. IQ was higher in less than everyday users in both groups. 
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Given that tobacco was suggested as a risk factor for psychosis (Gurillo, Jauhar, 
Murray, & MacCabe, 2015) it was also explored: a) tobacco use in the last 12 
months (yes/no) was significantly related to cannabis use (χ2(1)=287.7, p<0.001) in 
both cases and controls; b) tobacco use (yes/no) was inserted, along with group 
(case/controls) in a MANOVA with IQ, PAF and PSF as outcomes where cases 
resulted lower in all scores (all p<0.001) and tobacco use in the last year was 
significantly related to higher premorbid sociability (F(1,1635) = 24.8, p<0.001), 
lower academic premorbid adjustment (F(1,1635) = 53.1, p<0.001) and lower IQ 
(F(1,1635) = 25.9, p<0.001), independently from group belonging; c) the same was 
true after excluding subjects with a lifetime cannabis-use from the sample; i.e. 
tobacco smokers resulted lower in IQ (F(1,634) = 8.64, p=0.003) and PAF 
(F(1,634) = 15.9, p<0.001) while the effect on PSF was mostly attenuated (F(1,634) 
= 3.72, p=0.051), without differences between cases and controls; d) number of 
cigarettes smoked in the last 12 months resulted higher in patients with a lifetime 
everyday cannabis-use (interaction F(2,1781) = 12.8, p<0.001).  
 
12.2. Premorbid Adjustment in Childhood and First Adolescence  
 
In order to explain my results in terms of neurodevelopmental impairment 
(Murray & Lewis, 1987), I wanted to look back at the Premorbid Adjustment Scale 
(PAS) and its scales (see Appendix V). Each of the 4 items of the PAS (a part from 
socio-sexual adjustment) is administered twice to the subject: by referring to his/her 
childhood (before 12 years) and to his/her first adolescence (between 12 and 16 
years). Socio-sexual adjustment was excluded because it is not comparable at 
different ages. Thus, I performed again a PCA on PAS original reverse-scores, 
stratified by age (<12 years and 12-16 years). As expected, results were similar to 
the previous PCA performed on the nine scales, and clustered according to Kraiser’s 
criterion on two principal factors, stratified by age (Table 37): 
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Table 37. Factor Loading after Rotation PAS <12years and 16 Years and New Factors. 
Factor loading after rotation <12 years 
 
Component 
(PSF<12)  (PAF<12) 
PAS Soc <12 0.905 0.122 
PAS Peer <12 0.891 0.186 
PAS Schol <12 0.053 0.883 
PAS Adap <12 0.261 0.803 
 
Factor loading after rotation 12-16 years 
 
Component 
(PSF 16) (PAF 16) 
PAS Soc 16 0.910 0.104 
PAS Peer 16 0.901 0.148 
PAS Schol 16 0.089 0.874 
PAS Adap 16 0.154 0.857 
 
A MIXED ANCOVA model was applied to study the difference on PAF and PSF 
between the two times of PAS, controlling for age, gender, ethnicity and Country.  
I used group (case or control), time of PAS (<12 or 12-16 years) and frequency 
of cannabis use as independent variables, and a casual effect for id-patient was used 
to take into account the repeated measures (12 or 16 years) for each patient. 
In premorbid academic adjustment (PFA), cases performed worse (χ2(1) = 
141.29, p<0.001) and there was a significant interaction between frequency of 
cannabis use and time of PAS (χ2(2) = 54.76, p<0.001) (Figure 26). 
 
Figure 26. Premorbid Academic Factor in Childohood and First Adolescence by Cannabis. 
 
Legend: these two graphs rapresent the predicted values of PAF (Y axis), divided by cases and controls and 
by frequency of cannabis use (X axis). PAF<12 is rapresented by the blue line, while PAF-16 is in red.  
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That means, both cases and controls who never smoked cannabis in their 
lifetime, gained in their academic adjustment from childhood to early adolescence. 
Both cases and controls who later smoked cannabis sometime in their life stayed 
stable in their PAF, while cases and controls who became everyday smokers, had a 
drop in their PAF from childhood to first adolescence.  
Table 38 shows multiple comparisons on this effect, for both cases and controls 
considered together, corrected by Bonferroni. 
 
Table 38. MIXED MODEL on PAF Scores by Time. Cases and Controls. Corrected by Bonferroni. 
Variables Contrast SE z p-value 95% C.I. 
Never-16 vs Never>12 0.146 0.030 4.83 <0.001 0.057 0.236 
Less everyday-16 vs Less everyday>12 
Everyday-16 vs Everyday>12 
-0.052 
-0.237 
0.028 
0.044 
-1.83 
-5.31 
1.000 
<0.001 
-0.137 
-0.368 
0.031 
-0.105 
Legend: SE= Standard Error; C.I.= Confidence Interval. 
 
In premorbid social adjustment (PSA), cases had lower scores (χ2(1) = 92.3, 
p<0.001) and the only group that had a significant drop in sociability from 
childhood to early adolescence was made of patients that never smoked cannabis in 
their lifetime (interaction effect between group, cannabis and age of PAS: χ2(2) = 
7.5, p=0.024). 
Everyday cannabis smokers had a drop that became unsignificant after adjusting 
by Bonferroni (unadjusted p=0.016; adjusted p=0.241).  
The opposite was evident in the control group, where everyday smokers gained 
in sociability in their early adolescence, but this difference became unsignificant 
after adjusting by Bonferroni (unadjusted p=0.045; adjusted p=0.669). Those who 
later would become recreational smokers (less than everyday group) were stable in 
their sociability either in case and in control groups. In conclusion, both cases and 
controls who later will smoke cannabis less than everyday are stable in their 
academic and social adjustment from childhood to early adolescence, while both 
cases and controls everyday smokers have a drop in their academic adjustment, but 
not in social adjustment.  
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Finally, both cases and controls who never smoked cannabis, gained from 
childhood to adolescence in their academic adjustment, but cases have a drop in 
their sociability (Figure 27). 
 
Figure 27. Premorbid Social Factor in Childhood and First Adolescence by Cannabis use. 
 
Legend: these two graphs represent the predicted values of PSF (Y axis), divided by cases and controls and 
by frequency of cannabis use (X axis). PSF<12 is represented by the blue line, while PSF-16 is in red. 
 
 
Table 39 shows multiple comparisons of this effect. 
 
 
Table 39. MIXED MODEL on PSA Scores by Time and Group. Corrected by Bonferroni. 
Variables Contrast SE z p-value 95% C.I. 
Cases N-16 vs Cases N>12 -0.169 0.047 -3.63 0.004 -0.306 -0.032 
Cases L-16 vs Cases L>12 
Cases E-16 vs Cases E>12 
0.115 
-0.113 
0.043 
0.047 
0.27 
-2.41 
1.000 
0.241 
-0.115 
-0.250 
0.138 
0.025 
Controls N-16 vs Controls N>12 0.059 0.035 1.70 1.000 -0.043 0.161 
Controls L-16 vs Controls L>12 
Controls E-16 vs Controls E>12 
0.058 
0.168 
0.033 
0.083 
1.64 
2.01 
1.000 
0.669 
-0.043 
-0.077 
0.152 
0.413 
Legend: SE= Standard Error; C.I.= Confidence Interval. E=everyday; L=less than everyday; N=never. 
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2.3. IQ in Cases Who Smoked Cannabis Less than Everyday by Diagnosis  
 
I started from the hypothesis that there exists a subgroup of patients with a 
recreational use of cannabis, who are less cognitively impaired at the onset and less 
socially withdrawn in their premorbid period than other patients and this was true in 
our sample of affective and non-affective psychotic patients. 
At this point I wanted to have a look at first diagnosis attributed to the subjects at 
their admission, given that it was suggested that neurodevelopmental abnormalities 
are present in schizophrenia but not in bipolar disorders (Koenen et al., 2009; 
MacCabe et al., 2010) and that the latter show a much smaller premorbid deficit 
compared to schizophrenia (Trotta et al., 2015).  
An ANOVA was performed on case group only with frequency of cannabis use 
(never/less than everyday/everyday) and diagnosis (affective/non-affective) as fixed 
factors and IQ as dependent variable. 
The model was adjusted for Country, age, gender and ethnicity. Age was 
removed in the final mode because, as expected, resulted not significant within 
cases, given that in IQ calculation it is already taken into account. In this model, 
frequency of cannabis use was important in determining the IQ, in interaction with 
diagnosis (F (2,569) = 4.74, p=0.009).  
That means, less than everyday users with affective psychosis were the only 
group with a higher IQ compared to their non-affective counterpart (p=0.013) and, 
within the group, compared to never-users group, both affective (p=0.020) and non-
affective (p=0.010).  
There were no differences in terms of IQ between affective and non-affective 
psychosis into the never-used group (p=1.000) nor into the everyday-user group 
(p=1.000) (Figure 28).   
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Figure 28. IQ of Cases by Frequency of Cannabis Use and Diagnosis. 
 
Legend: this graph represents IQ scores (Y axis) by frequency of cannabis use (X axis) by affective 
psychosis (represented in blue) and non-affective psychosis (represented in red). 
 
12.4. Further Investigation on the IQ Model 
 
a) Premorbid adjustment factors (PSF and PAF) were inserted as explanatory 
variables in the IQ model performed on the entire sample of cases and controls and 
social factor resulted not significant (p=0.582), while school premorbid adjustment 
was significantly related to IQ (F(1,1692)=309.2, p<0.001) but it did not entirely 
explain its variations in relation to cannabis use. In fact, both cases and controls 
with a recreational use of cannabis still resulted in significantly higher IQ than 
never users (p<0.001). By additionally correcting the analysis for education and 
occupation, they both were significantly related to IQ (p<0.001) and ultimately 
dissolved the cannabis effect on IQ (p>0.05). That means, IQ differences observed 
in cases and controls, in relation to cannabis use, are probably due to premorbid 
academic adjustment and successive educational attainment (Figure 29) 
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Figure 29. IQ of Cases and Controls by Frequency of Cannabis Use and Education. 
 
Legend: on the Y axis there are standardized values of IQ, corrected for age, gender, ethnicity, country, 
education and occupation; on the x axis are grouped subjects with different patterns of cannabis use. 
Percentages of cases and controls included in each category are also indicated.  
 
b) The same analysis was applied on the above described IQ model performed on 
the basis of diagnosis and identical results were found: premorbid academic 
adjustment was significantly related to IQ (while sociability was not), but it did not 
explain the relationship between diagnosis and frequency of cannabis use in 
determining the IQ and cases recreational cannabis users with affective psychosis 
had still a higher IQ (p=0.027).  
After adjusting this analysis for education and occupation, the difference between 
affective and non-affective psychosis in the less than everyday group became 
attenuated and unsignificant (p=0.076), but the interaction effect between frequency 
of cannabis use and diagnosis stayed significant (F (2,557) = 3.25, p=0.039) 
(Figure 30).  
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Figure 30. IQ by Frequency of Use and Diagnosis Corrected for Education. 
 
Legend: this graph represents IQ scores (Y axis) by frequency of cannabis use (X axis) by affective 
psychosis (represented in blue) and non-affective psychosis (represented in red). The results are corrected 
for education 
 
This was due to the fact that patients with affective psychosis who used cannabis 
less than everyday had a higher IQ, compared to patients with non-affective 
psychosis that never used cannabis (p=0.045). This suggest that these two groups 
are different in IQ for reasons that are not related to early scholastic adjustment and 
subsequent scholastic achievement. 
 
c) WAIS full scale IQ was derived from four subtests that are also able to 
estimate some cognitive domains, described as follows (Taub & Benson, 2013): 
	  
•   Block Design: Perceptual Reasoning; 
•   Arithmetic: Working Memory; 
•   Digit Symbol: Processing Speed; 
•   Information: Verbal Comprehension. 
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The four scales of WAIS were entered instead of IQ into the MANOVA 
(corrected by age, gender, country and ethnicity), without any correction of 
premorbid adjustment, in order to see if any of them have a higher influence in 
determining the IQ effect observed in relation to cannabis use.  
Controls performed better in all scales, after correcting for potential confounders 
(F(4,1712)=131.97, p<0.001) and frequency of cannabis use influenced 
performance (F(4,1712)=4.73, p<0.001), as following described, without any 
significant interaction with group (p=0.113).  
 
•   Perceptual Reasoning: higher in cases and controls cannabis users, both 
everyday (p=0.002) and less than everyday (p=0.044). 
•   Working Memory: no differences in terms of cannabis use, taken alone. 
•   Processing Speed: a trend of worse performance in both cases and controls 
everyday users than in less than everyday (p=0.074). 
•   Verbal Comprehension: better in less than everyday users (p=0.007). 
 
The analysis was further corrected by education and occupational status, and 
results stayed identical for Perceptual Reasoning that resulted still higher in cases 
and controls heavy (p=0.001) and recreational users (p=0.014). 
There was an interaction effect between education and group in explaining both 
Processing Speed (p=0.012) and Verbal Comprehension (p=0.037), i.e. scores on 
these tests were better in controls with higher education but not in relation to 
cannabis use (Figure 31).  
These results indicate that Perceptual Reasoning, that is also part of the measure 
of executive functions (Wechsler, 1981) could be important in determining 
differences between cannabis users and non-users, regardless education. 
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Figure 31. IQ Scales by Group and Frequency of Cannabis Use. 
 
 
Legend: each graph on the highest part represents a different cognitive domain, which scaled scores are on 
the Y axis, by group (cases are in red and controls are in blue) and frequency of cannabis use (X axis). 
The two graphs in the lowest part, represent Processing Speed and Verbal Comprehension scaled scores (Y 
axis) in relation to education (X axis). 
 
12.5. What Does Augment the Risk to Smoke Cannabis? 
 
The manova allowed me to describe the outcomes in terms of premorbid 
adjustment and IQ, given certain conditions of cannabis use, abuse or abstinence.  
The IQ model was further designed with premorbid conditions and education as 
predictiors, because IQ results from a complex interaction of several aspects of an 
individual’s trajectory. For the same reason, and following previous studies, it was 
also subsequently divided into the main four scales used in its calculation. 
Given the complexity of the previous results, a multinomial regression was used 
in order to compare the risk to be everyday user or less than everyday user, rather 
6
7
8
9
10
11
Ne
ve
r
Le
ss
  th
an
  ev
ery
  da
y
Ev
ery
  da
y
control case
Perceptual  Reasoning
6
7
8
9
10
11
Ne
ve
r
Le
ss
  th
an
  ev
ery
  da
y
Ev
ery
  da
y
control case
Working  memory
6
7
8
9
10
11
Ne
ve
r
Le
ss
  th
an
  ev
ery
  da
y
Ev
ery
  da
y
control case
Processing  speed
6
7
8
9
10
11
Ne
ve
r
Le
ss
  th
an
  ev
ery
  da
y
Ev
ery
  da
y
control case
Verbal  comprehension
6
7
8
9
10
11
12
13
University-­post-­graduate first  level,  job  related compulsory  education no  education
control case
Verbal  comprehension
6
7
8
9
10
11
University-­post-­graduate first  level,  job  related compulsory  education no  education
control case
Processing  speed
	  
 141 
 
than never users, taking into account IQ scales, PAF and PSF as predictors, along 
with other variables (i.e. age, gender, ethnicity, country, education, and occupation).  
In the final model, group belonging (p=0.161) became non significant in 
determining the ratio of the relative risk (RRR) to be a recreational cannabis user or 
an abstinent subject, i.e. the risk to approach cannabis in a recreational pattern of 
use was similar in cases and controls, while group stayed significant in determining 
a higher risk to be an everyday user (RRR=3.6, p<0.001, CI 95% 2.38, 5.56), i.e. 
cases were 4 times more likely to be heavy cannabis users than controls.  
Holland presented a two-fold increased risk to have everyday smokers than 
abstinent subjects (RRR=2, p=0.005, CI 95% 1.23, 3.32), thus confirming previous 
descriptive statistics.  
Males were up to 2.6 fold more likely to be heavy cannabis smokers (p<0.001, CI 
95% 1.85, 3.79) and 1.6 more likely to be recreational smokers (p<0.001, CI 95% 
1.23, 2) than abstainers in both the case and control group. 
Unemployed people were 2 fold more likely to be heavy cannabis users than 
abstainers (RRR=2.2, p<0.001, CI 95% 1.52, 3.14), but this condition did not 
influence the probability to be recreational users (p=0.449). People with a 
compulsory education were less likely to be recreational smokers than people with a 
university degree (p=0.021).  
The risk to be a recreational user augments with higher scores of Verbal 
Comprehension (RRR=1.1, p=0.016, CI 95% 1, 1.08) and Perceptual Reasoning 
(RRR=1.1, p=0.002, CI 95% 1.02, 1.10).  
Even if higher scores in perceptual reasoning and a higher premorbid social 
adjustment, taken alone, augment the risk to be a recreational user, if they both are 
higher in the same subject ultimately reduce this risk (OR=0.96, p=0.017, CI 95% 
0.92, 0.99). 
Everyday use is predicted by higher scores of Perceptual Reasoning (RRR=1.1, 
p>0.001, CI 95% 1.06, 1.18) and Verbal comprehension (p=0.022), the latter in 
interaction with a higher sociability (OR= 0.94, p=0.009, CI 95% 0.89 0.98) and 
lower scores in Processing Speed (RRR=1.1, p=0.022, CI 95% 1, 1.1), the index 
less related to general IQ (Taub & Benson, 2013) but this latter effect is moderated 
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by higher levels of premorbid academic adjustment that reduce the risk of cannabis 
heavy use in people with lower scores of processing speed (RRR=0.9, p=0.009, CI 
95% 0.85, 0.98).  
A higher working memory (RRR=0.9, p=0.008, CI 95% 0.88, 0.98) moderates 
the role of a higher premorbid sociability in increasing the risk to be a heavy 
cannabis user, acting as a protective factor in more sociable people. 
 
12.6. What Regulates the Risk to Became a Recreational or an Everyday 
Cannabis User? 
 
We know that levels of THC in the cannabis used, age at first use and current use 
could be important in studying the relationship between the variables of this Study 
(Di Forti et al., 2007; Schoeler & Bhattacharyya, 2013).  
In our previous study (GAP sample), we did not find any relationship between 
age at first cannabis use, current use, type of cannabis used and IQ or premorbid IQ, 
probably due to the small numbers of the sample. In my opinion, the best way to 
look at them is in the role that they have in determining the risk to be users and 
recreational users, along with other variables of interest.  
As an exploratory analysis on these other variables, a logistic regression was 
computed, using frequency of cannabis use (only two categories) as an outcome 
variable in order to estimate the risk to be an everyday user or a less than everyday 
user, taking into account a list of predictors (age, gender, country, ethnicity, 
education, occupation, age at first use, % of THC, current use, PSF, PAF and the 
four scales of WAIS).  
In the final model, country, gender, age, ethnicity and current cannabis use were 
not significant and were subsequently excluded them from the analysis. The risk to 
be an everyday smoker was higher for cases, in interaction with age at first use, i.e. 
while the risk of controls diminishes when age at first use increases, this is not true 
for cases, whose risk stay higher even when age at first use increases (OR=1.2, 
p=0.001, CI 95% 1.09, 1.45).  
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The highest risk was for cases who smoked cannabis earlier in their life (see 
Figure 32).  
 
Figure 32. Probability to Be Everyday Cannabis User by Age at First Use and Group. 
 
Legend: on the Y axis is represented the probability to be an everyday smoker, while on the X axis are 
represented different ages at first cannabis use for cases (in red) and controls (in blue). 
 
THC absolute concentration >10% augmented almost 2 folds the risk to be an 
everyday smoker (OR=1.8, p=0.001, CI 95% 1.29, 2.60), and was not in interaction 
with any other variables.  
As already observed in previous analysis, unemployed people were more likely 
to be everyday users than recreational users (OR=1.9, p<0.001, CI 95% 1.40, 2.84).  
A higher premorbid social adjustment (OR=1.6, p=0.019, CI 95% 1.08, 2.60) and 
lower premorbid academic adjustment (OR=0.8, p=0.040, CI 95% 0.68, 0.99) 
increased the risk to be a heavy cannabis user, along with having completed 
compulsory or first level education or having no education (all p<0.05), compared 
with university degree. 
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Interestingly, higher scores of working memory moderate the role of sociability 
and education. So, even if both having an intermediate level of education and being 
more sociable before your 16th year increase the risk to be a cannabis heavy user 
rather than a recreational user, higher scores of working memory reduce this risk in 
more sociable people (OR=0.9, p=0.021, CI 95% 0.90, 0.99) and in people who 
completed compulsory school (RRR=0.7, p=0.012, CI 95% 0.62, 0.94) and 
achieved a diploma (RRR=0.8, p=0.005, CI 95% 0.67, 0.93).  
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Chapter 6  
Analysis and Discussion of the Findings  
 
 
 
1. Introduction  
 
In this chapter I will summarize the key finding of this thesis. I am going to 
comment on the results, by comparing them with the literature on this topic. I will 
address methodological issues, strengths and limitations of the study and I will 
suggest how my findings might contribute to the field of research into psychotic 
disorders. Finally, conclusions of the study will be displayed. 
 
 
2. Hypotheses  
 
2.1. Confirmatory Hypothesis  
 
1. I expected that cases would show a greater cognitive impairment (i.e. lower 
IQ) than controls overall, independent of potential confounders and across all 
countries. 
2. I expected that cases would be more socially and academically impaired in 
their premorbid period than controls overall, independent of potential confounders 
and across all countries. 
3. I expected that cases would be more likely to have smoked high potency 
cannabis, starting at an earlier age and with a higher frequency than controls. 
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2.2. Replication-Hypothesis 
 
I expected that cases who have used cannabis in their lifetime would be less 
cognitively impaired (i.e. higher IQ) than those who did not, independent from 
potential confounders.  
 
 
2.3. Original Hypotheses 
 
1. I expected that patients who used cannabis in their lifetime would show a 
better premorbid adjustment.  
2. I expected that “Country” significantly would affect the relationships between 
the variables of interest. 
3. I expected to find better premorbid adjustment (both social and academic) in 
cases who smoked cannabis in their lifetime “less frequently than everyday”, 
compared to people who smoked cannabis “everyday” and to people who did not 
smoke cannabis at all in their lifetime. I hypothesized the existence of a subgroup of 
patients with a recreational use of cannabis, who are less cognitively impaired at the 
onset and less socially withdrawn in the premorbid period than other patients. 
 
 
3. Findings 
 
The final sample of the study included 1,895 subjects 834 cases and 1,061 
controls), from different Countries. All differences between cases and controls in 
age, gender distribution, ethnicity, education, occupation, and relationship status 
were expected, as being male (Aleman et al., 2003; McGrath et al., 2004) 
unemployed, single and having poor education have been associated with an 
increased risk of psychosis (C Morgan et al., 2008; Stilo et al., 2013). Differences in 
age, are due to the fact that psychosis is a psychiatric disorder that shows a peak of 
incidence in young females (29-32 years) and even younger males (20-24 years) 
(Castle, Sham, & Murray, 1998) that are also overrepresented in case group. Males 
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in case group are younger (i.e. have an earlier age of onset) than females 
(exploratory analysis t(831)=-5.8, p<0.001), but this is not true in control group 
(p=0.337). Indeed, the control sample was recruited in order to be representative of 
the general population than matched with case group.  
A difference with previous findings on UK samples (C Morgan et al., 2008; Stilo 
et al., 2013), was represented by living status. In fact, our cases were less likely to 
have ever lived alone in their lifetime than controls and they were more likely to 
live with their parents or in other families. This difference could be due to the 
inclusion of countries different from UK (for example Spain and Italy) where young 
people (18-34 years) have been more likely to increasingly live with their parents 
over the last years (EUROSTAT, 2016) probably due to the economic crisis and/or 
to their cultural background, e.g. by exploratory analyses on our sample we know 
that 36.9%  of cases and controls in Spain are living with their parents (45.5% with 
parents, other family or institutions) vs. 8.3% who are living alone and 37.9% of 
cases and controls in Italy are living with their parents (50.6% with parents, other 
family or institutions) vs. 9.5%  who are living alone. According to the Eurostat 
report (2014) Spain and Italy have a higher proportion of unemployed people 
among young adults (18-34 years), who are also living with their parents, compared 
to UK (EUROSTAT, 2014) and the unemployed condition is overrepresented in our 
case group and this could be another reason for this difference in living status. 
As expected, cases showed a lower IQ than controls overall, independent of 
potential confounders and across all countries (Bora et al., 2010; Matheson, 
Shepherd, Laurens, & Carr, 2011; Mohamed, Paulsen, O’Leary, Arndt, & 
Andreasen, 1999; Zanelli et al., 2010). They were also more socially and 
academically impaired before their 16 years than controls, independent of potential 
confounders and across all countries (Cannon et al., 2001; Hans et al., 1992). 
Cases in our sample were also more likely to have used cannabis in their lifetime 
compared to controls (68.4% vs. 55.7%) and 24.3% of cases were currently using 
cannabis, a higher percentage compared to controls (13.3%), but lower than that 
referred in Myles and colleagues’ meta-analysis (33.3%) (Myles et al., 2016). This 
difference could be due to the period of the recruitment and assessment (from the 1st 
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of May 2010 to 30th of June 2015), given that rates of cannabis use show 
geographical variations and a modest decline in the last years, after a peak 
prevalence between 1995 and 2000, in psychotic patients (Myles, Myles, & Large, 
2016).  
I also confirmed expected data on pattern of cannabis use, i.e. males were more 
likely to smoke cannabis overall (Donoghue et al., 2014; Larsen et al., 2006; Sevy 
et al., 2010), cases were more likely to have smoked high potency cannabis, starting 
at an earlier age and with a higher frequency than controls (see also Di Forti et al., 
2009) and this effect was mostly attributed to tolerance induced by the substance. 
 
3.1. IQ in Cannabis Using Patients and Controls Across Europe 
 
I have tried to replicate on the EU-GEI sample previous findings on IQ described 
in Chapter 4.  
The role of other illegal drugs of abuse was ruled out in an explortory analysis 
where subjects with at least one drug of abuse in their lifetime were removed from 
the sample and the analysis were repeated, without any change in main results.  
Tobacco use in the last 12 months, in our sample, was related to a higher 
premorbid sociability, a lower premorbid academic adjustment and a lower IQ. This 
latter finding suggests that, in spite of the relationship between cannabis and 
tobacco use, cannabis users and tobacco users are not coincident in their cognitive 
characteristics, but merely in premorbid predisposition to substance-use and it is not 
surprising. However our data on tobacco-use were limited to recent pattern of 
smoking (i.e. in the last 12 months), thus it was not possible to go in depth of this 
association.  
Both patients and controls who smoked cannabis in their lifetime had a 2.02 
points higher mean IQ than their respective no-cannabis group and the analysis was 
corrected for age, gender, ethnicity and also occupation and education, in order to 
rule out the possible confounder of premorbid conditions influencing current IQ 
trough socio-economic status (Barona et al., 1984; Crawford & Allan, 1997).  
	  
 149 
 
In line with previous meta-analysis (Yücel et al., 2012; Potvin et al., 2008; Rabin 
et al., 2011), first episode psychotic patients that used cannabis in their lifetime 
showed a better IQ overall, thus replicating our previous findings on the GAP 
sample (Ferraro et al., 2013). 
This time, however, controls who reported to have smoked cannabis in their 
lifetime showed a higher IQ than no-cannabis control group and, to date, this is the 
first study that found a higher current IQ in healthy cannabis-users.  
Previous studies on subjects from the general population suggest no effects of 
cannabis on current cognition after 25 days of abstinence or a small residual 
detrimental effect, before this period (Schreiner & Dunn, 2012, Grant et al., 2003). 
Moreover, results from the Dunedin longitudinal cohort study show that subjects 
with more persistent cannabis dependence present an IQ decline over time, when 
compared to study members who never used cannabis, an effect not observed in 
previous meta-analyses (Meier et al., 2012). On the other hand, it was suggested an 
association between higher childhood IQ and subsequent cannabis recreational or 
discontinued use in adolescence (Ensminger et al., 2002; Fleming et al., 1982; 
Kellam et al., 1980; White & Batty, 2012; White, Gale, et al., 2012; White, 
Mortensen, et al., 2012) and subjects in the Dunedin study who reported a lifetime 
recreational use of cannabis, but not dependence, started with a higher IQ than those 
that never used cannabis and had a similar IQ at their 38 years (Meier et al., 2012). 
Thus, there are no reasons to sustain that the higher IQ detected in controls who 
used cannabis in their lifetime is subsequent to an ameliorative effect of the 
substance and it is more likely that it is due to better premorbid conditions, e.g. 
better IQ before cannabis use has started. The difference in IQ in control group 
could have been also identified thanks to the big proportion of the sample and to the 
differentiation and heterogeneity across different Countries. In fact, the difference 
in IQ was small (2.02 points) and lower than the established standard deviation of 
the WAIS (±3), thus suggesting a role of the sample size in detecting it. 
Additionally, we had the opportunity to look at an heterogeneous sample, different 
in terms of ethnicity distribution and socioeconomic status by country and able to 
overcome most of the selection bias (Heckman, 1979), some of which could have 
	  
 150 
 
been also implicated in previous studies like the abovementioned Dunedin Cohort 
Study (Gonzalez & Swanson, 2012).  
The factor “Country” resulted significant as a main effect but not in interaction 
with cannabis or group, i.e. across countries, IQ resulted similar in relation to 
cannabis use and group but shifted. In an exploratory analysis, the IQ shifting 
resulted from interactions between country and age, ethnicity, education and 
occupation, i.e. some cities included in different countries have more ethnic 
variation, are more educated, have different occupational conditions and are 
definitely “younger” than others, thus statistically indicating the importance of these 
variables in influencing IQ in different cultural contexts and the extraordinary 
opportunity offered by a cross-country design, able to recruit a sample tested with 
the same instruments (differently from meta-analytic samples) that stays 
heterogeneous even after a statistical correction for these variables. 
 
3.1. Premorbid Adjustment in Cannabis Using Patients and Controls Across 
Europe 
 
In order to look at premorbid adjustment, I first confirmed through the factorial 
analysis the structure of PAS and its suddivision in a Premorbid Social Factor and a 
Premorbid Academic Factor, the latter being a proxy for premorbid IQ (Barajas et 
al., 2013; Norman et al., 2005). 
Both cases and controls who smoked cannabis in their lifetime started with a 
lower premorbid academic adjustment, that was previously indicated as a 
predisposing factor for cannabis use (Wills, Walker & Resko, 2005) and was 
already observed in several studies on subjects from the general population 
(Apantaku-Olajide, James, & Smyth, 2014; Krohn, Lizotte, & Perez, 1997; Meier, 
Hill, Small, & Luthar, 2015; Lee, Winters, & Wall, 2010). In the previous GAP 
study, Premorbid IQ was estimated using the Wechsler Test of Adult Reading 
(WTAR), a reading test normed with the WAIS-III, which is able to provide a broad 
estimate of general ability before the illness (Holdnack, 2001) and results a pure 
measure of premorbid intelligence, strictly related to current IQ and different from 
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premorbid school adjustment (including both academic achievement and adaptation 
at school) that could be influenced by other factors independents from IQ.  
Nonetheless, this finding seems to be counterintuitive in relation to the higher IQ 
of cannabis-using subjects, given that these two measures (IQ and PAF) are related 
each other. Kandel (1978) has found similar results, that poor school performance is 
a common antecedent of substance use but substance use is positively related to a 
higher IQ. An analogous finding was reported by Legleye and colleagues (2010) 
who revealed also that adolescents who only experimented with the use of cannabis, 
without changing to subsequent daily use, were less likely to drop out of secondary 
school than adolescents who never used cannabis and they highlighted that the odds 
of dropping out increased with the frequency of use beside early cannabis use. This 
issue was addressed in the final model stratified by frequency of cannabis use. 
Differences in sociability were not significant in controls in relation to cannabis 
use, while first episode psychotic patients who used cannabis showed better 
premorbid sociability before 16 years than patient who did not, in contrast with a 
previous study that did not find such effect (Leeson, Harrison et al., 2011).  
It is possible to speculate that the relationship between cannabis use and 
premorbid sociability was different in cases and controls for at least two reasons: a) 
PAS is a test specifically designed for assessing premorbid conditions in psychosis 
and could be more sensitive to differences in this subgroup of people, in fact social 
adjustment factor alone is able to explain most of the variance of the premorbid 
adjustment in childhood and early adolescence in the case/control group; b) healthy 
controls, that are generally not pathologically impaired in sociability, present a 
small but not statistically detectable difference (p=0.053) of this aspect in relation to 
cannabis use, i.e. healthy people who do not smoke cannabis are not socially 
withdrawn, they are probably involved in different peer environments, not 
predisposing to drug-use initiation (Bauman & Ennett, 1996; Vervaeke et al., 2008). 
As hypothesized, given that premorbid sociability is the most impaired domain 
among affective and non-affective psychosis (Norman et al., 2005), this finding 
suggests a lower premorbid predisposition of this group to psychosis. 
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The factor “Country” resulted significant as a main effect in all these analyses 
but not in interaction with cannabis use, i.e. academic and social adjustment resulted 
similar in relation to cannabis use, but shifted in different Countries. The only 
difference by country (i.e. the shift), accounted for group and ethnicity, i.e. cases in 
Holland were better in their premorbid academic adjustment and closer to control 
group than other cases. Controls in Spain were better in their social adjustment than 
other countries and very different from respective cases. In some countries, minority 
Ethnicities revealed a better adjustment before their 16, e.g. in Holland and Spain 
they shown a better early sociability compared to white people and this could be 
related to a different early cultural environment, while in Italy they had a better 
premorbid academic adjustment, compared to minority Ethnicities from other 
countries, opposite to finding from other studies (G. Bhattacharyya, Ison, & Blair, 
2003) and this is probably due to the fact that, in Italy, they are mostly first 
generation migrants (100% of black people and 90.5% of other ethnicities are 
migrants), so they are referring to school adjustment in their original country. 
 
3.2. Is Frequency of Cannabis Use Lifetime of Crucial Importance in Relation 
to Premorbid Adjustment and IQ? 
 
As already mentioned, longitudinal studies on IQ and cannabis use have found a 
relationship depending on frequency of cannabis use, that means, between higher 
premorbid IQ and school adjustment and later recreational or discontinued use, 
though a lower premorbid IQ resulted as a predictor for regular or heavy cannabis 
use (Ensminger et al., 2002; Fried et al., 2002; Meier et al., 2012; White et al., 
2012; White & Batty, 2011; Kellam et al., 1980). Other important variables of 
interest are THC concentration in the cannabis used, age at first use (Di Forti et al., 
2007; Yücel et al., 2012) and current use (Pope, 2002).  
However, none of these variables, taken alone, is sufficient in explaining the 
potential harmful effect of cannabis without any indication of the frequency of its 
use, that is the estimated amount of the substance and the dependence-behaviour. 
E.g. we cannot have any information from recent-use, THC concentration or age of 
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first use if the substance was used just once or twice. Thus, “frequency of use” is a 
superordinate category and the stratification of the sample by a combination of 
these abovementioned variables (see for example Fried et al., 2002, 2005) would be 
a forced interaction strategy in looking at outcomes, that additionally risks to reduce 
the power of each observed condition, thus decreasing the probability to detect little 
differences. Instead, I decided to perform logistic models in order to look at the 
relationship between these variables and the risk to became heavy cannabis users. 
High frequency of use lifetime (everyday cannabis use) was predicted by an 
earlier age at initiation, especially in controls, and as a result of the selection of 
High Potency Cannabis (THC absolute concentration >10%). Current use was not 
related to frequency of cannabis use. Two further exploratory analysis were 
performed on this variable and their results are briefly described at this point of the 
work: a) as expected, once entered as fixed factor with current or not-current use in 
a MANOVA, were never users were excluded, frequency of use was able to predict 
IQ, PAS and PSF scores within cannabis users (F(3,1032)=10.30, p<0.001), while 
current use was not (p>0.005); b) in a MANOVA where current use was inserted 
alone and never users were codified as the baseline category (i.e. never used/ used 
but not currently/ currently use) patients and controls with current cannabis use 
were not different from abstainers counterparts in any of the outcomes 
(F(3,1028)=0.14, p=0.937) nor in interaction with group, so the lack of difference 
was present in both case and control group (F(3,1029)=1.92, p=0.125). 
However, it is not possible to give a definitive statement about acute or residual 
toxicity of cannabis starting from these results. In fact, the selected sample of 
cannabis smokers included abstinent and not abstinent users in this study. The cut-
off for current use was 12 months and, as a consequence, the group of current users 
included people that could suffer from residual effects, mixed with a proportion of 
people who last smoked cannabis more than 28 days before the assessment, thus not 
suffering of such effect (Pope et al., 2002). On the other hand, frequency of use 
referred to the period in which cannabis was mostly used in the lifetime.  
Thus, our frequency and current-use variables are more “behavioural indexes” 
and indicators of the amount of cannabis intake in a certain period of life, rather 
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than acute and current “intoxication indexes” (see also Schnakenberg Martin et al., 
2016).  
In the next paragraphs, I will summarize and comment on the results obtained by 
examining frequency of cannabis use. 1,739 subjects were included in the final 
analysis looking at relationships of group and frequency of cannabis use with 
premorbid conditions and IQ and the interaction between these variables resulted 
significant in determining the outcomes, as following described. 
 
3.2.1. Never Users  
 
As expected, cases in this subgroup performed significantly worse in IQ scores 
than recreational cannabis users (Ferraro et al., 2013; Yücel et al., 2012; Potvin et 
al., 2008; Rabin et al., 2011) and similarly to everyday users. The lack of difference 
in IQ between cases everyday users and never users was already found in previous 
studies (Joyal et al., 2003; Pencer & Addington, 2003; Sevy et al., 2007). The 
novelty of this result consists in having compared the three groups at the same time 
by matching them with their healthy control counterparts.  
The same IQ difference was detected between abstainers and recreational users in 
healthy controls and will be discussed in the following part.  
As expected, cases, but not controls, showed a poorer premorbid social 
adjustment, compared to both recreational and heavy cannabis users. Similar results 
were also incidentally found by Sevy et al., (2010) and Compton et al., (2011).  
Interestingly, this group of patients was the most impaired group in terms of 
sociability and had a further drop in sociability from childhood to early adolescence, 
in line with the neurodevelopmental hypothesis (R. Murray, O’Callaghan, Castle, & 
Lewis, 1992; R M Murray & Lewis, 1987). It was also suggested that a poor 
premorbid social adjustment is more often related to an insidious onset and later age 
of onset (Bailer et al., 1996), as is the case in our sample. 
Both cases and controls that never smoked cannabis had a higher academic 
adjustment before their 16th year compared with cannabis users (see also Sevy et al., 
2010; Compton et al., 2011). However, both groups presented a gain in their 
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scholastic adjustment from childhood to early adolescence. In this gain, the role of 
gender and diagnosis, for cases, were controlled and therefore excluded.  
While this could be intuitive for controls, it seems in contrast with previous 
results on premorbid academic adjustment in psychosis, that is normally considered 
impaired and in further decline from childhood to late adolescence (from 16 years) 
(D. N. Allen et al., 2013; Strauss et al., 2012) and was proposed as related to the 
genetic risk for schizophrenia (Walshe et al., 2007). However, we do not know if 
the gain continues in late adolescence or if, after a normal phase between childhood 
and first adolescence these subjects will show a decline in academic adjustment. We 
can imagine that it happens after their 16 years, because their IQ is the lowest 
between sub-groups of cases and similar to IQ scored in everyday cannabis users, 
that have instead a drop in premorbid academic adjustment from childhood to early 
adolescence.  
Looking at education, almost 41% of cases that never used cannabis achieved a 
diploma, but they were still mostly unemployed; and 42% of them had a partner at 
the moment of the interview, but they mostly lived with their parents at the onset.  
Age of onset of psychosis is another important point of interest in explaining this 
difference. In fact, this subgroup had significantly later age of onset and greater 
variance (34.8±12.1), compared with recreational cannabis users (29.1±9.3) and 
heavy cannabis users (26.8±7.7) and they were predominantly females (57%). In 
support of this consideration, a recent study, that divided a large cohort of 
schizophrenics into non-users, subjects with a lifetime history of cannabis use or 
dependency, found no differences in premorbid cognitive ability after controlling 
for age at onset of illness and socio-economic status (Power et al., 2015). 
A correlation between higher academic adjustment in childhood - but not in early 
adolescence - and later age of onset was found by Monte, Goulding and Compton 
(2008), along with lower social adjustment in early adolescence, as is the case in 
our sample. Nevertheless, their sample included 45.3% of patients with a cannabis 
abuse disorder and they did not divided or controlled for this variable (Monte et al., 
2008). In my opinion, this could have nulled the possibility to look at this relative 
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gain in early adolescence, given that cannabis users have a drop in premorbid 
academic adjustment.  
It is possible to speculate that this subgroup of abstinent patients, has a drop in its 
academic adjustment in late adolescence, i.e. after 16 years, close to the onset of the 
prodromal phase (Allen et al., 2013; Monte et al., 2008; Strauss et al., 2012) but not 
before, while social adjustment is impaired from childohood and has a drop in early 
adolescence, as expected (Sevy et a., 2010; Compton et al., 2011).  
Horton and colleagues (Horton, Tarbox, Olino, & Haas, 2015) show something 
similar in a graph enclosed in their recent study i.e. a little gain in academic 
premorbid adjustment in early adolescence, that was not statistically explored in its 
significance, followed by a drop in late adolescence, in a group of first episode 
psychotic patients that they defined with a stable-poor functioning. However, they 
did not look at cannabis use lifetime and just excluded patients with any substance 
abuse in the last 6 months. Authors who specifically linked the higher social 
deterioration with a later onset of psychosis and the higher academic deterioration 
with an earlier onset, divided these two conditions into the notion of Deficit or Not-
Deficit Syndrome, the first being predictive of a higher severity of negative 
symptoms (Galderisi et al., 2013; Rabinowitz et al., 2002).  
Even if Kirkpatrick et al. (1996) have initially identified a less severe prevalence 
of lifetime cannabis use in deficit compared to non deficit syndrome, but no 
differences in terms of current use (Kirkpatrick et al., 1996), none of the studies on 
the Deficit Syndrome looked at cannabis use in adolescence as a risk factor for a 
earlier age of onset (Di Forti et al., 2009, 2014) in non-deficit syndrome, or they 
merely excluded recent substance abuse (Bucci et al., 2016; Chang et al., 2013; 
Strauss et al., 2012; Allen et al., 2013).  
This group of subjects constituted our control group of abstinent patients, and the 
findings suggest that their neuropsychological and early social deficits could 
underlay a profile of people at-risk to develop psychosis without the need for the 
additional risk factor of cannabis use (Di Forti et al., 2007). 
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 3.2.2. Recreational Cannabis Users  
 
As hypothesized, cases in this subgroup performed significantly better in IQ 
scores than never users, without no differences with everyday users. That means, 
better IQ reported in both cases and controls cannabis smokers is due to the 
subgroup of those who smoked cannabis less than everyday, thus accounting for the 
higher IQ reported in cannabis users overall. In fact, they generally represent the 
bigger proportion of smokers (Myles et al., 2016) and they accounted for the 48% 
of the control sample overall and for the 37.2% of the case sample in this study and 
for 52.2% of controls and 40.3% of cases in GAP study (see Chapter 4).  
As expected, this sub-group of patients started with a better premorbid academic 
adjustment before their 12 years, that stayed stable between childhood and up to 16 
years. Nearly after this period they tried cannabis for the first time (17.5 was the 
mean age and 16 the median age). In my knowledge, previous studies that explored 
premorbid academic conditions in psychotic patients cannabis users are rare and 
have selected only current or heavy users by comparing them with never users, thus 
revealing a worse pemorbid academic functioning (Compton et al., 2011; Sevy et 
al., 2010; Ringen et al., 2013).  
The pattern of cannabis use in cases “less than everyday” users was not current in 
the 71.1% of them and mostly social (85%), but they still preferred high potency 
cannabis, they were mostly single and living with their parents. Neverthless, their 
educational/occupational trajectory seems to be better than other patients, in fact 
they have more years of education than never users and everyday users, they 
represented 37.2% of the proportion of cases that achieved a diploma, 46.6% of 
whom with a university degree and 43.5% of cases employed or student.  
This group of patients, as expected, started also with a better premorbid 
sociability before their 12 years, that stayed stable between childhood and up to 16 
years and this is, in my knowledge, the first study detecting this relationship by 
cannabis use. Leeson and colleagues, have found a better IQ (preserved in relation 
to premorbid IQ) in FEP cannabis recreational users in their lifetime compared to 
everyday users, but no differences in premorbid social adjustment (Leeson, 
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Harrison, et al., 2011). In another study, the same group found out that psychotic 
patients with preserved IQ showed a correlation between both premorbid or current 
IQ at baseline and social employment/occupational adjustment scale (using the 
Social Function Scale by Birchwood et al., 1990), but no other clinical feature 
distinguished the groups, including the level of premorbid social functioning 
measured by PAS (Leeson, Sharma, et al., 2011).  
Among cases, diagnosis at first contact was important in determining the higher 
IQ of this subgroup of patients. Affective psychoses accounted for the higher IQ of 
cannabis recreational users, even after controlling for premorbid adjustment, and the 
difference with never users (both affective and non-affective) stayed significant 
even after adjusting for education and occupational status. We know that more 
affective features are associated with less cognitive impairment (Hill et al., 2013, 
2008) in psychosis and a little proportion of schizophrenic patients appear 
indistinguishable from IQ-matched healthy controls (MacCabe et al., 2012). In an 
exploratory analysis, recreational cannabis users with non-affective psychosis were 
similar to non-smokers and everyday smokers in term of IQ and premorbid 
academic adjustment, but they were more sociable. In our sample, it seem more 
likely that the deficit in IQ is driven by the majority of cases, while the higher IQ is 
represented by a subgroup of mostly affective-psychosis with higher education and 
recreational cannabis use, which link with affective outcomes has been less evident 
in previous research (Moore et al., 2007).  
Cases in this subgroup have also an intermediate age of onset (29.1±9.3), they 
are younger than never users but developed psychosis later than everyday users and 
started the use of cannabis at a later age than everyday users. 
In controls, similarly to cases, the better IQ of cannabis recreational users 
accounted for the higher IQ of the cannabis-group and was associated with a better 
academic adjustment before 16 years, that stayed stable from childhood to early 
adolescence. In fact, group belonging became non-significant in determining the 
risk to be a recreational cannabis user or an abstinent subject in the multicomponent 
analysis, i.e. once inserted in a model considering IQ, premorbid adjustment and 
several other confounders, cases were not more at risk to be cannabis recreational 
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users than controls. They were also the group with more years of education and the 
most represented group among people with a university degree (51%) and having a 
job or a student position (50%).  
They tried cannabis for the first time at a mean age of 18 years (most of them at 
17 years, median age) and they mostly subsequently stopped its use (88.6%). 
Almost all of them (95.5%) smoked socially, sharing the substance with their 
friends. There were no differences in the type of cannabis preferred and they were 
more likely to have tried other drugs than everyday cannabis users. Allen and 
colleagues indicated in their meta-analysis that the influence of peers for cannabis 
use increases as the age of the participant increases (r =0.157) (M. Allen et al., 
2003). All these data, taken together, suggest an explorative behaviour within a 
social context of friends, that is not capable to interrupt the trajectory of their life.  
Additionally, given that these subjects are also more educated and the risk to 
become recreational cannabis-users in both cases and controls is higher for people 
with a university degree, we can speculate that they entered in contact with the 
substance during their academic career, that would be, in turn, responsible for their 
higher IQ, along with the higher occupational status (Dickens et al., 2001).  
In fact, by performing the analysis with frequency of cannabis use as predictor 
and correcting for education, the effect of cannabis on IQ disappeared.  
Looking at different scales of IQ, the risk to be a recreational user for both cases 
and controls augments with higher scores of Verbal Comprehension, that is a hold 
intellectual capacity related with premorbid IQ (O’Connor et al., 2012; Wechsler et 
al., 1981). A higher Perceptual Reasoning index (see also Coulston et al., 2007), 
that is also an index for executive functions (Wechsler et al., 1981) augments the 
risk to be a recreational cannabis user, and its effect is enhanced in people with a 
good premorbid sociability. 
As already mentioned, Legleye and colleagues (2010) have found that 
adolescents that smoked cannabis with a recreational pattern of use, were less likely 
to drop out of secondary school and speculated that cannabis experimentation is 
very common among adolescents and may reflect successful peer integration and 
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thus a positive social experience that may, in turn, be protective for educational 
attainment (Legleye et al., 2010).  
Another suggestion came from studies that relate anxiety and cannabis use 
(Buckner & Zvolensky, 2014; Foster et al., 2015, 2016), given that a link between 
higher IQ and anxiety in healthy subjects was proposed by Coplan and colleagues 
(Coplan et al., 2006, 2011). The majority of our patients (81.1%) and controls 
(71.5%) stated to have smoked cannabis (any pattern of use) to feel more relaxed 
and, if it would be of critical importance, it could suggest a common vulnerability to 
mood dysregulation in cases and controls, whit subsequent cannabis use propensity, 
where cases have additional genes susceptibility for psychosis.  
Moreover, we know that anxiety and mood disorders are typical of the prodromal 
phase of schizophrenia (Howes & Murray, 2014), that in this subgroup of patients 
could be started at a later age, thus determining a later contact with the substance. 
However, we cannot test this hypothesis in our sample, we have only evidence of a 
relationship between affective psychosis, cannabis recreational use and higher IQ 
(Koenen et al., 2009; MacCabe et al., 2010).  
These results, taken together, suggest that a good premorbid IQ, an early 
sociability and integration at school, coupled with higher education, could result in 
a better IQ, and this is not surprising. Cannabis or other-drug experimentation in 
this group seems to be just an incidental factor that could indicate their involvement 
in particular groups, thanks to the higher sociability (for example colleagues at 
university or during first level education), that prompted for cannabis use, but at a 
later age, thus reducing the risk to become everyday users, as later discussed.  
 
3.2.3. Everyday Users 
 
The IQ of everyday users, both cases and controls, was in an intermediate 
position between never users and less than everyday users and did not differ from 
any of the two.  
As already mentioned, even if both cases and controls everyday users were more 
likely to be current users, not all everyday users were currently smokers, therefore 
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what we observed is unlikely due to an acute or residual cannabis effect. 
Additionally, the IQ of everyday cannabis users is a little higher than never users in 
our group (84.15±18.2 vs. 81.2±19.8 of never users) and the difference was even 
higher, but not significant, in a exploratory analysis where current cannabis users 
were removed (85.9±19.4 vs. 81.2±19.8 of never users). 
Studies on abstinent (>28 days) cannabis abusing patients have found a better 
performance of these subjects in some domains (e.g. processing speed, working 
memory, executive functions) (Jockers-Scherübl et al., 2007; Schnell et al., 2009) 
but the lowest levels of schooling, although premorbid IQ was within normal limits 
and comparable to that of the non-abusers (Jockers-Scherübl et al., 2007).  
Among cases and controls of our sample, everyday use, rather than non-use, was 
predicted by higher levels of perceptual reasoning (see also Coulston, Perdices, & 
Tennant, 2007) and verbal comprehension, which is a proxy for a higher premorbid-
IQ (Wechsler, 1981). However, the risk to be a heavy cannabis user, rather than 
abstainers, was also augmented by a lower processing speed that resulted moderated 
by the protective role of a higher premorbid academic adjustment. This difference 
with previous studies, probably due to some residual effect of cannabis in this 
subgroup of patients (Jockers-Scherübl et al., 2007; Schnell et al., 2009) or to a 
premorbid condition that reduced the control on the substance (Wills et al., 2008). 
The higher premorbid sociability and the lower premorbid academic adjustment 
that was observed in this group was also witnessed, along with less educational 
attainment and lower self-socioeconomic status, in cannabis abusers by Sevy et al. 
(2010) and, in poly-drug users, in a review by Larsen and collegues (2006). 
Other studies found no association between premorbid scores and drug or 
cannabis abuse (González-Blanch et al., 2015; Rabinowitz et al., 1998; Van 
Mastrigt, Addington, & Addington, 2004) probably because they merely looked at 
PAS mean scores without any distinction between social and academic factor, thus 
losing the effect.  
The risk factor constituted by a higher premorbid sociability and lower education 
is moderated by higher scores of working memory, that has been indicated as 
impaired in schizophrenia (Silver et al., 2003) and in cannabis users (Solowij and 
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Battisti, 2008), i.e. when working memory is higher, it reduces the probability to be 
heavy cannabis-users, rather than recreational-user, in cases and controls, even if 
they are more sociable or with an intermediate education (compulsory education or 
diploma instead of university degree). However, we don’t know the causal direction 
of this relationship. 
Thus, measures of cognitive control and executive functions have to be read in 
relationship with the moderator role of the early premorbid adjustment, probably in 
a two-way direction.  
About controls, everyday users had a lower IQ than recreational users and no 
differences were found with never users (see also Grant et al., 2003; Schreiner & 
Dunn, 2012). As espected, everyday users had a lower academic adjustment before 
their 16 years (Apantaku-Olajide, James, & Smyth, 2014; Krohn, Lizotte, & Perez, 
1997; Lee, Winters, & Wall, 2010) and a good early social adjustment (see also 
Kellam et al., 1980). Thus, cases and controls behaved very similarly in relation to 
everyday cannabis use, a part from the absolute difference in IQ and premorbid 
scores, that were lower in cases than in controls overall. 
By summing-up, these results are more likely to be attributed to a complex 
mechanismn, involving several variables. 
Cases and controls who became everyday smokers, had a significant drop in their 
academic functioning from childhood to first adolescence and it is possible to 
hypothesize that this could have affect the educational and occupational trajectory. 
Actually, 41% of cases with no education were everyday smokers and, in turn, 
having a lower education augmented up to 3 times the probability to be an everyday 
smoker than a subject with a university degree, regardless the group.  
Everyday users were also more likely to be unemployed at the moment of the 
interview, compared to never users and less than everyday users, in case group but 
not in controls. In this latter group, lower education could have contributed in 
influencing their IQ, but not in impairing occupational and social functioning, also 
because it stayed in a normal range (mean IQ = 101±17.2).  
In terms of sociability, while controls were not different in relationship to 
cannabis use and resulted in a slightly better adjustment in first adolescence than in 
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childhood, the opposite was true for cases. Cannabis smokers were more sociable 
overall, but everyday smokers developed a little deterioration in their premorbid 
social adjustment, during the period in which they started smoking cannabis, i.e. at 
their 15, that was the median age (15.6 mean age for controls; 16.1 mean age for 
cases) but these findings became non-significant according to Bonferroni’s 
correction, thus it is possible to say that both groups stayed stable in their 
sociability. However, cases heavy users were more likely to have smoked cannabis 
alone, and to have used other drugs than less than everyday users and they were also 
more likely to live with their parents or in other families or institutions than never 
users and less than everyday users, despite the similar premorbid sociability with 
this latter group; thus they showed a more compromised functional adjustment than 
recreational users and never users, that perhaps started before the illness and that 
could be related to a more severe course of it (Caspari, 1999; Grech, Van Os, Jones, 
Lewis, & Murray, 2005; Linszen, Dingemans, & Lenior, 1994). They have also the 
lowest age of onset (Di Forti et al., 2014), at around 26 years.  
Cases everyday smokers, but not controls, have preferentially chosen high 
potency cannabis and they referred that tolerance has increased their amount of 
cannabis used. In fact, the risk to be an everyday smoker was augmented by higher 
THC concentration-cannabis use, independently from group belonging.  
The question is, if the drop in premorbid adjustment (greater at school) is a 
consequence of the pattern of cannabis misuse or the correlate of a prodromal phase 
with an earlier neurodevelopmental trigger for psychosis, that could lead in turn to 
an earlier and more persistent cannabis use, where genes have a crucial role.  
Ringen and colleagues sustain the primacy of premorbid predisposition, that can 
affect both later cannabis use and neurocognition (Ringen et al., 2013). It was also 
suggested that a combination of genetic and environmental factors (e.g. parental 
substance use, Kirisci et al., 2009) is able to explain inclination to cannabis use that, 
in turn, influences the liability to affiliate with deviant peers (Gillespie et al., 2009) 
and that genetic factors play an increasingly important role during maturation in 
individuals’ choice of peers, while early environment becomes less influential 
(Kendler et al., 2007). It was also suggested that poor self control (neurobehavioural 
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disinhibition), could lead to a specific and deviant peer environment – through 
cognitive distortions (Kirisci, Mezzich, Reynolds, Tarter, & Aytaclar, 2009) – 
which in turn mediates the relationship between neurobehavioural disinhibition and 
cannabis abuse (Feske et al., 2008).  
Our cases and controls everyday smokers start with a worse premorbid academic 
adjustment in childhood, compared to never and recreational users, that became 
even worse in first adolescence, thus indicating an early and inexorable decline 
where cannabis is probably first selected, depending from predisposing factors (for 
example higher early sociability and/or poor self-control etc.), and after reinforced, 
by involving the subject in an even less challenging and stimulating world (see also 
Fergusson et al., 2003).  
If cannabis use persists over time, the vicious circle can be maintained, thus 
gradually reducing both premorbid social (González-Blanche et al., 2015; Ringen et 
al., 2013) and academic adjustment and, consequently, IQ (Meier et al., 2012). In 
fact, as Salyers and Muser highlighted in their study, the better social skills of this 
group are not necessarly related to good interpersonal relationships (Salyers & 
Mueser, 2001).  
 
 
4. Summary and Future Directions 
 
Various risk factors play a role in individuals becoming heavy users, most of 
them related to the contact with the substance. Among cannabis everyday users, 
better premorbid conditions and peer influence might have triggered cannabis-use, 
as was probably true for recreational-users. However, heavy cannabis-users choose 
a high THC concentration-cannabis and they had an earlier age of initiation in its 
use and this might be responsible for the loss of control on the substance. In fact, 
risk-taking and sensation seeking behaviours are higher in males than in females 
and decline between adolescence and adulthood, possibly because of changes in the 
brain’s cognitive control system, which improve individuals’ capacity for self-
regulation (Steinberg, 2008). Genetic factors, coupled with early environment, 
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could also have a role in poor self-control – i.e. executive functions – that could, in 
turn, explain other risk-factors as, for example, deviant peer affiliation, lack of 
coping strategies and more lifetime stress. On the other hand, good self-control 
could have protective effects through promoting better academic competence (see 
also Novak & Clayton, 2001; Wills et al., 2001, 2008; Wills & Stoolmiller, 2002). 
This complex interaction between predisposition and early cannabis abuse could 
have determined a different trajectory of life, by reducing the capability to achieve 
higher education, for example due to a lesser learning ability (that is the acute and 
residual effect of cannabis use), thus involving the individual in an even more poor 
environment and enhancing the risk to develop psychosis in people predisposed.  
On the other hand, patients who smoked cannabis less than everyday seem to be 
the less vulnerable group, and further studies are required to clarify the role of 
recreational cannabis-use in the onset of psychosis in interaction with other risk 
factors as, for example, affective vulnerability or early traumatic experiences (Sideli 
et al., 2015). Both cases and controls with a recreational cannabis use exhibited a 
higher IQ and they also achieved a higher education level. If the hypothesis of a 
neuroprotective action of cannabis on a neurodegenerative process was true, we 
would have changed it into an “improving hypothesis”, i.e. cannabis is able to 
enhance IQ, regardless any diagnosis of psychosis and in spite of the amount of 
experimental research that have demonstrate detrimental cognitive effects or no 
long term effects of cannabis on the brain. Finally, cases who never used cannabis 
represent the group more neurodevelopmental predisposed to psychosis (i.e. with a 
lower IQ and a higher social premorbid impairment), they have a stable poor 
functioning, a later onset of psychosis and a probably later deterioration in their 
academic premorbid adjustment. This group of patients, have not the same 
opportunity to enter in contact with the illegal substance and develop psychosis 
without the need of this additional risk factor. 
In conclusion, these data suggest that premorbid cognition is greatly related to 
what we observe in people when a test is administered as adults. The long-term 
effects of cannabis use on cognitive functioning and IQ, that is «the global capacity 
of a person to act purposefully, to think rationally, and to deal effectively with his 
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environment» (Wechsler, 1939), take a larger route than the simple direct biological 
effect, due to the neuro-anatomic alterations related to heavy and earlier cannabis 
use (Lorenzetti et al., 2016); indeed, the final effect involves several aspects of an 
individuals’ life, such as the failure in the academic achievement, preferred deviant 
friendships, subsequent lower socio-economic status, etc. (Rogeberg, 2013a) that 
could ultimately impair his cognition in the long term. Additionally, in vulnerable 
subjects, heavy cannabis use could multiply the risk of developing psychosis that, in 
turn, causes a further functional impairment, which starts in the prodromal phase 
and involves all the above mentioned areas and even more. 
Future directions include further exploration of differences by gender and 
diagnosis, a deeper look to cannabis recreational-use and a cross exploration of the 
main findings in interaction with the polygenic risk score for psychosis. 
 
 
5. Conclusions  
 
The study confirmed that patients who used cannabis in their lifetime with a 
recreational pattern of cannabis use have higher IQ scores and a better and more 
stable premorbid adjustment than other patients. The study is also compatible with 
the view that the better premorbid social adjustment of patients with cannabis-use 
was responsible for the contact with the substance and that cannabis use increased 
the risk of psychosis in a subgroup of patients with less neurodevelopmental 
vulnerability. 
Taken together, these results are able to rule out the alternative explanation of a 
neuroprotective role of cannabis use on cognition, in favour of the hypothesis of a 
complex relationship between premorbid predisposition and different pattern of 
cannabis use in determining this paradoxical result.  
If the trends of lower age at initiation of cannabis use and public acceptance of its 
use continue, along with a lack of information on these issues, a larger proportion of 
young people from the general population may develop cannabis abuse in the future 
with consequences that are not easily preventable. 
	  
 167 
 
6. Limitations and Strengths 
 
The EU-GEI study has strengths, such as the large sample size, the 
differentiation of the sample across several countries, the reliability tests that were 
performed with researchers, and other strengths, as described in chapter 3. 
At the end of this work I want to address some potential limitations that could be 
noticed in this study design.  
Even if a prospective cohort study would be able to provide most robust design 
for establishing causal connections, in relation to psychosis, such a design is 
problematic, because psychosis is a rare disorder, with a large time lag between the 
occurrence of environmental adversities and the onset.  
The case-control design framed into an observational epidemiological study, 
allows us to make comparisons of the prevalence of several exposures (putative risk 
factors) between a group of individuals who have the outcome of interest (in this 
case people affected by their first episode of psychosis) and a group of healthy 
people, with similar features to cases but without the disease of interest (controls) 
and representative of the general population. Case-control studies are easier and less 
expensive and time consuming than prospective cohort studies, because the disease 
has already occurred. They don’t require large sample size unless the variable of 
exposure is very rare (Greenland, 2009) and have the advantage of allowing the 
study of several risk factors at the same time. Furthermore, the recruitment of a 
large multi-centre sample of incident cases of schizophrenia spectrum disorders and 
controls (such as EU-GEI) is able to provide an invaluable pool of subjects (with 
detailed clinical, environmental, and genetic data) from which is possible to detect 
even small effects for the values of interest (Annex I - “Description of Work, in 
www.eu-gei.edu).  
I acknowledge that a case-control study may have some disadvantages such as 
selection bias if, for example the control group selected was not representative of 
the population, or it should represent the population at risk of the disease (i.e. they 
should be individuals who, if they had experienced the disease outcome, would 
have been included as cases in the study). Another source of bias is recall bias, 
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because the information about exposure to risk factors is collected retrospectively 
and people with the disease might be more likely to recall risk factors (Greenland, 
2009) as, for example, could occur in PAS interview. However, one of the aims of 
the study was to ensure at least one corroborative source of information for each 
case (e.g. family, clinical notes, other clinicians etc.). Additionally, the predictive 
and concurrent validity of the PAS was supported in persons with schizophrenia by 
comparing it with both a similar but more elaborate retrospective measure and with 
data collected during late adolescence (Brill, Reichenberg, Weiser, & Rabinowitz, 
2008). Socio-economic status in childhood could be a confounder in these analysis, 
difficult to be addressed as a unique index in a European study, where each country 
has a different meaning of its socio-economic distribution. However, Meier and 
colleagues tried to rule out the possible pre-morbid confounder of socio-economic 
status in adolescence and they still found an inferior educational achievement in 
cannabis users, especially if the use was persistent through the four years of their 
study (Meier et al., 2015). Everyday users in our study were also more likely to be 
unemployed at the moment of the interview, compared to never users and less than 
everyday users, in case group but not in controls. This suggests that the diagnosis of 
psychosis could be associated to a lower personal socio-economic adjustment, more 
than cannabis abuse per se.   
We examined patients at their first episode of psychosis, which minimizes the 
influence from variables inherent to those with chronic illness and/or the effects of 
continuous pharmacological treatment on cognition. However, patients were not 
medication naïve and, as is well known, medication could have affected current 
neuropsychological performance (i.e. IQ) even in the short period between initial 
contact with the services and our cognitive testing. On the other hand, this could 
only be related to a flattering effect on the relationship between cannabis use and 
IQ, equally distributed among cases, that did not occur in this study, where IQ of 
cases and controls was similarly related to cannabis use. The big difference in 
everyday cannabis users between cases and controls could be due to the difficulty in 
involving people included in this subgroup from the general population. However, 
as already discussed in Di Forti et al. (2009), it seems unlikely that the difference in 
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frequency and type of cannabis used between cases and control group was driven by 
a recruitment bias.  
Another point of concern could be due to the fact that cannabis use was self-
reported. Nonetheless, as already mentioned, we had the opportunity to measure the 
reliability of the self-reported data on current users in a random sample of 56 cases 
from the GAP sample, by carrying out a urinary drug screening (UDS) and the 
accuracy of self-report data on current use in our sample was high. For obvious 
reasons, a history of lifetime use of cannabis cannot be assessed by a biological test. 
Gurillo and colleagues (2015) have recently suggested that daily tobacco use 
could be associated with increased risk of psychosis and an earlier age at onset of 
psychotic illness. Even if it was not a goal of this study, it would have been 
important try to rule out its possible confounding effect, as was possible for other 
drug abuse in the lifetime and, since our information on tobacco use were limited, it 
was not feasible. However, tobacco current use was related to a lower IQ and this 
was not true for current cannabis smokers nor for cannabis lifetime users overall 
(any pattern of cannabis use); thus this two groups are not coincident, a part from 
early better sociability and lower worse scholastic adjustment as is true for patients 
with an earlier onset of psychosis, that was also detected in tobacco smokers (see 
also Gurillo et al., 2015).  
Another limitation is due to the impossibility to look at symptoms dimension (i.e. 
negative and positive symptoms), due to the length in the cleaning effort of these 
data that is currently ongoing. Even if symptoms are not of principal interest in this 
work, they could have changed some results (for example IQ) or confounded 
specific analyses, even if the similarities of cases and controls in relationship to 
cannabis use let us to consider the possibility that symptoms are not so important in 
the relationship between the variables of interest. However, future directions of the 
study will have the opportunity to look at these aspects.  
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Appendix I: MRC Sociodemographic Schedule 1-2 
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Appendix II: OPCRIT Item Checklist 
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Appendix III: CEQ and CIDI 
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Appendix IV: WAIS-III Abbreviated Version 
 
	  
 221 
 
 
 
 
 
 
	  
 222 
 
 
 
 
 
	  
 223 
 
 
 
 
 
	  
 224 
 
 
 
 
 
	  
 225 
 
 
 
	  
 226 
 
Appendix V: Premorbid Adjustment Scale (PAS) 
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